Studies on Bioactive Heterocycles by Savant, Mahesh M.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Savant, Mahesh M., 2010, “Studies on Bioactive Heterocycles”,  thesis PhD, 
Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/459 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
STUDIES ON BIOACTIVE 
HETEROCYCLES 
  
A  
THESIS  
SUBMITTED TO  
THE SAURASHTRA UNIVERSITY 
IN  
THE FACULTY OF SCIENCE 
FOR  
THE DEGREE  
OF 
 
Doctor of Philosophy 
 
IN 
CHEMISTRY 
BY 
MAHESH M. SAVANT 
UNDER THE GUIDANCE OF 
Dr. YOGESH T. NALIAPARA 
 
DEPARTMENT OF CHEMISTRY 
SAURASHTRA UNIVERSITY 
RAJKOT – 360 005  
GUJARAT, INDIA 
 
MARCH 2010 
 
 
 
Statement under O.Ph.D.7 of Saurashtra University 
 
 
 
The work included in the thesis is done by me under the supervision of Dr. 
Yogesh T. Naliapara and the contribution made thereof is my own work.  
 
 
 
Date:  
Place: Rajkot       Mahesh M. Savant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Certificate 
 
This is to certify that the present work “Studies on Bioactive Heterocycles” submitted for 
the Ph. D. Degree Chemistry of Saurashtra University, Rajkot, Gujarat, India by Mr. 
Mahesh M. Savant has been the result of work carried out under my supervision and is a 
significant contribution in the field of synthetic organic chemistry and medicinal chemistry. 
 
 
 
Date:       Dr. Yogesh T. Naliapara 
Place: Rajkot      Assistant Professor, 
Department of Chemistry, 
Saurashtra University, 
Rajkot-360005 
Gujarat, India. 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to  
My Family 
 
Acknowledgement 
 
 
Firstly, I bow my head humbly before the Almighty God for making me capable of 
completing my Ph.D. Thesis; with his blessings only I have accomplished this huge task. 
 
My feelings go beyond limit to thank Prof. H. Junjappa, Department of chemistry, North 
Eastern Hill University, Shillong and Prof. H. Ila, Indian Institute of Technology, Kanpur, 
India, for their affection, valuable help, suggestions and the memorable moments I shared 
with them during my stay at K.L.E.S’s College of Pharmacy, under the program “Drug 
Discovery and Process Research”. They have shared with me a lot of their expertise and 
research insight. Their wide knowledge in the field of ketene dithioacetals and precious 
guidance has been helpful for me during this thesis work.     
 
I express deep sense of gratitude and thankfulness to my supervisor Dr. Yogesh T. 
Naliapara who has helped me at each and every point of my research work with patience 
and enthusiasm. I am much indebted to him for his inspiring guidance, affection, generosity 
and everlasting enthusiasm throughout the tenure of my research work. 
 
I sincerely grateful to Prof. Anamik shah for their continuous support and inspiration 
during my research work and as a result I am capable to complete this work. He had helped 
me all along to speed up my research work. 
 
I am very thankful to Dr. P. H. Parsania, Professor and Head, Department of Chemistry, 
Saurashtra University, Rajkot for his encouragement and providing adequate research 
facilities. I am also thankful to Prof. Ashok R. Shelar, former HOD, Department of 
Chemistry, Shivaji University, Kolhapur and Dr. L. S. Shet, R & D Manager, Gharada 
Chemicals, Khed, Maharashtra. 
 
My heartily thanks to my colleagues and labmates Piyush Pipaliya, Anil Patel and Vipul 
Audichya for their kind help and support. My special thanks to Dr. Chirag Bhuva, Dr. 
Akshay Pansuriya, Dr. Naval Kapuriya and Dr. Jyoti Singh. 
 
I offer my gratitude to my friends Naimish, Rakesh, Jagdish, Sandip, Ravi, Bunty, Jignesh, 
Nayan, Dharmesh, Ghetiya, Kapil, Haresh, Chintan, Rakshit, Roni, Harshad and all the 
Ph.D. students for their fruitful discussion at various stages. I also thankful to my best 
friends Keyur, Digu, Dilu, Ritesh, Kalpesh, Karan, Chotu, Gopu and Dr. Ashish for their  
help, entertainment  & coordination extended by them.  
 
Big thanks to all teaching and non teaching staff of my Department, as well as Department 
of Bioscience, for their direct or indirect support during this work. I am also thankful to 
Prof. B. R. M. Vyas, A. R. Jadeja and S. K. Upadhyay for their generous support during this 
work. I am profoundly indebted to Department of Chemistry, Saurashtra University for 
providing me the excellent laboratory facility for accomplishing this work.  
 
I am thankful to FIST-DST and SAP-UGC for their generous financial and instrumentation 
support. Special thanks are due to “National Facility for Drug Discovery through New 
Chemical Entities (NCE's) Development & Instrumentation Support to Small 
Manufacturing Pharma Enterprises” Programme under Drug & Pharma Research Support 
(DPRS) jointly funded by Department of Science & Technology, New Delhi, Government of 
Gujarat Industries Commissionerate & Saurashtra University, Rajkot. I am also thankful to 
SAIF, CIL, Chandigarh and NRC, IISc, Bangalore for providing spectroscopic analysis. 
Special thanks to Prof. Christophe Pannecouque, Rega Institute for Medical Research, 
Katholieke Universiteit Leuven, Minderbroedersstraat, Belgium, for providing anti-viral 
screening and Prof. Sridhar, Department of Studies in Physics, Manasagangotri, Mysore, 
India, for providing X-Day Diffraction analysis. 
 
At Last, I have no words to state anything about my parents but at this occasion, I would 
like to thanks my father and mother, without their support, motivation and understanding 
it would have been impossible for me to finish my research work. I sincerely thank to my 
whole family for encouraging me and providing every help to fulfill my task. My special 
gratitude is due to my brother pratik, my sister and her family for their loving support 
during tenure of my work. To them I dedicate this thesis. 
 
 
 
Mahesh M. Savant 
Content 
 
Chapter 1 Etidronic acid catalyzed synthesis of novel 3,4-dihydro-6-(2-hydroxy 
phenyl)-5-nitro-4arylpyrimidin-2(1H)-one derivatives and evaluation for 
anti-viral activity. 
 
1.1 Introduction          1 
1.2 Methods for the preparation of nitrodihydropyrimidines    2 
1.3 Biological activity of some 4-aryl-1,4-dihydropyridines and  5-nitro DHPMs 4 
1.4 Alternative synthetic routes for better yield, shorter reaction time to synthesize  
new analogs          9 
1.5 Current research work        17 
1.6 Results and Discussion        18 
1.7 Antiviral activity                    23   
1.8 Conclusion          27 
1.9 Experimental section         28 
1.10 References          42 
 
 
Chapter 2 Water mediated construction of trifunctionalized pyrazoles library using 
ketene dithioacetals. 
 
2.1 Introduction          46 
2.2 Biological activity of various substituted pyrazoles     46 
2.3 Synthesis of functionalized pyrazole derivatives using various synthetic  
approaches                     51 
2.4 Various oxidizing agent for oxidation of sulfide to sulfones    58 
2.5 Current research work        60 
2.6 Results and Discussion        61 
2.7 Conclusion          67 
2.8 Experimental section         68 
2.9 References                     80
        
 
Chapter 3 Water mediated construction of trifunctionalized isoxazoles library using 
ketene dithioacetals.  
 
3.1 Introduction          82 
3.2 Biological activity of various substituted isoxazole derivatives   82 
3.3 Synthesis of functionalized isoxazoles using various synthetic approaches  90 
3.4 Current research work        97 
3.5 Results and Discussion        98 
3.6 Conclusion                   102 
3.7 Experimental section                  103 
3.8 References                   117
   
 
 
 
Chapter 4 A novel synthetic strategy to 2,3-substituted-4H-chromen-4-one via 
intramolecular heteroannulation and facile C-N bond formation with 
various amines. 
 
4.1 Introduction                    120 
4.2 Biological activity of various chromenone derivatives.              121 
4.3 Synthesis of various chromenone derivatives.               127 
4.4 Current research work                  136 
4.5 Results and Discussion                  137 
4.6 Conclusion                    142 
4.7 Experimental section                   143 
4.8 References                    158 
 
 
Chapter 5 Synthesis, characterization and anti-viral screening of novel 3-amino-4,5-
dihydro-6-methyl-4-oxo-N-aryl-1H-pyrazolo[4,3,c]pyridine-7-
carboxamide derivatives. 
 
5.1 Introduction                    161 
5.2 Biological activity of several fused pyrazolopyridine and pyrazolopyrimidine       162 
derivatives. 
5.3 Various synthetic approaches for substituted pyrazolopyridines and 
pyrazolopyrmidines.                   168 
5.4 Current research work                  174 
5.5 Results and discussion                  175 
5.6 Anti-viral screening                   178 
5.7 Conclusion                    186 
5.8 Experimental section                    187 
5.9 References                     199 
 
Chapter 6 X-ray diffraction study of 3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-
phenylpyrimidin-2(1H)-one and 2-(methylthio)-3-nitro-4H-chromen-4-
one. 
 
6.1 Crystal and Molecular Structure of 3,4-dihydro-6-(2-hydroxy phenyl)-5-nitro-4-
phenylpyrimidin-2(1H)-one                 201 
6.2 Procedure for the development of single crystals              201 
6.3 Single crystal X-ray Diffraction analysis               202 
6.4 Crystal and Molecular Structure of 2-(methylthio)-3-nitro-4H-chromen-4-one      208 
6.5 Procedure for the development of single crystals              208 
6.6 Single Crystal X-ray Diffraction and Structure Determination            209 
6.7 Conclusion                   215 
6.8 References                   216 
 
 Summary                   217 
 List of Publications                  219 
 
Abbreviations 
 
 
 
2HNA   2-hydrxoy-ω-nitroacetophenone 
AIDS   Aquired immune deficiency syndrome 
αAKDTA  α-acyl ketene dithioacetal 
CS2   Carbon disulfide 
DMSO   Dimethyl sulfoxide 
DMS   Dimethyl sulfate 
DHP   Dihydropyridine 
DHPM   Dihydropyrimidine 
EDA   Etidronic acid 
HIV   Human immunodeficiency virus 
MDC   Methylene dichloride 
mCPBA  meta-chloro perbenzoic acid 
SPC   Sodium percarbonate 
SPB   Sodium perborate 
THF   Tetrahydrofuran 
TMS   Trimethyl silane 
UPLC   Ultra performance liquid chromatography 
iPA   iso-propyl alcohol 
h   hour (time) 
min   minute (time) 
rt   room temperature 
mp   melting point 
 
Chapter 1 
 
 
Etidronic Acid Catalyzed Synthesis of Novel  
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Chapter 1  Nitro Functionalized Dihydropyrimidines 
1.1       INTRODUCTION 
 
 The pyrimidine fragment is present in the molecules of a series of biologically active 
compounds, many of which have found use in medical practice (soporific, anti-inflammatory, 
antitumor, and other products).1,2 In this connection, great attention has recently been paid to 
derivatives of pyrimidine, including their hydrogenation products. The first investigations 
into the synthesis of such compounds appeared more than a hundred years ago (e.g., the 
Biginelli reaction),3  and for a long time they remained unused. Only in the last decade have 
methods been developed specifically for the production of hydrogenated pyrimidine systems 
and their physicochemical properties been studied. This is explained by the high reactivity 
and wide range of biological activity with these scaffolds. Thus, for example, 2-substituted 5-
alkoxycarbonyl-4-aryl-l,4-dihydropyrimidines, which are structural analogs of hantzsch 
esters, are modulators of the transport of calcium through membranes.4-7 Many hydrogenated 
pyrimidines exhibit antimicrobial,8 hypoglemic,9  herbicidal,10 and pesticidal11 activity. 
Publications devoted to these problems have been summarized in a number of reviews.9-14  
 
Of great interest among the investigated compounds are the nitro-substituted 
dihydropyrimidines. They readily undergo various chemical transformations, among which 
the unique ability to undergo recyclization to heterocyclic and carbocyclic compounds should 
be noted in particular. The interest in the nitrodihydropyrimidines is also due to the fact that 
these compounds represent the active principle or act as metabolites responsible for the 
physiological action of nitropyrimidines. Recently, products having antimicrobial,15 
antiviral16-18 activity and also products suitable for the treatment of cardiovascular diseases19-
22 have been found among them.  
 
5-Nitrodihydropyrimidines can be described by five structures, having one (1,4-, 1,6-, and 
1,2-) or two (2,5- and 4,5-dihydropyrimidine systems) geminal centers, the carbon atoms of 
which are characterized by sp3 hybridization (Figure 1). 
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Figure 1 
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The 5-nitro-l,2-, 5-nitro-l,4-, and 5-nitro-l,6-dihydropyrimidines are cyclic enamines, in 
which the electron pair of the sp3-hybridized nitrogen atom is in conjugation with the four π 
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electrons of the C=C and C=N double bonds. On account of the mobility of the hydrogen 
atom of the NH group, the 5-nitro-1,4- and 5-nitro-1,6-dihydropyrimidines can be in 
tautomeric equilibrium. At the same time the 5-nitro-2,5- and 5-nitro-4,5-dihydropyrimidines 
are cyclic imines, in which there is no conjugation.23  
 
1.2. Methods for the preparation of nitrodihydropyrimidines  
The methods for the production of dihydropyrimidines described in the literature can 
be divided into two main groups such as: synthesis from acyclic compounds and 
transformations based on pyrimidine derivatives (Figure 2). Analysis of the published data 
makes it possible to conclude that the first methods have advantages over the other. However, 
the second methods are used more widely if an electron withdrawing group, and particularly 
a nitro group, is introduced into the pyrimidine molecule. (One of the acyclic compounds 
contains a nitro group.)  
 
 
Figure 2 
 
? Synthesis from acyclic compounds  
 Only derivatives of 5-nitro-l,4-dihydropyrimidine have been obtained from acyclic 
compounds (Figure 3). Three-component (A) and two-component (B, C) versions of 
cyclocondensation, based on the Biginelli reaction,17,24-26 and also intramolecular cyclization 
of the already prepared six-membered chain (version D) have been used for this. Nitro 
ketones (versions A, C) and 1-arylidene-l-nitropropan-2-ones (version B) are used as nitro 
components in these reactions and derivatives of urea, arninopyrazole and amidines are used 
as N-C-N fragments. 
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Figure 3 
 
The proposed methods of cyclocondensation are interrelated. As a rule, realization of the 
reactions by one of the methods leads not to the final product but to an intermediate 
compound, which is in turn the starting compound for another method of cyclization. 
 
The formation of 5-nitro-4,6-diphenyl-l,4-dihydropyrimidin-2(1H)-one (Figure 4) from 
benzylidenebisurea and α-nitroacetophenone  was first described in 1972.27 According to the 
mechanism of the Biginelli reaction,26 at the first stage the urea fragment is clearly 
substituted by the nitroketone residue, and this is followed by cyclization of the six-
membered intermediate in the acidic medium. 
 
PhCH(NHCONH2)2
PhCOCH2NO2
BuOH, HCl
HN
N
H
Ph
NO2
PhO
 
Figure 4 
 
In the reaction of aromatic aldehydes with nitro acetone and a two-fold excess of urea or N-
methyl urea in boiling ethanol in the presence of HCI 4-aryl-6-methyl- or 4-aryl-l,6-dimethyl-
5-nitro-l,4-dihydropyrimidin-2(1H)-ones were obtained (Figure 5).23,28 The latter are also 
formed as a result of the two-component cyclization  of the respective 1-arylidene-l-
nitropropan-2-ones with urea or N-methyl urea. 
 
MeCOCH2NO2
EtOH, HCl
HN
N
Ar
NO2
MeO
NH2CONHR
ArCHO
Ar
H COMe
NO2
R
R = H, Me  
Figure 5 
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By analysis of the spectral characteristics it is possible to assign compounds (Figure 5) the 
1,2,3,4-tetrahydropyrimidine structure. It should be noted that almost any aromatic aldehydes 
enter into the described transformations. This is important during comparison of the 
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pharmacological activity of compounds of this series with the corresponding derivatives of 4-
aryl-l,4-dihydropyridines. 
 
? Synthesis based on nitropyrimidines 
 Owing to their reactivity, nitropyrimidines, which contain accepting nitro groups and 
"pyrimidines" nitrogen atoms, have found use as synthons for the production of various 
derivatives of pyrimidine and also various other types of organic compounds whose synthesis 
by other methods is difficult or practically impossible.29-31 
 
5-Nitropyrimidines do not form covalent σ adducts with uncharged O-nucleophiles. The 
amination of highly π-deficient six-membered nitroaza aromatic compounds was conducted 
successfully in the liquid ammonia-potassium permanganate system.32 When dissolved in 
liquid NH3, depending on the temp., 5-nitropyrimidine forms σ adducts at positions 2 and 4 of 
the heterocycle, and they are detected spectrally (Figure 6).33 
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Figure 6 
 
1.3. Biological activity of some 4-aryl-1,4-dihydropyridines and  5-nitro DHPMs  
 4-Aryl-1,4-dihydropyridines (DHPs, e.g. nifedipine) are the most studied class of 
organic calcium channel modulators. More than 30 years after the introduction of nifedipine 
many DHP analogs have now been synthesized and numerous second-generation commercial 
products have appeared on the market.34,35 
 
Nowadays, interest has also focused on aza-analogs such as dihydropyrimidines (DHPMs) 
which shows a very similar pharmacological profile to classical dihydropyridine calcium 
channel modulators.5-7, 36-43 Over the past few years several lead-compounds were developed 
(i.e. SQ 32,926) that are superior in potency and duration of antihypertensive activity to 
classical DHP drugs, and compare favorable with second-generation analogs such as 
amlodipine and nicardipine (Figure 7). 
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Figure 7 
 
Barrow et al reported in vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as 
potent and selective r1A receptor antagonists for the treatment of benign prostatic hyperplasia 
(Figure 8). R1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and 
R1 receptor antagonists such as terazosin are used to treat both hypertension and benign 
prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been 
identified, with the R1A receptor being most prevalent in lower urinary tract tissue. Barrow et 
al reported 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C5 
amide as selective R1A receptor subtype antagonists. In receptor binding assays, these types 
of compounds generally display Ki values for the R1a receptor subtype <1 nM while being 
greater than 100-fold selective versus the R1b and R1d receptor subtypes. Many of these 
compounds were also evaluated in vivo and found to be more potent than terazosin in both a 
rat model of prostate tone and a dog model of intra-urethral pressure without significantly 
affecting blood pressure. While many of the compounds tested displayed poor 
pharmacokinetics, one compound was found to have adequate bioavailability (>20%) and 
half-life (>6 h) in both rats and dogs. Due to its selectivity for the R1a over the R1b and R1d 
receptors as well as its favorable pharmacokinetic profile, it has the potential to relieve the 
symptoms of BPH without eliciting effects on the cardiovascular system.44,45 
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The 4-aryldihydropyrimidinone heterocycles attached to an aminopropyl-4-arylpiperidine via 
a C5 amide has proved to be an excellent template for selective R1A receptor subtype 
antagonists. These types of compounds are exceptionally potent in both cloned receptor 
binding studies as well as in vivo pharmacodynamic models of prostatic tone. 
Chapter 1  Nitro Functionalized Dihydropyrimidines 
Atwal et al have examined a series of novel dihydropyrimidine calcium channel blockers that 
contain a basic group attached to either C5 or N3 of the heterocyclic ring (Figure 9). 
Structure-activity studies show that l-(phenylmethyl)-4-piperidinyl carbamate moiety at N3 
and sulfur at C2 are optimal for vasorelaxant activity in vitro and impart potent and long-
acting antihypertensive activity in vivo. One of these compounds was identified as a lead, and 
the individual enantiomers were synthesized. Two key steps of the synthesis were (1) the 
efficient separation of the diastereomeric ureido derivatives and (2) the high-yield 
transformation of 2-methoxy intermediate to the (p-methoxybenzyl)thio intermediates. 
Chirality’s was demonstrated to be a significant determinant of biological activity, with the 
DHP receptor recognizing the enamines ester moiety but not the carbamate moiety. DHPM is 
equipotent to nifidepine and amlodipine in vitro. In the spontaneously hypertensive rat, 
DHPM is more potent and longer acting than both nifidepine and the long-acting amlodipine 
(DHP derivative). DHPM has the potential advantage of being a single enantiomer.46,47 
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Figure 9 
 
In order to explain the potent antihypertensive activity of the modestly active (ICw = 3.2 pM) 
DHPM calcium channel blocker, Atwal et al carried out drug metabolism studies in the rat 
and found it is metabolized. Two of the metabolites (ICw = 16 nM) and (ICw = 12 nM), were 
found to be responsible for the antihypertensive activity of compound. Potential metabolism 
in vivo precluded interest in pursuing compounds related to it. Structure-activity studies 
aimed at identifying additional aryl-substituted analogues led to comparable potential in vivo, 
though these compounds were less potent in vitro. To investigate the effects of absolute 
stereochemistry on potency, authors resolved via diastereomeric ureas, prepared by treatment 
with (R)-α-methylbenzylamine. The results demonstrate that the active R-(-)-enantiomer is 
more potent and longer acting than nifedipine as an antihypertensive agent in the SHR. The in 
vivo potency and duration is comparable to the long-acting DHP amlodipine. The superior 
oral antihypertensive activity compared to that of previously described carbamates 
(R2=COOEt) could be explained by its improved oral bioavailability, possibly resulting from 
increased stability of the urea functionality (Figure 10).6 
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Figure 10 
 
Authors modified the structure of previously described DHPM i.e. 3-substituted 1,4-
dihydropyrimidines. Structure-activity studies using potassium-depolarized rabbit aorta show 
that ortho, meta-disubstituted aryl derivatives are more potent than either ortho or meta-
monosubstituted compounds. While vasorelaxant activity was critically dependent on the size 
of the C5 ester group, isopropyl ester being the best, a variety of substituents (carbamate, 
acyl, sulfonyl, and alkyl) were tolerated at N3. The results show DHPMs are significantly 
more potent than corresponding 2- heteroalkyl-l,4-dihydropyrimidines and only slightly less 
potent than similarly substituted 2-heteroalkyl-1-4-dihydropyridines (Figure 11). Where as 
DHP enantiomer usually show 10-15-fold difference in activity, the enantiomer of DHPM 
show more than a 1000-fold difference in activity. These results strengthen the requirement 
of an enaminoester for binding to the dihydropyridine receptor and indicate a nonspecific role 
for the N3-substituent. 
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Figure 11 
 
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylicesters (Figure 12), 
which lack the potential symmetry of DHP calcium channel blockers, were prepared and 
evaluated for biological activity. Biological assays using potassium-depolarized rabbit aorta 
and radio ligand binding techniques showed that some of these compounds are potent mimics 
of DHP calcium channel blockers.35 
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Bryzgalov A. O. et. al. have been studied the antiarrhythmic activity of 4,6-di(het)aryl-5-
nitro-3,4-dihydropyrimidin-(1H)-2-ones(Figure 13) toward two types of experimental rat 
arrhythmia. With CaCl2 induced arrhythmia model, several agents have demonstrated high 
Antiarrhythmic activity and the lack of influence on arterial pressure of rats.48 
 
HN
N
H
Ar
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Figure 13 
 
Remennikov G. Y. et al,20 have been synthesized some novel 4-aryl-5-nitro substituted 
DHPMs (Figure 14) using nitroacetone and screened as calcium modulators. They have 
studied the pharmacological properties of 6-methyl- and 1,6-dimethyl-4-aryl-5-nitro-2-oxo-
l,2,3,4-tetrahydropyrimidines with different substituents in the aryl fragment, i.e. 
unsubstituted, ortho, meta, para, di, and tri-substituted compounds and observed that 5-nitro 
DHPMs bearing unsubstituted, ortho and tri-substitution on aryl moieties at C4 position 
reduced blood pressure and inhibited myocardial contractile activity. The second group 
consisted meta, para and di-substituted aryl moieties with DHPMs increased blood pressure 
and had positive inotropic effects. The compounds with the highest hypotensive activity were 
containing substituents in the ortho position of the phenyl fragment. Thus, compounds having 
substitution on aryl moieties which had pronounced vasodilator and weak cardio depressive 
actions, increased cardiac pump function (SV). When inhibition of myocardial contractile 
function predominated, there was a reduction in SV. The effect of compounds of the first 
group on heart rate was variable, though most reduced heart rate. In addition, a reflex 
increase in heart rate might be expected because of the reduction in blood pressure. The 
reference preparation for compounds of this group was the calcium antagonist nifedipine. The 
pharmacological profile of compounds of the first group were analogous to that of nifedipine. 
This suggests that they share a common mechanism of action - blockade of calcium ion 
influx 
HN
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O
NO2
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R2
R3
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R1= H, OMe, NO2
R2= H, OMe, OH, Cl
R3= H, OMe
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Figure 14 
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1.4 Alternative synthetic routes for better yield, shorter reaction time to synthesize 
new analogs 
 Various modifications have been applied to Biginelli reaction to get better yield and 
to synthesize biologically active analogs. Different catalysts have been reported to increase 
the yield of the reaction. Microwave synthesis strategies have also been applied to shorten the 
reaction time. Solid phase synthesis and combinatorial chemistry has made possible to 
generate library of DHPM analogs. The various modifications are discussed in the following 
section. 
 
? Catalysts 
 Min Yang and coworkers49 have synthesized the different DHPMs by using different 
inorganic salts as a catalyst (Figure 15). They found that the yields of the one-pot Biginelli 
reaction can be increased from 20-50% to 81-99%, while the reaction time shorted for 18-24 
h to 20-30 min. This report a new and simple modification of the Biginelli type reaction by 
using Yb(OTf)3 and YbCl3 as a catalyst under solvent free conditions. One additional 
important feature of this protocol is the catalyst can be easily recovered and reused.  
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Figure 15 
 
Indium (III) chloride was emerged as a powerful Lewis catalyst imparting high region and 
chemo selectivity in various chemical transformations. B. C. Ranu and co-workers50 reported 
indium (III) chloride (InCl3) as an efficient catalyst for the synthesis of 3,4-dihydropyrimidn-
2(1H)-ones (Figure 16). A variety of substituted aromatic, aliphatic and heterocyclic 
aldehydes have been subjected to this condensation very efficiently.  Thiourea has been used 
with similar success to provide the corresponding dihydropyrimidin-2(1H)-thiones. 
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Figure 16 
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Majid M. Heravi et al. have reported a simple, efficient and cost-effective method for the 
synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot three-component 
cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde and urea or thiourea 
using 12-tungstophosphoric acid51 and 12-molybdophosphoric acid52 as  recyclable catalyst 
(Figure 17). 
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Figure 17 
 
An improved approach has been found to carry out the Biginelli reaction for the synthesis of 
3,4- dihydropyrimidine- 2(1H)-one derivatives. This synthesis was performed in the presence 
of hydrochloric acid and β-cyclodextrin in ethanol solution. Compared with the classical 
Biginelli reaction conditions, this new approach has the advantage of excellent yields and 
short reaction time.53   
 
An efficient synthesis of 3,4-DHPMs from the aldehyde, β-keto ester and urea in ethanol, 
using ferric chloride hexahydrate or nickel chloride hexahydrate as the catalyst, was 
described. Compared with the classical Biginelli reaction conditions, this new method has the 
advantage of excellent yields (53-97%) and short reaction time (4-5 hours).54  
 
5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2-ones were synthesized by the one-pot 
reactions of aldehydes, β-ketoesters and urea using a catalytic amount of phosphotungstic 
acid (PTA) in ethanol. The modified Biginelli cyclocondensation not only shortens the 
reaction period and simplifies the operation, but also improves the yields.55
Ruthenium (III) chloride efficiently catalyzes the three-component Biginelli reaction of an 
aldehyde, a β-keto ester, and urea or thiourea under solvent-free conditions to afford the 
corresponding 3,4-dihydropyrimidine-2-(1H)-ones in excellent yields.56
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The Biginelli reaction, a one-pot condensation of aldehydes, urea or thiourea and β-
dicarbonyl compounds, is efficiently catalyzed by samarium diiodide. The biologically active 
dihydropyrimidinones are easily synthesized in moderate to excellent yields under solvent-
free conditions.57
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Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently catalyses the three 
components Biginelli reaction between an aldehyde, ethyl acetoacetate and urea in refluxing 
toluene to afford the corresponding dihydropyrimidinones in high yields.58
Sc(III)triflate efficiently catalyzes the three-component condensation reaction of an aldehyde, 
a β-ketoester and urea in refluxing acetonitrile to afford the corresponding 3,4-
dihydropyrimidin-2(1H)-ones in excellent yields (Figure 18). The catalyst can be recovered 
and reused, making this method friendly and environmentally acceptable.59 
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Very recently, chiral phosphoric acid is reported as highly enantioselective catalyst for 
Biginelli reaction. Reaction is reported in presence of 10 mol % of chiral phosphoric acid to 
produce desired enantioselective product. This is the first organocatalytic asymmetric 
Biginelli reaction. The optimal chiral phosphoric acid afforded the reaction in high yields 
with excellent enantioselectivities of up to 97% ee. A wide variety of substrates, including 
aldehydes and α-keto esters, could be tolerated. This reaction has an advantage of avoiding 
the contamination of transition metals in the manufacture of the medicinally relevant chiral 
3,4-dihydropyrimidin-2-(1H)-ones (Figure 19).60 
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Shkurko, O. P. et al have been synthesized 4,6-diaryl-5- nitro-3,4-dihydropyrimidin-2(1H)-
ones and N-benzoyl-N'-(1-aryl-2-nitroethyl)ureas (Figure 20) using ω-nitro acetophenone, 
aromatic aldehydes and urea in the presence of iron(III), cobalt(II), nickel(II), and copper(II) 
salts as catalyst with moderate to poor yields.61 
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Figure 20 
 
An efficient three-component synthesis of 3,4-dihydropyrimidinones using 
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for Biginelli 
reaction in ethanol or DMF under reflux condition.62 Many researchers63-68 have investigated 
Biginelli reaction under solvent-free conditions for one-pot synthesis of 3,4-
dihydropyrimidine-2-(1H)ones/thiones using various catalyst as described under.  
 
? Solid phase synthesis 
 The generation of combinatorial libraries of heterocyclic compounds by solid phase 
synthesis is of great interest for accelerating lead discovery and lead optimization in 
pharmaceutical research. Multi-component reactions (MCRs)29,69-75 leading to heterocycles 
are particularly useful for the creation of diverse chemical libraries, since the combination of 
any 3 small molecular weight building blocks in a single operation leads to high 
combinatorial efficiency. Therefore, solid phase modifications of MCRs are rapidly become 
the cornerstone of combinatorial synthesis of small-molecule libraries.  
 
The first solid-phase modification of the Biginelli condensation was reported by Wipf and 
Cunningham76 in 1995 (Figure 21). In this sequence, γ-aminobutyric acid derived urea was 
attached to Wang resin using standard procedures. The resulting polymer-bound urea was 
condensed with excess β-ketoester and aromatic aldehydes in THF at 55 °C in the presence of 
a catalytic amount of HCl to afford the corresponding immobilized DHPMs. Subsequent 
cleavage of product from the resin by 50 % trifluoroacetic acid (TFA) provided DHPMs in 
high yields and excellent purity. 
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Figure 21 
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Li W. and Lam Y.77 have described the synthesis of 3,4-dihydropyrimidin-2- 
(1H)ones/thiones using sodium benzenesulfinate as a traceless linker (Figure 22). The key 
steps involved in the solid-phase synthetic procedure were sulfinate acidification, 
condensation of urea or thiourea with aldehydes and sulfinic acid and traceless product 
release by a one-pot cyclization-dehydration process. Since a variety of reagents can be used, 
the overall strategy appears to be applicable to library generation. 
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Figure 22 
 
Gross et al.78 developed a protocol to increase the diversity of DHPM which based on 
immobilized α-ketoamides (Figure 23). The resulting synthetic protocol proved to be suitable 
for the preparation of a small library using different building blocks. They found that the 
aromatic aldehyde and α-ketoamide building blocks were formed the expected DHPM 
derivatives in high purity and yield. The usage of an aliphatic aldehyde leads to an isomeric 
DHPM mixture. Purities and yields were not affected, when thiourea was used instead of 
urea. 
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? Liquid phase synthesis 
Studies on Bioactive Heterocycles 13
 In the solid phase synthesis there are some disadvantages of this methodology 
compared to standard solution-phase synthesis, such as difficulties to monitor reaction 
progress, the large excess of reagents typically used in solid-phase supported synthesis, low 
loading capacity and limited solubility during the reaction progress and the heterogeneous 
reaction condition with solid phase.79 Recently, organic synthesis of small molecular 
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compounds on soluble polymers, i.e. liquid phase chemistry has increasingly become 
attractive field.80 It couples the advantages of homogeneous solution chemistry with those of 
solid phase chemistry. 
 
Moreover owing to the homogeneity of liquid-phase reactions, the reaction conditions can be 
readily shifted from solution-phase systems without large changes and the amount of 
excessive reagents is less than that in solid-phase reactions. In the recent years, Task Specific 
room temperature Ionic Liquids (TSILs) has emerged as a powerful alternative to 
conventional molecular organic solvents or catalysts. Liu Z. et al81 have reported cheap and 
reusable TSILs for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones via one-pot three 
component Biginelli reaction. 
 
Ionic liquid-phase bound acetoacetate reacts with thiourea and various aldehydes with a 
cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-thiones, 
which reported by Bazureau J. P. and co-workers82 (Figure 24). 3,4-Dihydropyrimidinones 
were synthesized in one-pot, by the reaction of aldehydes, β-dicarbonyl compounds and urea, 
catalyzed by non-toxic room temperature ionic liquid 1-n-butyl-3-methylimidazolium 
saccharinate (BMImSac).83 
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? Microwave assisted synthesis 
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 In general, the standard procedure for the Biginelli condensation involves one pot 
condensation of the three building blocks in a solvent such as ethanol using a strongly acidic 
catalyst that is hydrochloric acid. One major drawback of this procedure, apart from the long 
reaction time involving reflux temperature, is the moderate yields frequently observed when 
using more complex building blocks. Microwave irradiation (MW) has become accepted tool 
in organic synthesis, because the rate enhancement, higher yields and often, improved 
selectivity with respect to conventional reaction conditions.84 The publication by Dandia A. et 
al85 described microwave-enhanced solution-phase Biginelli reactions employing ethyl 
acetoacetate, thiourea and a wide variety of aromatic aldehydes as building blocks (Figure 
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25). Upon irradiation of the individual reaction mixtures (ethanol, catalytic HCl) in an open 
glass beaker inside the cavity of a domestic microwave oven the reaction times were reduced 
from 2–24 hours of conventional heating 80 °C, reflux to 3–11 minutes under microwave 
activation (ca. 200 –300 W). At the same time the yields of DHPMs obtained were distinctly 
improved compared to those reported earlier using conventional conditions. 
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In recent years, solvent free reactions using either organic or inorganic solid supports have 
received more attention.86 There are several advantages to perform synthesis in dry media: (i) 
short reaction times, (ii) increased safety, (iii) economic advantages due to the absence of 
solvent. In addition, solvent free MW processes are also clean and efficient. Gopalakrishnan 
M. and co-workers have reported Biginelli reaction under microwave irradiation in solvent-
free conditions using activated fly ash as catalyst, an industrial waste (pollutant) is an 
efficient and novel catalyst for some selected organic reactions in solvent free conditions 
under microwave irradiation.87 
 
? Ultrasound assisted synthesis 
 Ultrasound as a green synthetic approach has gradually been used in organic synthesis 
over the last three decades. Compared with the traditional methods, it is more convenient, 
easier to be controlled and consumes less power. With the use of ultrasound irradiation, a 
large number of organic reactions can be carried out in milder conditions with shorter 
reaction time and higher product yields.88 Ultrasound irradiated and amidosulfonicacid 
(NH2SO3H) catalyzed synthesis of 3,4-dihydropyrimidi-2-(1H)ones have reported by Li J. T. 
and co-workers89 using aldehydes, β-ketoester and urea. 
 
Liu C. et al.90 have synthesized a novel series of 4-substituted pyrazolyl- 3,4-
dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium perchlorate 
[Mg(ClO4)2] as catalyst (Figure 26), by the condensation of 5-chloro/phenoxyl-3-methyl-1-
phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and urea or thiourea in moderate yields. 
The catalyst exhibited remarkable reactivity and can be recycled. 
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Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of solvent (ethanol) 
or solvent-less dry media (bentonite clay) by supporting-zirconium chloride (ZrCl4)  as 
catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4- tetrahydropyrimidine-
5-carboxylic acid ethyl esters proficiently in high yields, which reported by Harish Kumar et 
al. (Figure 27).91 
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1.5 CURRENT RESEARCH WORK 
 
Our group is involved in the development of various synthetic methodologies for the 
synthesis of functionalized 1,4-DHPs and DHPMs for last few years. Substitution of Nitro 
functionality for COOAlk in the DHPM moiety may alters their biological action. Reports 
reveal that nitro group functionalized dihydropyrimidines which might have potential 
biological activities were less studied. Very promising results may obtain with these 
modifications to DHPM skeleton. This concept prompted us to introduce NO2 group at C5 
position in DHPM skeleton. For this modification ω-nitroacetophenone was required as a 
precursor which was synthesized by reported the procedure in literature.92  
 
During the course of our ongoing interest on the development of useful synthetic 
methodologies by utilizing acid catalysts93, we were observed that bisphosphonic acid is an 
efficient catalyst for the synthesis of pyrimidines via biginelli condensation. In extension of 
this work and to explore further, the utility of etidronic acid as a catalyst in multicomponent 
cyclocondensation reaction, we have synthesized some novel nitro group at C5 bearing 
dihydropyrimidine derivatives using 2-hydroxy-ω-nitro acetophenone instead of 1,3 diketone. 
The reaction of various aryl aldehydes, urea and substituted ω-nitro acetophenone under 
microwave irradiation using etidronic acid as a catalyst and THF as solvent afforded nitro 
functionalized novel DHPMs with excellent yield. The newly synthesized compounds were 
characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. Among 
them, compound 3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one was 
confirmed by X-Ray Diffraction Technique. The detail study of X-Ray Crystallography study 
is described in chapter 6. All the synthesized compounds were screened for in vitro anti-viral 
activity against IIIB and ROD strains.  
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1.6 RESULTS AND DISCUSSION 
 
Etidronic acid [(1-hydroxyethylidene) bisphosphonic acid] is one of the 
bisphosphonic acid derivative and also known as bisphosphonate having molecular formula 
C2H8O7P2. The two PO3 (phosphonate) groups covalently linked to carbon atom (Figure 28).  
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Figure 28: Bisphosphonic acid 
 
It is differ from Polyphosphate ester and polyphosphoric acid. Various bisphosphonic acids 
are known.94,95 Etidronic acid is mild enough as compare to another strong acid such as 
polyphosphoric acid etc. moreover, the catalyst did not affect acid sensitive aldehydes.  
 
 
Scheme-1: Etidronic acid catalyzed one-pot synthesis of nitro functionalized 
dihydropyrimidines under microwave irradiation. 
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Table 1: Optimization of the reaction conditions for the synthesis of 4a 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indeed, condensation of the 1-(2-hydroxyphenyl)-2-nitroethanone 1 with benzaldehyde 2a 
and urea 3 took place smoothly in the presence of EDA in THF resulted in the formation of 
dihydropyrimidine 4a in 89% yield (entry 1, Table 1). We found that the final product 
obtained was dihydro biginelli product 4a (Scheme-1). The condensation of 1 with 2a and 3 
to generate 4a was investigated under a variety of conditions (Table 1), as a test case, to 
optimize the yield, and the results are gathered in Table 1. The condensation took place even 
with a catalytic amount of EDA (10%, entry 3). Though the condensation reaction with a 
catalytic amount of EDA was cleaned, it took a longer time (6 h). On the other hand, the 
reaction was relatively fast (4 hr) when one equiv. of EDA was employed (entry 1). However, 
the reaction carried out under microwave irradiation gave excellent yields (entry 4, 2). The 
yield of desired product 4a was moderate when methanol and ethanol was used as solvent 
(entry 5-8). 
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Entry Catalyst(equiv) Solvent Yield % Time 
1 EDA(1.0) THF 89 4.0 h 
2 EDA(1.0) THF 95 3.5 min 
3 EDA(0.1) THF 86 6.0 h 
4 EDA(0.1) THF 93 3.0 min 
5 EDA(0.1) MeOH 73 11.5 h 
6 EDA(0.1) MeOH 82 6.5 min 
7 EDA(0.1) EtOH 78 9.0 h 
8 EDA(0.1) EtOH 86 5.5 min 
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Table 2: Synthesis of nitro dihydropyrimidines 4a using various catalyst and THF 
under microwave irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the optimized conditions in hand, the reactions of 1 with benzaldehyde 2a and urea 3 
with various bisphosphonic acids were examined to explore the utility of these catalysts in 
multicomponent cyclocondensation reaction under microwave irradiation in THF. We found 
that bisphosphonic acid linked with alkyl amines (Table 2, entry 2-4) or with heterocyclic 
moieties (Table 2, entry 5-8) showed very poor catalytic activity compared to EDA (Table 2, 
entry 1). This can be explained by the fact that electron donating moieties attached with 
bisphosphonic acid at C2 position may decreases the reactivity of these catalysts leading to 
moderate or poor yields of 4a. Thus, it is clear from the aforementioned experiments that the 
best yield of compound 4a could be obtained by employing catalytic amount of etidronic acid 
in THF under microwave irradiation.  
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Entry R Catalyst (equiv) Yield % Time min 
1 -H Etidronic acid (0.1) 93 3.0 
2 -CH2NH2 Pamidronic acid(0.1) 65 9.5 
3 -CH2NH2 Pamidronic acid(1.0) 68 8.0 
4 -(CH2)2NH2 Alendronic acid (0.1) 66 8.0 
5 -(CH2)2NH2 Alendronic acid (1.0) 67 9.5 
6 -3-Pyridyl Risedronic acid (0.1) 55 11.0 
7 -3-Pyridyl Risedronic acid (1.0) 59 9.5 
8 -1-imidazolyl Zoledronic acid (0.1) 45 11.5 
9 -1-imidazolyl Zoledronic acid (1.0) 51 11.0 
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Table 3: Synthesis of nitro functionalized dihydropyrimidines using etidronic acid 
(catalyst) and THF under microwave irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When the reaction of the 1-(2-hydroxyphenyl)-2-nitroethanone 1 with various arylaldehydes 
2a and urea 3 was conducted it was observed that the electron deficiency and nature of the 
substituents on the aromatic ring aldehydes effect the conversion rate; aromatic aldehydes 
having electron-withdrawing groups on the aromatic ring (Table 3, entries 6, 8, 9) reacted 
faster than electron-donating groups (Table 3, entries 2, 11, 12). The synthesized compounds 
were characterized by spectroscopy analysis. In mass spectrum of 4a molecular ion peak 
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Entry  R1 Products Yields (%)  Time min  
MMS-1 H 4a 93 3.0 
MMS-2 3-Cl 4b 86 4.5 
MMS-3 4-OCH3 4c 91 4.0 
MMS-4 4-Cl 4d 89 4.0 
MMS-5 4-F 4e 90 4.5 
MMS-6 3-OCH3 4f 92 3.0 
MMS-7 2-Cl 4g 86 4.5 
MMS-8 4-NO2 4h 93 2.5 
MMS-9 3-NO2 4i 91 3.0 
MMS-10 3,4-di-OCH3 4j 93 3.5 
MMS-11 4-OH 4k 88 4.0 
MMS-12 3-OH 4l 86 4.5 
MMS-13 3-Br 4m 86 4.0 
MMS-14 2,4-di-Cl 4n 89 3.5 
MMS-15 2,5-di-OCH3 4o 91 4.5 
MMS-16 2-NO2 4p 78 3.5 
MMS-17 4-CH3 4q 88 3.0 
MMS-18 2-OH 4r 75 4.0 
MMS-19 2-OCH3 4s 82 3.5 
MMS-20 2-OCH3, 4-NO2 4t 72 4.0 
Ch
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appears at 311 m/z which reveal the formation of dihydropyrimidine. The 1H NMR spectrum 
of 4a displayed one characteristic doublet for the methane proton at 5.74 δ ppm and one –OH 
proton at 9.64 δ ppm. The overall study indicates the catalyst is efficient to synthesize nitro 
dihydropyrimidines. The anti-viral activity results are depicted in table 5. The mechanism for 
the formation of DHPM96 involves acid-catalyzed formation of an N-acyliminium ion 
intermediate of type (Figure 29) from the aldehyde (1) and urea (2) precursors. Interception 
of the iminium ion (4) by ω-nitroacetophenone (5), presumably through its active methylene 
produces an open chain ureide (6) which subsequently cyclizes to hexahydropyrimidine (7). 
Acid-catalyzed elimination of water from (7) ultimately leads to the final DHPM product (8). 
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Figure 29: Mechanism for the formation of DHPM 
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1.7 ANTIVIRAL ACTIVITY 
 
Table 5: The in-vitro anti-viral activity against HIV-1 IIIB and ROD strains using MTT method. 
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Code Name Strain Exp.no. IC50(µg/ml) CC50(µg/ml) SI 
Max Prot 
(%) 
Appr. 
Average 
IC50(µg/ml) 
Average 
CC50(µg/ml) 
SD SI Remarks 
MMS-01 IIIB P3.4836 > 57.3 57.3 1 11 1       
   P3.4842 >60.4 60.4 1 0 1 >60.95 60.95 5.36 <1   
  ROD P3.4837 >68.7 68.7 1 6 1           
    P3.4843 >57.4 57.4 1 1 1 >60.95 60.95 5.36 <1   
MMS-02 IIIB P3.4836 >22.5 22.5 1 15 1       
   P3.4842 >22.5 22.5 1 4 1 >24.28 24.28 5.20 <1   
  ROD P3.4837 >31.9 31.9 1 21 1           
    P3.4843 >20.2 20.2 1 11 1 >24.28 24.28 5.20 <1   
MMS-03 IIIB P3.4836 >20.6 20.6 1 13 1       
   P3.4842 >45.9 45.9 1 1 1 >40.18 40.18 14.23 <1   
  ROD P3.4837 >54 54 1 13 1           
    P3.4843 >40.2 40.2 1 7 1 >40.18 40.18 14.23 <1   
MMS-04 IIIB P3.4836 >10.5 10.5 1 5 1       
   P3.4842 >27 27 1 6 1 >21.88 21.88 10.16 <1   
  ROD P3.4837 >33.2 33.2 1 9 1           
    P3.4843 >16.8 16.8 1 5 1 >21.88 21.88 10.16 <1   
MMS-05 IIIB P3.4836 >15.8 15.8 1 9 1       
   P3.4842 >24.9 24.9 1 0 1 >21.03 21.03 4.01 <1   
  ROD P3.4837 >20.1 20.1 1 8 1           
    P3.4843 >23.3 23.3 1 10 1 >21.03 21.03 4.01 <1   
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MMS-06 IIIB P3.4836 >68.4 68.4 1 14 1       
   P3.4842 >65.3 65.3 1 8 1 >64.83 64.83 9.99 <1   
  ROD P3.4837 >74.6 74.6 1 19 1           
    P3.4843 >51 51 1 8 1 >64.83 64.83 9.99 <1   
MMS-07 IIIB P3.4836 >72.1 72.1 1 7 1       
   P3.4842 >61.1 61.1 1 0 1 >65.60 65.60 12.56 <1   
  ROD P3.4837 >78.9 78.9 1 11 1           
    P3.4843 >50.3 50.3 1 0 1 >65.60 65.60 12.56 <1   
MMS-08 IIIB P3.4836 >75.3 75.3 1 16 1       
   P3.4842 >59.7 59.7 1 6 1 >67.30 67.30 8.09 <1   
  ROD P3.4837 >73.2 73.2 1 10 1           
    P3.4843 >61 61 1 1 1 >67.30 67.30 8.09 <1   
MMS-09 IIIB P3.4842 >44.3 44.3 1 2 1           
   P3.4848 >50.9 50.9 1 0 1 >52.55 52.55 7.52 <1   
  ROD P3.4843 >62.5 62.5 1 10 1           
    P3.4849 >52.5 52.5 1 3 1 >52.55 52.55 7.52 <1   
MMS-10 IIIB P3.4842 >52.9 52.9 1 11 1       
   P3.4848 >53.3 53.3 1 0 1 >50.53 50.53 4.39 <1   
  ROD P3.4843 >51.9 51.9 1 9 1           
    P3.4849 >44 44 1 4 1 >50.53 50.53 4.39 <1   
MMS-11 IIIB P3.4842 >41.8 41.8 1 8 1       
   P3.4848 >41.3 41.3 1 2 1 >41.68 41.68 4.25 <1   
  ROD P3.4843 >36.6 36.6 1 17 1           
    P3.4849 >47 47 1 13 1 >41.68 41.68 4.25 <1   
MMS-12 IIIB P3.4842 >8.75 8.75 1 4 1       
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   P3.4848 >9.04 9.04 1 7 1 >10.75 10.75 2.20 <1   
  ROD P3.4843 >12 12 1 8 1           
    P3.4849 >13.2 13.2 1 6 1 >10.75 10.75 2.20 <1   
MMS-13 IIIB P3.4842 >45 45 1 7 1       
   P3.4848 >62.8 62.8 1 1 1 >61.20 61.20 11.58 <1   
  ROD P3.4843 >64.6 64.6 1 10 1           
    P3.4849 >72.4 72.4 1 9 1 >61.20 61.20 11.58 <1   
MMS-14 IIIB P3.4842 >47.2 47.2 1 9 1       
   P3.4848 >49.8 49.8 1 3 1 >49.60 49.60 2.11 <1   
  ROD P3.4843 >52.3 52.3 1 11 1           
    P3.4849 >49.1 49.1 1 30 1 >49.60 49.60 2.11 <1   
MMS-15 IIIB P3.4842 >60 60 1 6 1       
   P3.4848 >69.1 69.1 1 4 1 >66.35 66.35 6.96 <1   
  ROD P3.4843 >61.4 61.4 1 9 1           
    P3.4849 >74.9 74.9 1 4 1 >66.35 66.35 6.96 <1   
MMS-16 IIIB P3.4842 >49 49 1 5 1       
   P3.4848 >68.3 68.3 1 8 1 >57.15 57.15 8.07 <1   
  ROD P3.4843 >55.8 55.8 1 7 1           
    P3.4849 >55.5 55.5 1 0 1 >57.15 57.15 8.07 <1   
MMS-17 IIIB P3.4842 >70.7 70.7 1 12 1       
   P3.4848 >88.5 88.5 1 0 1 >83.13 83.13 10.66 <1   
  ROD P3.4843 >78.5 78.5 1 12 1           
    P3.4849 >94.8 94.8 1 16 1 >83.13 83.13 10.66 <1   
MMS-18 IIIB P3.4842 >53.7 53.7 1 10 1       
   P3.4848 >61.9 61.9 1 0 1 >57.80 57.80 6.48 <1   
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  ROD P3.4843 >51 51 1 5 1           
    P3.4849 >64.6 64.6 1 7 1 >57.80 57.80 6.48 <1   
MMS-19 IIIB P3.4842 >15.1 15.1 1 16 1       
   P3.4848 >14.8 14.8 1 2 1 >15.63 15.63 1.60 <1   
  ROD P3.4843 >14.6 14.6 1 7 1           
    P3.4849 >18 18 1 0 1 >15.63 15.63 1.60 <1   
MMS-20 IIIB P3.4842 >62.3 62.3 1 9 1     Cryst. 
   P3.4848 >96.3 96.3 1 11 1 >86.38 86.38 16.13 <1 observ. at 
  ROD P3.4843 >94.6 94.6 1 22 1         1 µg/ml 
    P3.4849 >92.3 92.3 1 30 1 >86.38 86.38 16.13 <1   
 
Ch
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From the above results, it has been concluded that the synthesized compounds are inactive against IIIB and ROD strains. 
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1.8 CONCLUSION 
 
In summary, we have demonstrated a simple route for the synthesis of nitro group containing 
dihydropyrimidines via cyclocondensation reaction using etidronic acid as an efficient 
homogeneous catalyst. The use of etidronic acid was well tolerated with a range of aldehydes. 
This protocol is general and provides dihydropyrimidines in good to excellent yields 
depending on the reactivity of arylaldehydes. Thus, the present synthesis of pyrimidines will 
serve as an exclusive method of preparative importance for this class of compounds. 
However, the newly synthesized compounds were inactive against HIV-1 IIIB and ROD 
strains. 
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1.9 EXPERIMENTAL SECTION 
 
1HNMR (400 MHz) and 13CNMR (100 MHz) spectra were recorded in DMSO, and 
TMS was used as an internal reference on a Bruker AVANCE II spectrometer. Mass spectra 
were determined using direct inlet probe on a GCMSQP2010 mass spectrometer. IR spectra 
were recorded on KBr discs, using FTIR-8400 spectrophotometer. The syntheses were 
carried out in a Questron Technologies Corporation QPro-M microwave synthesizer. Melting 
points were measured in open capillaries and are uncorrected. 
 
? General procedure for the synthesis of nitro dihydropyrimidines MMS 1-20. 
To a mixture of various aromatic aldehydes (10 mmol, 2a-n) and urea (10 mmol) in dry THF 
(5 mL) was added etidronic acid (0.1 mmol) and stirred it for 5 min at rt to this add 1-(2-
hydroxyphenyl)-2-nitroethanone (10 mmol) and subjected to microwave irradiation at 360 W 
for appropriate time (Table 3). The reaction was being monitored by TLC. After completion 
of the reaction, the reaction mixture was concentrated under reduced pressure. The separated 
solid was washed with water and followed by methanol, filtered, dried and crystallized from 
glacial acetic acid to furnish analytically pure products.  
 
 
? Spectral data of the synthesized compounds MMS 1-20 
 
3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one (MMS-1): 
Lemon yellow solid; mp 241-243 °C; IR (KBr): 3624, 3076, 2976, 1674, 1554, 1201 cm-1 ; 
1H NMR: δ 5.74 (d, 1H, J=3.16 Hz), 6.90-7.59 (m, 9H, Ar-H), 7.68 (s, 1H, NH), 8.97 (s, 1H, 
NH), 9.64 (s, 1H, OH); 13C NMR: 55.30, 114.54, 116.08, 119.31, 120.38, 126.99, 128.73, 
131.61, 142.12, 146.22, 151.53, 166.05; MS m/z: 311(M+); Anal. Calcd. for C16H13N3O4: C, 
61.73; H, 4.21; N, 13.50%. Found: C, 61.58; H, 4.08; N, 13.33%. 
 
4-(3-chlorophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-2): Yellow solid; mp 255-257 °C; IR (KBr): 3556, 3290, 2901, 1672, 1494, 1218 cm-
1; 1H NMR: δ 5.71 (d, 1H, J=3.52 Hz), 6.91-7.93 (m, 8H, Ar-H), 7.94 (s, 1H, NH), 9.17 (s, 
1H, NH), 9.78 (s, 1H, OH); 13C NMR: 54.40, 115.52, 117.18, 120.25, 122.31, 127.63, 
129.63, 134.63, 145.22, 148.34, 153.53, 163.12; MS m/z: 345(M+); Anal. Calcd. for 
C16H12ClN3O4: C,55.58; H, 3.50; N, 12.15;. Found: C, 55.42; H, 3.38; N, 12.03%. 
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3,4-dihydro-6-(2-hydroxyphenyl)-4-(4-methoxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-3): Pale yellow solid; mp 246-248 °C; IR (KBr): 3649, 3292, 2899, 1678, 1504, 1193 
cm-1; 1H NMR: δ 3.79 (s, 1H, OCH3), 5.65 (d, 1H, J=3.36 Hz), 6.86-7.49 (m, 8H, Ar-H), 7.95 
(s, 1H, NH), 9.42 (s, 1H, NH), 9.71 (s, 1H, OH); 13C NMR: 54.65, 55.28, 113.91, 115.97, 
119.24, 128.22, 128.61, 131.22, 134.45, 135.44, 136.30, 151.52, 159.28, 172.96, 181.34; MS 
m/z: 341(M+); Anal. Calcd. for C17H15N3O5: C, 59.83; H, 4.43; N, 12.31%. Found: C, 59.66; 
H, 4.32; N, 12.18%. 
 
4-(4-chlorophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-4): Lemon yellow solid; mp 250-252 °C; IR (KBr): 3610, 3088, 2928, 1714, 1531, 
1176 cm-1; MS m/z: 345(M+); Anal. Calcd. for C16H12ClN3O4: C, 55.58; H, 3.50; N, 12.15%. 
Found: C, 55.47; H, 3.38; N, 12.13%. 
 
4-(4-fluorophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-5): Yellow solid; mp 262-264 °C; IR (KBr): 3621, 3288, 2968, 1689, 1531, 1186 cm-
1; MS m/z: 329(M+); Anal. Calcd. for C16H12ClN3O4: C, 58.36; H, 3.67; N, 12.76%. Found: 
C, 58.25; H, 3.60; N, 12.65%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(3-methoxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-6): Pale yellow solid; mp 255-257 °C; IR (KBr): 3639, 3312, 2814, 1698, 1494, 1093 
cm-1; MS m/z: 341(M+); Anal. Calcd. for C17H15N3O5: C, 59.83; H, 4.43; N, 12.31%. Found: 
C, 59.69; H, 4.35; N, 12.20%. 
 
4-(2-chlorophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-7): Yellow solid; mp 248-250 °C; IR (KBr): 3567, 3308, 2941, 1721, 1587, 1162 cm-
1; MS m/z: 345(M+); Anal. Calcd. for C16H12ClN3O4: C, 55.58; H, 3.50; N, 12.15%. Found: 
C, 55.50; H, 3.37; N, 12.03%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(4-nitrophenyl)-5-nitropyrimidin-2(1H)-one (MMS-
8): Lemon yellow solid; mp 268-270 °C; IR (KBr): 3487, 3247, 2864, 1688,1499, 1057 cm-1; 
1H NMR: δ 5.82 (d, 1H, J=3.64 Hz), 6.92-7.84 (m, 6H, Ar-H), 8.14 (s, 1H, NH), 8.20-8.22 
(q, 2H, Ar-H), 9.31(s, 1H, NH), 9.76 (s, 1H, OH); MS m/z: 356 (M+); Anal. Calcd. for 
C16H12N4O6: C, 53.94; H, 3.39; N, 15.73%. Found: C, 53.75; H, 3.24; N, 15.56%. 
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3,4-dihydro-6-(2-hydroxyphenyl)-4-(3-nitrophenyl)-5-nitropyrimidin-2(1H)-one (MMS-
9): Lemon yellow solid; mp 247-249 °C; IR (KBr): 3605, 3221, 2928, 1724, 1511, 1084 cm-1 
; MS m/z: 345(M+); Anal. Calcd. for C16H12ClN3O4: C, 55.58; H, 3.50; N, 12.15%. Found: C, 
55.46; H, 3.46; N, 12.08%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(3,4-dimethoxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-10): Yellow solid; mp 264-266 °C; IR (KBr): 3610, 3314, 2957, 1698, 1521, 1096 
cm-1; MS m/z: 371(M+); Anal. Calcd. for C18H17N3O4: C, 58.22; H, 4.61; N, 11.32%. Found: 
C, 58.17; H, 4.48; N, 11.18%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(4-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-11): Yellow solid; mp 237-239 °C; IR (KBr): 3622, 3274, 2904, 1724, 1531, 1210 
cm-1; MS m/z: 327(M+); Anal. Calcd. for C16H13N3O5: C, 58.72; H, 4.00; N, 12.84%. Found: 
C, 58.59; H, 3.88; N, 12.71%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(3-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-12): Yellow solid; mp 248-250 °C; IR (KBr): 3654, 3225, 2965, 1741, 1564, 1157 
cm-1; MS m/z: 327(M+); Anal. Calcd. for C16H13N3O5: C, 58.72; H, 4.00; N, 12.84%. Found: 
C, 58.61; H, 3.86; N, 12.74% 
 
4-(3-bromophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-13): Lemon yellow solid; mp 262-264 °C; IR (KBr): 3610, 3242, 2928, 1714, 1531, 
1176 cm-1; MS m/z: 390(M+); Anal. Calcd. for C16H12BrN3O4: C, 49.25; H, 3.10; N, 10.77%. 
Found: C, 49.17; H, 2.98; N, 10.70%. 
 
4-(2,4-dichlorophenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-14): Lemon yellow solid; mp 244-246 °C; IR (KBr): 3610, 3258, 2932, 1726, 1491, 
1154 cm-1; MS m/z: 380(M+); Anal. Calcd. for C16H11Cl2N3O4: C, 50.55; H, 2.92; N, 11.05%. 
Found: C, 50.47; H, 3.04; N, 11.03%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(2,5-dimethoxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-15): Yellow solid; mp 255-257 °C; IR (KBr): 3574, 3294, 2857, 1718, 1521, 1161 
cm-1; MS m/z: 371(M+); Anal. Calcd. for C18H17N3O4: C, 58.22; H, 4.61; N, 11.32%. Found: 
C, 58.15; H, 4.52; N, 11.18%. 
 
Studies on Bioactive Heterocycles 30
 
Chapter 1  Nitro Functionalized Dihydropyrimidines 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(2-nitrophenyl)-5-nitropyrimidin-2(1H)-one (MMS-
16): Lemon yellow solid; mp 262-264 °C; IR (KBr): 3514, 3317, 2924, 1698,1598, 1107 cm-
1; MS m/z: 356 (M+); Anal. Calcd. for C16H12N4O6: C, 53.94; H, 3.39; N, 15.73%. Found: C, 
53.77; H, 3.29; N, 15.58%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(4-methylphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-17): Pale yellow solid; mp 238-240 °C; IR (KBr): 3608, 3223, 2928, 1734, 1521, 
1167 cm-1; MS m/z: 325(M+); Anal. Calcd. for C17H15N3O4: C, 62.76; H, 4.65; N, 12.92%. 
Found: C, 62.67; H, 4.52; N, 12.83%. 
 
4-(4-(dimethylamino)phenyl)-3,4-dihydro-6-(2-hydroxyphenyl)-5-nitropyrimidin-2(1H)-
one (MMS-18): Lemon yellow solid; mp 250-252 °C; IR (KBr): 3628, 3247, 2936, 1678, 
1511, 1086 cm-1; MS m/z: 354(M+); Anal. Calcd. for C18H18N4O4: C, 61.01; H, 5.12; N, 
15.81%. Found: C, 61.05; H, 5.04; N, 15.73%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(2-methoxyphenyl)-5-nitropyrimidin-2(1H)-one 
(MMS-19): Yellow solid; mp 248-250 °C; IR (KBr): 3658, 3312, 2914, 1727, 1533, 1171 
cm-1; MS m/z: 341(M+); Anal. Calcd. for C17H15N3O5: C, 59.83; H, 4.43; N, 12.31%. Found: 
C, 59.70; H, 4.38; N, 12.25%. 
 
3,4-dihydro-6-(2-hydroxyphenyl)-4-(2-methoxy-4-nitrophenyl)-5-nitropyrimidin-2(1H)-
one (MMS-20): Lemon yellow solid; mp 258-260 °C; IR (KBr): 3605, 3373, 2934, 1722, 
1565, 1106 cm-1; MS m/z: 386(M+); Anal. Calcd. for C17H14N4O7: C, 52.85; H, 3.65; N, 
14.50%. Found: C, 52.67; H, 3.58; N, 14.43%. 
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1H NMR spectrum of compound MMS-1 
  
 
Expanded 1H NMR spectrum of compound MMS-1 
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1H NMR spectrum of compound MMS-2 
 
 
Expanded 1H NMR spectrum of compound MMS-2 
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1H NMR spectrum of compound MMS-6 
 
 
Expanded 1H NMR spectrum of compound MMS-6 
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1H NMR spectrum of compound MMS-7 
 
 
Expanded 1H NMR spectrum of compound MMS-7 
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13C NMR spectrum of compound MMS-1 
 
 
Expanded 13C NMR spectrum of compound MMS-1 
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13C NMR spectrum of compound MMS-7 
 
 
Expanded 13C NMR spectrum of compound MMS-7 
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Mass spectrum of compound MMS-1 
 
 
Mass spectrum of compound MMS-2 
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Mass spectrum of compound MMS-5 
 
 
Mass spectrum of compound MMS-8 
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IR spectrum of compound MMS-1 
 
 
IR spectrum of compound MMS-2 
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IR spectrum of compound MMS-5 
 
 
IR spectrum of compound MMS-7 
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Chapter 2       Synthesis of Trifunctionalized Pyrazoles 
2.1 INTRODUCTION  
 
 Pyrazoles are well known five member heterocyclic compounds and several 
procedures for its synthesis have been extensively studied (Figure 1). Such studies have been 
stimulated by various promising applications, especially in the case of highly substituted 
pyrazole derivatives. In fact, certain substituted pyrazoles are used as analgesic, anti-
inflammatory, antipyretic, agrochemicals whereas some others are being studied for their 
medicinal interest. The pyrazole ring system consists of a doubly unsaturated five member 
ring containing two adjacent nitrogen atoms. The knowledge of such applications has pointed 
out that trisubstituted pyrazole are important target to be prepared to our interest on synthesis 
and molecular structure determination of some types of pyrazole.  
 
N
H
N
 
Figure 1 
 
The discovery of pyrazole derivatives as antipyretic agents dates back to 1884, when the 
German chemist Ludwig Knorr1 attempted to synthesize quinoline derivatives with 
antipyretic activity and accidentally obtained antipyrine (2,3-dimethyl-1-phenyl-3-pyrazolin-
5-one), which has analgesic, antipyretic and antirheumatic activity. Aminopyrine, a more 
potent analogue was synthesized there after and these drugs were widely used in market as 
antipyretics. 
 
2.2 Biological activity of various substituted pyrazoles.  
 Pyrazole derivatives possessed diverse biological activities such as 
antihyperglycemic, analgesic, anti-inflammatory, antipyretic, antibacterial, and sedative-
hypnotic activity, cyclooxygenase-2 (Cox-2) inhibitors, IL-1 synthesis inhibitors, protein 
kinase inhibitors, as well as useful activities in conditions like schizophrenia, hypertension, 
and Alzheimer’s disease.2 In addition, they also have agrochemical properties including 
herbicidal and soil fungicidal activity; thus, they have been used as pesticides and 
insecticides3 which are described briefly as follows.  
 
Anti-inflammatory preparations are widely used in the modern clinic, as pathogenetic agents 
in the treatment of many illnesses and pathological processes, alone or more frequently in 
combination with other drugs. However many of the known anti-inflammatory agents cause a 
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range of side phenomena and complications in addition to the main effect. Consequently the 
search for and study of new more active anti-inflammatory agents of low toxicity is one of 
the urgent problems of contemporary science (Figure 2).4 
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Figure 2 
 
Tanitame A. et al5 have synthesized pyrazole derivatives possesses antibacterial activity and 
inhibitory activity against DNA gyrase and topoisomerase IV. They have synthesized new 
pyrazole derivatives and found that 5-[(E)-2-(5-chloroindol-3-yl)vinyl]pyrazole (Figure 3) 
possesses potent antibacterial activity and selective inhibitory activity against bacterial 
topoisomerases. Many of the synthesized pyrazole derivatives were potent against clinically 
isolated quinolone coumarin-resistant Gram-positive strains and had minimal inhibitory 
concentration values against these strains equivalent to those against susceptible strains. 
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Figure 3 
 
In 2004, Edwards P. J. et al6 have synthesized numerous highly functionalized pyrazole 
derivatives (Figure 4) using various diketone and substituted hydrazine hydrate and screened 
for HIV mediated diseases. Among them such compounds were found to useful in the 
treatment of a variety of disorders including those in which the inhibition of reverse 
transcriptase is implicated. Disorders of interest include those caused by HIV and genetically 
related reteoviruses, such as AIDS. 
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Figure 4 
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Bagley M. C. and co workers7 have synthesized substituted N-pyrazole urea under the 
microwave irradiation. The reaction of substituted hydrazines and β-ketoesters afforded 5-
aminopyrazoles in excellent yield, which can be transformed to the corresponding N-carbonyl 
derivatives by treatment with an isocyanate or chloroformate. Derivatization of 4-
nitronaphth-1-ol using predominantly microwave heating methods and reaction with an N-
pyrazole carbamate provides a rapid route to the N-pyrazole urea BIRB 796 (Figure 5) in 
high purity, as a potent and selective inhibitor of p38a mitogen-activated protein kinase for 
the study of accelerated ageing in Werner syndrome cells. 
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Figure 5 
 
Stein R.G. et al8 have combined the features of the pyrazole ring, a substituted quinoline, 
and an "antimalarial" side chain in one molecule for antimalarial testing. The key 
intermediate required was a 4-chloro-1H-pyrazolo [3,4-b]quinoline (Figure 6), in which the 
active C1 could be replaced with suitable amines expected to impart antimlalarial activity to 
the final products. 
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Figure 6 
 
 
? Biologically active molecules containing alkyl, sulfone and carboxamide 
functional groups  
Pyrazoles bearing sulfones and carboxamide moieties demonstrated to have 
significant pharmacological applications which are discussed as under. 
 
The role of the cyclooxygenase-2 isoform in inflammation9 and the attractiveness of COX-2 
as a therapeutic target for the development of anti-inflammatory drugs are very well 
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recognized.10 COX-2 selective inhibitors have proven to be effective anti-inflammatory and 
analgesic medicines with lower chronic gastrointestinal (GI) toxicity than traditional non-
steroidal anti-inflammatory drugs (NSAIDs), which non-selectively inhibit COX-2 and COX-
1. Prostaglandin (PG)-dependent and PG-independent factors are responsible for NSAID 
induced GI toxicity. Decreased PG production due to COX-1 inhibition may adversely affect 
mucus-bicarbonate secretion, acid secretion, and mucosal blood flow. COX inhibition may 
also elicit an increase in 5-lipoxygenase activity that would potentiate production of 
leukotriene-B4 and vasoconstrictor peptido-leukotrienes by the lipoxygenase pathway, and 
this may also contribute to the vascular and other mucosal damage induced by 
NSAIDs11Celecoxib (Figure 7) is one of the COX-2 selective inhibitors and are currently 
prescribed for the treatment of arthritis and inflammatory diseases. They show anti-
inflammatory activity with reduced GI side effects. 
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Figure 7 
 
Sondhi S. M. et al12 were carried out anti-inflammatory and analgesic activity of some 
amidine and hydrazone derivatives which possess sulfone group (Figure 8). The anti-
inflammatory activity was carried out using carrageenin-induced paw edema assay and 
Analgesic activity evaluation was carried out using acetic acid writhing assay. 
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Figure 8 
 
Moreover, Propargylic sulfones are known as pH-dependent DNA cleaving agents. In this 
context, Nishimoto S. et al13 have designed a novel propargylic sulfone conjugated with an 
anthraquinone structure and evaluated its DNA binding and cleavage characteristics. The 
propargylic sulfone (Figure 9) showed high intercalating ability attributable to anthraquinone 
chromophore, leading to the efficient alkylation of DNA. The anthraquinone chromophore in 
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also acted as a photosensitizer and photoirradiation of this sulfone with DNA induced one-
electron oxidation, resulting in the further DNA cleavage. Evaluation of the effect of 
propargylic sulfone against EMT6/KU cells revealed that it exhibited potent cytotoxicity, 
even without photoirradiation. 
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Figure 9 
 
The synthesis of a series of novel pyrazoles containing a nitrate (ONO2) moiety as a nitric 
oxide (NO)-donor functionality was reported by Ranatunge R. R. and coworkers.14 Their 
COX-1 and COX-2 inhibitory activities in human whole blood were profiled and 
demonstrates that pyrazole ring substituents play an important role in COX-2 selective 
inhibition, such that a cycloalkyl containing pyrazole was found to be a potent and selective 
COX-2 inhibitor. Other modifications at the 3 position of the central pyrazole ring enhanced 
COX-2 inhibitory potency. Among the pyrazoles synthesized, the oxime (Figure 10) was 
identified as the most potent COX-2 selective inhibitor.  
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Figure 10 
 
In addition, Bonacorso H. G. et al15 have synthesized some novel N-substituted pyrazoles 
containing sulfone and trifluoromethyl groups at N and C5 position of pyrazole ring (Figure 
11) and evaluated for antimicrobial activity. All the synthesized compounds were shown 
promising antimicrobial activity. The best activity was obtained when the structure possessed 
a 4-fluorophenyl substituent linked at the carbon-3 of the pyrazoline ring. 
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Figure 11 
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The identification of several potent pyrazole-based inhibitors of bacterial dihydroorotate 
dehydrogenase (DHODase) via a directed parallel synthetic approach is described below 
(Figure 12). The initial pyrazole-containing lead compounds were optimized for potency 
against Helicobacter pylori DHODase.16 Using three successive focused libraries, inhibitors 
were rapidly identified with the following characteristics: Ki<10 µM against H. pylori 
DHODase, sub-µg/mL H. pylori minimum inhibitory concentration activity, low molecular 
weight, and >10 000-fold selectivity over human DHODase.  
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Figure 12 
 
Helicobacter pylori is a Gram-negative microaerophilic bacterium that infects up to 50% of 
the world’s human population.17 H. pylori resides in the acidic surroundings of the stomach, 
utilizing a high urease enzyme activity to provide a locally alkaline environment. H. pylori 
has been implicated in numerous gastrointestinal disorders and is associated with gastric 
ulcers, gastritis, and gastric cancer.18 The current treatment of H. pylori infections typically 
utilizes a multiple drug therapy involving at least one broad spectrum antibiotic 
(antimicrobial therapy) and a proton pump inhibitor (antisecretory therapy). However, a H. 
pylori specific antimicrobial would be very desirable; a specific agent should avoid many of 
the negative gastrointestinal side effects associated with a broad spectrum antibacterial 
resulting from eradication of the normal gastrointestinal flora. 
 
2.3 Synthesis of functionalized pyrazole derivatives using various synthetic 
approaches 
In 2005, Sakya S. M. et al19 have offered fluoride-mediated nucleophilic substitution 
reactions of 1-(4-methylsulfonyl (or sulfonamido)-2-pyridyl)-5-chloro-4- cyano pyrazoles 
(Figure 13) with various amines and alcohols under mild conditions. The further reaction of 
novel pyrazoles provides the 5-alkyl amino and ether pyrazoles in moderate to high yields. 
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Figure 13 
 
Recently, Dong D. and coworkers20 have developed an efficient and divergent synthesis of 
fully substituted 1H-pyrazoles using cyclopropyl oximes (Figure 14). Under Vilsmeier 
conditions (POCl3/DMF), substituted 1H-pyrazoles were synthesized from 1-carbamoyl, 1-
oximyl cyclopropanes via sequential ring-opening, chlorovinylation, and intramolecular aza-
cyclization. 
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Figure 14 
 
A novel approach to the synthesis of pyrazole derivatives from tosylhydrazones of α,β-
unsaturated carbonyl compounds possessing a β-hydrogen was proposed by Rosa R. and 
coworkers (Figure 15),21 exploiting microwave (MW) activation coupled with solvent free 
reaction conditions. The cycloaddition was studied on three ketones (trans-4-phenyl-3-buten-
2-one, β-ionone and trans-chalcone). The corresponding 3,5-disubstitued-1H-pyrazoles were 
obtained in high yields and after short reaction times. 
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Figure 15 
 
Tang L. et al22 have synthesized the pyrazole analogs (Figure 16) from a common aryl 
isocyanide intermediate. The cyclization of isocyanide with the oxime or BOC-protected 
hydrazones of ethyl bromopyruvate furnished the pyrazole carboxy esters. 
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Figure 16 
 
Kim J. N. et al23 have reported the regio-selective synthesis of 1,3,4,5-tetrasubstituted 
pyrazole derivatives from the reaction of Baylis-Hillman adducts of alkyl vinyl ketone and 
hydrazine derivatives (Figure 17). During the continuous studies on the chemical 
transformations of Baylis-Hillman adducts including the synthesis of pyrazole. 
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Figure 17 
 
Junjappa H. et al24 have developed highly efficient and regioselective synthesis of 1-aryl-3,4-
substituted/annulated-5-(methylthio)-pyrazoles and 1-aryl-3-(methylthio)-4,5-substituted/ 
annulated pyrazoles via cyclocondensation of arylhydrazines with either α-oxoketene 
dithioacetals or α-oxodithioesters (Figure 18). 
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Elgemeie G. H. et al25 were readily prepared novel ketene N,S-acetals by the reaction of 
cyanoacetamide or cyanothioacetamide with phenylisothiocyanate in the presence of 
potassium hydroxide, followed by alkylation of the produced salts with methyl iodide. 
Further, the reaction of ketene N,S-acetals with hydrazine afforded different substituted 
pyrazoles in excellent yields (Figure 19). 
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Figure 19 
 
Junjappa H. et al26 have demonstrated that 1-bis(methoxy)-4-bis(methylthio)-3-buten-2-one 
has been to a useful three carbon synthon for efficient regiospecific synthesis of a variety 
pyrazoles with mask or unmask aldehyde functionality by cyclocondensation with hydrazine 
hydrate in alcohol (Figure 20). 
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Kuettel S. et al27 have synthesized 4-(3-phenylisoxazol-5-yl)morpholine derrivatives (Figure 
21) using ketene dithioacetals. The reaction of substituted acetophenones with carbon 
disulfide in the presence of base and followed by alkylation with methyl iodide afforded 4-
phenoxyphenyl-2,2- bis(methylthio)vinyl ketones, which were further reacts with hydrazine 
hydrate to give substituted pyrazoles through in situ cyclization of the resulting N,S-acetals. 
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Figure 21 
 
Kurz T. et al28 have synthesized novel fluorinated ketene N,S-acetals by the reaction of 
fluorosubstituted cyanoacetamide derivatives with arylisothiocyanate in the presence of 
potassium hydroxide, followed by the alkylation with methyl iodide. The reaction of 
fluorinated ketene N,S-acetals with hydrazine afforded different fluorosubstituted pyrazole 
derivatives in good yield (Figure 22). 
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Figure 22 
 
Elgemeie G. H. et al29 synthesized  variety of novel α-cyanoketene S,S-acetals, readily 
prepared by the reaction of cyanoacetanilides or cyanothioacetamide with carbon disulfide, 
followed by alkylation, react smoothly with nucleophile to afford variously substituted 
methylthio derivatives of pyrazole (Figure 23). 
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? Synthesis of functionalized pyrazoles using combinatorial chemistry approach. 
In recent decades, combinatorial chemistry tools have enabled the rapid synthesis of a 
large number of heterocyclic small molecule libraries and it is recognized now as a key 
element of early drug discovery.30 The main advantage of the combinatorial technique is the 
speed at which diverse types of organic compounds can be synthesized, formulated, and 
tested for a particular application. Moreover, in combinatorial study the quantity of required 
material is less in comparison to conventional methods, which makes it more suitable when 
the materials are expensive.31 
 
In 2009, Laborde E. et al32 have developed an efficient three-component, two-step “catch and 
release” solid-phase synthesis of 3,4,5-trisubstituted pyrazoles (Figure 24). The reaction 
involves a base-promoted condensation of a 2-sulfonyl acetonitrile derivative 1 with an 
isothiocyanate 2 and in situ immobilization of the resulting thiolate anion 3 on Merrifield 
resin. Reaction of the resin-bound sulfonyl intermediate 4 with hydrazine, followed by 
release from the resin and intramoleculer cyclization, afforded 3,5-diamino-4-(arylsulfonyl)-
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1H-pyrazoles 5. However, this methodology has some drawback such as; long reaction time, 
isolation of product and high reaction temperature.  
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Figure 24 
 
Recently, Laufer, S. et al33 have synthesized structurally diverse and medicinally interesting 
series of 1, 4-dihydropyrano[2,3-c]pyrazoles via a three-component reaction using solution 
phase synthesis in excellent yields (Figure 25). 
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Figure 25 
 
Ivachtchenko A. V. et al34 have reported the parallel solution-phase approach of more than 
2200 7-trifluoromethyl-substituted pyrazole[1,5-a]pyrimidine (Figure 26) and 4,5,6,7-
tetrahydropyrazolo[1,5-a]pyrimidine carboxamides on a 50-100-mg scale. The reactions were 
include assembly of the pyrazole[1,5-a]pyrimidine ring by condensation of 5-aminopyrazole 
derivatives with the corresponding trifluoromethyl-α-diketones. The libraries from libraries 
were then obtained in good yields and purities using solution-phase acylation and reduction 
methodologies. Simple manual techniques for parallel reactions using special CombiSyn 
synthesizers were coupled with easy purification procedures (crystallization from the reaction 
mixtures) to give high-purity final products.  
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Figure 26 
Studies on Bioactive Heterocycles 56
Chapter 2       Synthesis of Trifunctionalized Pyrazoles 
Yang H. Z. et al35 have developed a small combinatorial library containing pyrazolyl- 
pyrazoles and pyrazole[1,5-a]pyrimidines (Figure 27) by traditional organic synthesis and 
parallel-liquid-phase combinatorial synthesis using α-S,S-acetal of ethyl cyanoacetate as key 
synthon and hydrazine hydrate. 
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Figure 27 
 
Organ M. G. et al36 have developed a library of 4-(5-Iodo-3-Methylpyrazolyl)Phenyl- 
sulfonamide derivatives (Figure 28) via solution-phase Suzuki coupling using Pd/C as a 
solid-supported catalyst. 
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Figure 28 
 
Taddei M. et al37 have developed the libraries of substituted pyrazole through in situ 
generation of polymer-bound enaminones (Figure 29). The synthetic protocol makes use of 
commercially available aniline cellulose, a low-cost and versatile biopolymer, under very 
mild conditions. This new support allowed carrying out reactions in polar solvents under both 
conventional heating and MW irradiation without degradation of the polymer. The reaction 
between cellulose-bound enaminones and hydrazine to afford the target heterocycles in high 
yields directly in solution is the key step. The support can be conveniently recycled. 
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Figure 29 
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2.4 Various oxidizing agent for oxidation of sulfide to sulfones. 
Functional group oxidation is a fundamental process in organic synthesis, and an 
enormous range of reagents, reagent combinations and conditions is available for almost 
every conceivable type of oxidative transformation. The search for new, modified and 
improved procedures continues unabated, however, driven largely by the need for higher 
efficiency and cleaner selectivity and, to an increasingly significant extent, by economic and 
environmental constraints. Exquisite selectivity can be achieved for some functional group 
oxidations,38 especially for small scale laboratory operations, but for most transformations, 
and for larger scale applications in particular, the ultimate objective of cheap, safe oxidation 
under catalytic conditions has not been reached. The use of stoichiometric amounts of 
oxidizing agents will therefore necessarily continue until that goal is attained.  
The cheapest oxidizing agents are air, chlorine and nitric acid, all of which have important 
uses. Each also has associated disadvantages and/or limitations:  
(i)Air: the need for heterogeneous catalysts or biocatalysts; often rather poor 
selectivity; and high capital plant costs.  
(ii)Chlorine: side reactions due to chlorination; environmental problems, especially in 
effluent disposal.  
(iii)Nitric acid: limited selectivity in oxidation; side reactions; generation of nitrogen 
oxides. 
 
The fourth cheapest oxidant is hydrogen peroxide, which is environmentally friendly and 
relatively easy to handle. However, it is quite a weak oxidizing agent which often requires 
specific activation towards the functional group to be transformed. The persalts such as; 
sodium percarbonate or sodium perborate one, means of providing such activation; they are 
also granular solids which can be an additional handling advantage in small to medium scale 
synthetic work.  
 
In this context recently, Habibi D. et al39 have developed a process for chemoselective 
catalytic oxidation of sulfides. A variety of aliphatic and aromatic sulfides were subjected to 
the sulfoxidation reaction by treatment of SPB and/or SPC, silica sulfuric acid (SSA) and 
catalytic amounts of KBr in the presence of wet SiO2 (50% w/w) in dichloromethane at room 
temperature with moderate to good yields (Figure 30). 
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Figure 30 
 
In addition, Kappe O. et al40 were synthesized 2-substituted pyrimidines via sequential 
oxidation of 2- methylthiodihydropyrimidines with manganese dioxide and then with oxone 
to provide 2-methylsulfonyl-pyrimidines (Figure 31) which on nucleophilic displacement of 
the reactive sulfonyl group with nitrogen, oxygen, sulfur, and carbon nucleophiles afforded 
substituted pyrimidines. 
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Figure 31 
 
A survey of the literature41 revealed that a adduct between H2O2 and urea (UHP) is a cheap, 
safe and stable source of pure H2O2 for oxidation. Several systems containing UHP with 
some acid anhydrides were used as efficient oxidizing agents for sulfides (Figure 32).  
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Moreover, a review42 of literature reveled that the SPB (Figure 33) has been proved an 
efficient and excellent reagent for the oxidation of thiols and selenols to disulfides and 
diselenides, and of sulfides to sulfones.  
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2.5 CURRENT RESEARCH WORK 
 
The pyrazole nucleus is present in a wide variety of biologically  interesting 
compounds, which exhibit antihyperglycemic, analgesic, anti-inflammatory, antipyretic, 
antibacterial, hypoglycemic, sedative-hypnotic activity.1-5 As we described, the tremendous 
biological potential of the sulfone group and carboxamide group bearing pyrazole scaffolds 
have attracted many chemists to synthesize this class of molecules. Thus, continuous efforts 
have been devoted to the development of general and versatile synthetic methodologies to 
this class of compounds. Many research groups have been synthesized pyrazole derivatives 
using various methods. However, the existing methods suffered with some drawbacks such 
as; long reaction time, product isolation, etc. Thus, the practical synthesis of structurally 
diverse pyrazole based small molecules is of great significance. 
 
Nowadays, a great deal of effort has been focused on the field of green chemistry in adopting 
methods and processes. As a part of this “green” concept, toxic and/or flammable organic 
solvents are replaced by alternative non-toxic and nonflammable media. In this context, many 
efforts have been made to use aqueous media. Among alternative green solvents, water has 
been the solvent of choice for a variety of transformations.21 On the other hand; 
functionalized ketene dithioacetals are versatile intermediates in organic synthesis for the 
construction of substituted heterocycles. Given the importance of sulfone and carboxamide 
groups containing pyrazoles, and our ongoing interest on the synthesis various heterocycles 
using novel ketene dithioacetals starting from acetoacetanilides, encouraged us to utilize the 
novel ketene dithioacetals for the construction of small molecule library of 3-methyl-5-
(methylsulfonyl)-N-aryl-1H-pyrazole-4-carboxamide derivatives in aqueous medium. The 
newly synthesized compounds were characterized by IR, Mass, 1H NMR, 13C NMR 
spectroscopy and elemental analysis. The biological screening of the synthesized compounds 
is under process. Chemical purity of all the newly synthesized compounds was examined by 
UPLC. 
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2.6 RESULTS AND DISCUSSION 
 
Scheme 1: Water mediated synthesis of pyrazoles containing methyl, sulfone and 
carboxamide groups. 
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A series of various α-AKDTAs 1a-w was prepared by some modification in reported 
procedure.43 Initially, condensation of α -AKDTA 1a with hydrazine hydrate 2 took place 
smoothly in isopropyl alcohol reflux to afford the 3-methyl-5-(methylsulfonyl)-N-phenyl-1H-
pyrazole-4-carboxamide 3a in good yield (Scheme 1; Table 1, entry 1). The condensation of 
1a with 2 to generate pyrazole 3a was investigated using a variety of solvents, as a part of the 
“green chemistry” concept and to optimize the yield, and the results are summarized in Table 
1. 
 
Table 1: Synthesis of 3-methyl-5-(methylthio)-N-phenyl-1H-pyrazole-4-carboxamide 
using variety of solvents. 
Entry Solvents Time h Yield % 
1 iPrOH 2.8 85 
2 MeOH 4.0 81 
3 EtOH 3.5 83 
4 THF 4.5 79 
5 CH3CN 4.0 75 
6 Dioxane 3.5 80 
7 Water 3.0 97 
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The condensation reaction was clean in water and the yield of desired product was higher 
(Entry 7, Table 1). On the other hand, the reaction was relatively fast when iPrOH was used 
as a solvent with 12% lower yield (Entry 1, Table 1). The yield of desired product was 
reasonable when MeOH, EtOH and dioxane were used as a solvent (Entry 2,3,6, Table 1). 
The other solvents THF and acetonitrile gave lower yield with higher reaction time (Entry 
4,5, Table 1). Thus, it is clear from the aforementioned experiments that the best yield of 
pyrazoles 3a could be obtained by employing water as a solvent. 
 
To test generality of the condensation and to realize synthesis of a small combinatorial library 
of  substituted pyrazoles various α-AKDTAs were reacted with hydrazine hydrate to furnish 
pyrazoles 3a-w in excellent yield using water as a solvent (Scheme 1, Table 2). The 
synthesized compounds were characterized by spectral data. The 1H NMR spectra of 
compound 3c displayed characteristic singlet for methyl, mehtylthio and methoxy hydrogen, 
respectively, at δ 2.54, 2.64 and 3.92. The two singlets appeared for pyrazole NH at δ 10.12 
and amide hydrogen at δ 9.62 which revealed the formation of pyrazole ring.  
 
Table 2: 3-mehtyl, 5-methylthio, 4-carboxamide substituted pyrazoles. 
Entry R Time h Yield % mp ºC 
3a Ph 3.0 97 120-122 
3b 4-CH3Ph 3.5 95 125-127 
3c 4-OCH3Ph 3.0 96 118-120 
3d 4-FPh 2.8 94 132-134 
3e 2-OCH3Ph 2.9 92 126-128 
3f 2-CH3Ph 3.2 93 122-124 
3g 4-ClPh 3.8 94 128-130 
3h 4-EtPh 3.5 95 130-132 
3i 4-NO2Ph  2.5 91 135-137 
3j 3-Cl,4-FPh 3.2 90 128-130 
3k 5-Cl,2-MeOPh 3.0 93 136-138 
3l 2,5-diClPh 3.4 89 126-128 
3m 2,5-diCH3Ph 3.2 91 122-124 
3n 4-Cl,2-CH3Ph 2.9 94 121-123 
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3o 3,4-diFPh 3.2 93 130-132 
3p 2-ClPh 3.5 94 142-144 
3q 2-FPh 3.5 96 133-135 
3r 4-BrPh 4.0 95 121-123 
3s 3,4-diClPh 4.0 90 151-152 
3t 3-NO2Ph 3.2 88 115-117 
3u 3-CH3Ph 3.5 94 165-167 
3v 2,3-diCH3Ph 3.8 85 158-160 
3w 2-OCH3,4-NO2Ph 4.0 96 148-150 
 
 
Since, the remarkable utility of sulfone group in pharmaceutical and to develop library of 
pyrazole and isoxazole functionalized with alkyl, carboxamide and sulfone, we next planned 
to oxidize the sulfides to sulfones. Although sulfides can be easily oxidized by a wide variety 
of oxidizing reagents, but unfortunately, some of these reagents are not satisfactory for the 
oxidation of sulfide to sulfone due to low yields of products, toxicity and expensive reagents 
or catalysts.44 the reaction condition for oxidation of sulfide to sulfone was optimized with 
variety of oxidizing agent in various solvent (Table 3). 
 
Table 3: Optimization of the reaction condition for oxidation of 3a to its sulfone.  
 
Entrya Oxidant b Solvent Yieldc % Time min 
1 mCPBA CH2Cl2 74 125 
2 mCPBA Acetone 56 95 
3 mCPBA Water 65 75 
4 SPB CH2Cl2 79 110 
5 SPB Acetone 62 95 
6 SPB Water 91 60 
7 SPC CH2Cl2 59 120 
8 SPC Acetone 52 90 
9 SPC Water 75 60 
aAll solution-phase reactions were heated at reflux temperature of the solvent used. bOxidant: mCPBA-2 equiv, SPB-3 equiv 
and SPC-3 equiv. cIsolated yield after purification. 
Studies on Bioactive Heterocycles 63
Chapter 2       Synthesis of Trifunctionalized Pyrazoles 
The results gathered in table 3, indicate that when dichloromethane was used as a solvent the 
yield of sulfone was higher with mCPBA as compared to SPC and SPB, but it required high 
reaction time (Entry 1,4,7, Table 3). The yields of desired products were very poor when 
acetone was used as solvent and the products were isolated using column chromatography 
(Entry 2,5,8, Table 3). The best results were obtained when water was used as solvent with 
the SPB and the sulfide underwent oxidation to the corresponding sulfone in 45 min with 
excellent yield (Entry 6, Table 3). However, an excess amount of SPC did not improve yield. 
When the amount of SPB was reduced, the yield of desired product was lower. The above 
results indicate, the cheap, environmentally friendly and effective oxidizing agent in water 
was SPB and gave quantitatively yield of product without use of any activator. With this 
oxidizing system, all the synthesized pyrazoles were oxidized to generate sulfone containing 
pyrazoles and isoxazole based small molecule library using solution phase synthesis and the 
results are gathered in table 4.  
 
Table 4: 3-mehtyl, 5-sulfone, 4-carboxamide functionalized library of pyrazoles. 
 
Entry R Time min Yield % mp ºC 
HPMS-1 Ph 60 91 168-170 
HPMS-2 4-CH3Ph 45 92 172-174 
HPMS-3 4-OCH3Ph 55 89 166-168 
HPMS-4 4-FPh 50 88 175-177 
HPMS-5 2-OCH3Ph 60 90 170-172 
HPMS-6 2-CH3 50 94 165-167 
HPMS-7 4-ClPh 55 89 173-175 
HPMS-8 4-EtPh 65 92 177-179 
HPMS-9 4-NO2Ph 55 92 181-183 
HPMS-10 3-Cl,4-FPh 50 91 176-178 
HPMS-11 5-Cl,2-OCH3Ph 50 93 186-188 
HPMS-12 2,5-diClPh 65 88 176-178 
HPMS-13 2,5-diCH3Ph 60 87 170-172 
HPMS-14 4-Cl,2-CH3Ph 55 89 171-173 
HPMS-15 3,4-diFPh 50 85 181-183 
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HPMS-16 2-ClPh 60 91 186-188 
HPMS-17 2-FPh 50 88 172-174 
HPMS-18 4-BrPh 60 89 181-182 
HPMS-19 3,4-diClPh 55 92 167-168 
HPMS-20 3-NO2Ph 65 78 154-156 
HPMS-21 3-CH3Ph 55 86 169-171 
HPMS-22 2,3-diCH3Ph 60 90 184-186 
HPMS-23 2-OCH3,4-NO2Ph 65 92 154-156 
 
 
 
 
The chemical purity of all the newly synthesized compounds was examined using UPLC. 
Among all the final compounds, compound HPMS-11 has shown less than 95% chemical 
purity and other shown more than 95% chemical purity (Figure 34). The 1H NMR spectrum 
of pyrazole HPMS-10 displayed two characteristic singlets for methyl and methylthio proton, 
respectively, at δ 2.53 and 3.64. However, two singlets appeared for pyrazole NH at δ 12.97 
and amide hydrogen at δ 9.61. 
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Figure 34: Chemical purity of trifunctionalized pyrazoles using UPLC. 
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The mechanism (Figure 35), in ketene dithioacetal system the carbonyl carbon and β-carbon 
atoms regarded as hard and soft electrophilic centers, since the carbonyl carbon is adjacent to 
the hard-base oxygen while the β-carbon is flanked by the soft-base methylthio groups. Thus, 
the binucleophile hydrazine hydrate attack on β-carbon of systems and formed heterocyclic 
product by removal of methylthio and group as good leaving group and water molecule. The 
pyrazoles on oxidation by sodium perborate afford sulfone containing pyrazoles.  
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Figure 35: Proposed mechanism for the formation of pyrazole. 
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2.7 CONCLUSION  
 
In Summary, we have synthesized solution-phase library of pyrazoles functionalized with 
methyl, sulfone and carboxamide groups in two steps with excellent yield and chemical 
purity for biological interest. Water was emerged as an efficient and green solvent in the 
condensation reaction of various ketene dithioacetals with hydrazine hydrate. Further, the 
facile synthesis of sulfone containing pyrazoles was achieved via oxidation of sulfide to 
sulfone. A comparative study of various oxidants has been performed, and revealed that SPB 
is more efficient and effective for oxidation of sulfide to sulfone in aqueous medium. This 
procedure offers a good scope for the synthesis of a wide variety of pyrazoles containing 
caboxamide and sulfone in two steps with excellent yield, purity and simple isolation of 
products. 
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2.8 EXPERIMENTAL SECTION 
 
Melting points were determined in open capillaries and are uncorrected. Thin-layer 
chromatography was accomplished on 0.2-mm precoated plates of silica gel G60 F254 
(Merck). Visualization was made with UV light (254 and 365nm) or with an iodine vapor. IR 
spectra were recorded on a FTIR-8400 spectrophotometer using DRS prob. 1H (400 MHz) 
and 13C (100 MHz) NMR spectra were recorded on a Bruker AVANCE II spectrometer in 
CDCl3. Chemical shifts are expressed in δ ppm downfield from TMS as an internal standard. 
Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 mass 
spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary evaporator. 
Chemical purity was determined on Waters Acquity UPLC with PDA Detector using Acquity 
BEH C18, 50 × 2.1, 1.7µm column at 210-400nm. 
 
? Gradient Program for UPLC 
Mobile Phase: A - 10 mM Ammonium dihydrogenphosphate pH = 2.5, 
 B – Acetonitrile 
 
Entry Time Flow %A %B 
1 Initial 0.2 mL 95 05 
2 4.0 0.2 mL 05 95 
3 4.1 0.2 mL 95 05 
4 5.0 0.2 mL 95 05 
 
 
? General procedure for the synthesis of various α-acylketene dithioacetals 1a-w. 
To a well-stirred suspension of sodium tert-butoxide (30 mmol) in THF (15 mL) at 0-
5 ºC was added CS2 (15 mmol) diluted with 10 mL THF along with N-(aryl)-3-
oxobutanamide (15 mmol) over a period of 30 min. After completion of the addition, the 
reaction mixture was stirred at 0-5 ºC for 1.0 h. Appearance of reddish solid in the reaction 
medium indicated the formation of disodium salt. To this reaction, a solution of methyl iodide 
(30 mmol) in THF (5 mL) was added dropwise within 15 min at 0-5 ºC. The mixture was 
allowed to warm to room temperature and stirred for 5 h, and then poured onto crushed ice 
under stirring. The separated solid was collected by filtration, washed with water (2 × 100 
mL), dried in vacuo and crystallized from chloroform to furnish the analytically pure 
products in excellent yield.  
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? General procedure for the synthesis of trisubstituted pyrazoles 4a-w. 
To a suspension of various α-acylketene dithioacetals 1a-w (10 mmol) in water (25 
mL), hydrazine hydrate 80% (20 mmol) was added and the reaction mixture was refluxed for 
appropriate time (Table 2) with constant stirring. After completion of the reaction, the 
reaction mixtures were cooled to room temperature and add cold water (50 mL). The 
separated solid was filtered, washed with water (2 × 50 mL), dried and crystallized from 
methanol to afford analytically pure products which were used for next step without further 
purification. 
 
? General procedure for the oxidation of sulfide to sulfones HPMS 1-23. 
The appropriate compound 3a-w (6 mmol) in water (15 mL) was added sodium per 
borate (18 mmol) and the resulting mixture was then heated to reflux for appropriate time 
(Table 2). The mixture was cooled to room temperature and extracted with ethyl acetate (2 × 
15 mL). The organic layer was washed with water (2× 20 mL) and dried over magnesium 
sulphate. The solvent was evaporated at room temperature and product was isolated by 
crystallization technique in excellent yield. 
 
3-methyl-5-(methylsulfonyl)-N-phenyl-1H-pyrazole-4-carboxamide (HPMS-1): White 
solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3250, 3230, 3032, 2926, 1647, 1548, 1281 cm-1; 
1H NMR: δ 2.54 (s, 3H, CH3), 3.63 (s, 3H, CH3), 7.11-7.15 (t, 1H, ArH), 7.68-7.73 (m, 2H, 
ArH), 7.83 (d, J=8.1 Hz, 2H, ArH), 9.60 (s, 1H, NH), 12.86 (s, 1H, NH); 13C NMR: δ 12.32, 
46.92, 111.51, 121.38, 132.86, 138.57, 143.02, 154.13, 162.55; MS (m/z): 279 (M+); Anal. 
Calcd for C12H13N3O3S: C, 51.60; H, 4.69; N, 15.05; Found: C, 51.48; H, 4.56; N, 15.12. 
 
N-(4-methylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
2): White solid; Rf 0.35 (6:4 hexane-EtOAc); IR (KBr): 3242, 3211, 3029, 1647, 1596, 1435, 
1247 cm-1; 1H NMR: δ 2.37 (s, 3H, CH3), 2.58 (s, 3H, CH3), 3.66 (s, 3H, CH3), 7.22-7.28 (t, 
2H, ArH), 7.61 (d, J=7.5 Hz, 1H, ArH), 7.63 (J=7.8 Hz. 1H, ArH), 9.79 (s, 1H, NH), 12.97 
(s, 1H, NH); 13C NMR: δ 12.37, 18.26, 46.89, 114.64, 120.03, 121.60, 129.51, 134.27, 
136.27, 138.93, 146.66, 158.36, 161.09; MS (m/z): 293 (M+); Anal. Calcd for C13H15N3O3S: 
C, 53.23; H, 5.15; N, 14.32; Found: C, 53.08; H, 5.13; N, 14.19. 
 
N-(4-methoxyphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
3): White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3252, 3214, 2985, 1675, 1598, 1548, 
1124 cm-1; MS (m/z): 309 (M+); Anal. Calcd for C13H15N3O4S: C, 50.48; H, 4.89; N,  
13.58; Found: C, 50.36; H, 4.73; N, 13.45. 
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N-(4-fluorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
4): White solid; Rf 0.37 (6:4 hexane-EtOAc); IR (KBr): 3242, 3124, 2985, 1658, 1518, 1489, 
1214 cm-1; MS (m/z): 297 (M+); Anal. Calcd for C12H12FN3O3S: C, 48.48; H, 4.07; N, 14.13; 
Found: C, 48.34; H, 3.93; N, 14.03. 
 
N-(2-methoxyphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
5): White solid; Rf 0.37 (7:3 hexane-EtOAc); IR (KBr): 3272, 3164, 2885, 1695, 1527, 1448, 
1264 cm-1; 13C NMR: δ 12.50, 46.98, 55.87, 110.27, 114.64. 120.43, 121.10, 123.60, 128.13, 
138.03, 148.62, 153.12, 161.19; MS (m/z): 309 (M+); Anal. Calcd for C13H15N3O4S: C, 50.48; 
H, 4.89; N, 13.58; Found: C, 50.38; H, 4.79; N, 13.44. 
 
N-(2-methylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
6): White solid; Rf 0.38 (6:4 hexane-EtOAc); IR (KBr): 3233, 3114, 2945, 1675, 1588, 1448, 
1164 cm-1; MS (m/z): 293 (M+); Anal. Calcd for C13H15N3O3S: C, 53.23; H, 5.15; N, 14.32; 
Found: C, 53.11; H, 5.09; N, 14.21. 
 
N-(4-chlorophenyl)-3-methyl-5-(methysulfonyl)-1H-pyrazole-4-carboxamide (HPMS-7): 
White solid; Rf 0.35 (6:4 hexane-EtOAc); IR (KBr): 3252, 3214, 2985, 1675, 1598, 1548, 
1124 cm-1; MS (m/z): 313 (M+); Anal. Calcd for C12H12ClN3O3S: C, 45.94; H, 3.85; N, 13.39; 
Found: C, 45.83; H, 3.74; N, 13.27.  
 
N-(4-ethylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-8): 
White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3242, 3224, 2985, 1676, 1578, 1518, 
1124 cm-1; MS (m/z): 307 (M+); Anal. Calcd for C14H17N3O3S: C, 54.71; H, 5.57; N, 13.67; 
Found: C, 54.64; H, 5.46; N, 13.54. 
 
N-(4-nitrophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-9): 
White solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3256, 3224, 2975, 1685, 1578, 1498, 
1227 cm-1; MS (m/z): 324 (M+); Anal. Calcd for C12H12N4O5S: C, 44.44; H, 3.73; N, 17.28; 
Found: C, 44.32; H, 3.34; N, 17.20. 
 
N-(3-chloro-4-fluorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-10): White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3274, 3104, 2958, 1656, 
1558, 1468, 1224 cm-1; 1H NMR: δ 2.53 (s, 3H, CH3), 3.64 (s, 3H, CH3), 7.12-7.16 (t, 1H, 
ArH), 7.46-7.49 (m, 1H, ArH), 7.96-7.98 (q, 1H, ArH), 9.61 (s, 1H, NH), 12.97 (s, 1H, NH); 
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MS (m/z): 331 (M+); Anal. Calcd for C12H11ClFN3O3S: C, 43.45; H, 3.34; N, 12.67; Found: 
C, 43.34; H, 3.29; N, 12.58. 
 
N-(5-chloro-2-methoxyphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-11): White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3282, 3243, 2985, 1686, 
1554, 1427, 1124 cm-1; MS (m/z): 343 (M+); Anal. Calcd for C13H14ClN3O4S: C, 45.42; H, 
4.10; N, 12.22; Found: C, 45.34; H, 4.03; N, 12.13. 
 
N-(2,5-dichlorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-12): White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3255, 3218, 3085, 1685, 
1598, 1588, 1224, 1147 cm-1; MS (m/z): 348 (M+); Anal. Calcd for C12H11Cl2N3O3S: C, 
41.39; H, 3.18; N, 12.07; Found: C, 41.26; H, 3.04; N, 11.95. 
 
N-(2,5-dimethylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS- 13): White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3251, 3171, 2817, 1735, 
1675, 1448, 1164 cm-1; 1H NMR: δ 2.33 (d, J = 7.6 Hz, 6H), 2.58 (s, 3H), 3.84 (s, 3H), 6.84-
6.87 (q, 1H), 7.08 (d, J = 7.68 Hz, 1H), 7.68 (d, J = 1.28 Hz, 1H), 9.03 (s, 1H), 12.94 (s, 1H); 
IR (KBr): 3254, 3211, 3014, 1715, 1657, 1588, 1467, 1124 cm-1; MS (m/z): 307 (M+); Anal. 
Calcd for C14H17N3O3S: C, 54.71; H, 5.57; N, 13.67; Found: C, 54.64; H, 5.44; N, 13.58. 
 
N-(4-chloro-2-methylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-14): White solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3252, 3214, 2985, 1675, 
1598, 1548, 1124 cm-1; MS (m/z): 327 (M+); Anal. Calcd for C13H14ClN3O3S: C, 47.64; H, 
4.30; N, 12.82; Found: C, 47.51; H, 4.17; N, 12.69. 
 
N-(3,4-difluorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-15): White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3242, 3194, 3085, 1695, 
1587, 1471, 1224 cm-1; MS (m/z): 315 (M+); Anal. Calcd for C12H11F2N3O3S: C, 45.71; H, 
3.52; N, 13.33; Found: C, 45.59; H, 3.38; N, 13.21. 
 
N-(2-chlorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
16): White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3232, 3094, 2865, 1795, 1687, 
1471, 1124 cm-1; MS (m/z): 313 (M+); Anal. Calcd for C12H12ClN3O3S: 45.94; H, 3.85; N, 
13.39; Found: C, 45.84; H, 3.73; N, 13.25. 
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N-(2-fluorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
17): White solid; Rf 0.36 (6:4 hexane-EtOAc); IR (KBr): 3244, 3114, 2955, 1678, 1528, 
1499, 1114 cm-1; MS (m/z): 297 (M+); Anal. Calcd for C12H12FN3O3S: C, 48.48; H, 4.07; N, 
 14.13; Found: C, 48.32; H, 3.91; N, 14.05. 
 
N-(4-bromophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
18): White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3265, 3234, 2915, 1685, 1588, 
1448, 1127 cm-1; MS (m/z): 356 (M+); Anal. Calcd for C12H12BrN3O3S: C, 40.24; H, 3.38; N, 
11.73; Found: C, 40.13; H, 3.27; N, 17.62. 
 
N-(3,4-dichlorophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-19): White solid; Rf 0.30 (6:4 hexane-EtOAc); IR (KBr): 3275, 3118, 3085, 1675, 
1558, 1488, 1224, 1047 cm-1; MS (m/z): 348 (M+); Anal. Calcd for C12H11Cl2N3O3S: C, 
41.39; H, 3.18; N, 12.07; Found: C, 41.34; H, 3.04; N, 11.91. 
 
N-(3-nitrophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
20): White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3255, 3244, 2975, 1665, 1548, 
1498, 1127 cm-1; MS (m/z): 324 (M+); Anal. Calcd for C12H12N4O5S: C, 44.44; H, 3.73; N, 
17.28; Found: C, 44.33; H, 3.31; N, 17.22. 
N-(3-methylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide (HPMS-
21): White solid; Rf 0.37 (6:4 hexane-EtOAc); IR (KBr): 3243, 3154, 2915, 1695, 1578, 
1348, 1364 cm-1; MS (m/z): 293 (M+); Anal. Calcd for C13H15N3O3S: C, 53.23; H, 5.15; N, 
14.32; Found: C, 53.10; H, 5.04; N, 14.20. 
 
N-(2,3-dimethylphenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-22): White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3253, 3174, 2815, 1725, 
1678, 1448, 1164 cm-1; MS (m/z): 307 (M+); Anal. Calcd for C14H17N3O3S: C, 54.71; H, 5.57; 
N, 13.67; Found: C, 54.65; H, 5.43; N, 13.60. 
 
N-(2-methoxy,4-nitrophenyl)-3-methyl-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide 
(HPMS-23): White solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3253, 3175, 2805, 1765, 
1678, 1348, 1264, 1174 cm-1; MS (m/z): 354 (M+); Anal. Calcd for C13H14N4O6S: C, 44.06; 
H, 3.98; N, 15.81; Found: C, 44.05; H, 3.83; N, 15.66. 
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1H NMR spectrum of compound 3c 
 
 
Expanded 1H NMR spectrum of compound 3c 
 
 
Studies on Bioactive Heterocycles 73
Chapter 2       Synthesis of Trifunctionalized Pyrazoles 
1H NMR spectrum of compound HPMS-10 
 
  
 1H NMR spectrum of compound HPMS-13 
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13C NMR spectrum of compound-3c 
 
 
 
13C NMR spectrum of HPMS-2 
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13C NMR spectrum of HPMS-5 
 
 
Mass spectrum of compound-1a 
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Mass spectrum of HPMS-4 
 
 
 
Mass spectrum of HPMS-8 
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IR Spectrum of HPMS-1 
 
 
 
IR spectrum HPMS-2 
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Chemical purity of compound HPMS-1 
 
 
 
Chemical purity of compound HPMS-9 
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3.1 INTRODUCTION  
 
Isoxazole is a five member heterocyclic compound having two hetero atoms oxygen 
at position 1 and nitrogen at position 2. In 1888, Claisen et al have first synthesized an 
isoxazole molecule (Figure 1) with the reaction of 1,3-diketone with hydroxylamine.1 
Subsequently a solid foundation for the chemistry of isoxazole was laid down by Claisen and 
his students. It was shown to possess typical properties of an aromatic system but under 
certain reaction conditions. Particularly in reducing or basic media, it becomes very highly 
labile. 
 
N
O
 
Figure 1 
 
The next important contribution to the chemistry of isoxazoles was made by Quelico.2 In 
1945, when he began to study the formation of isoxazoles from nitrile N-oxide and 
unsaturated compounds. 
 
3.2      Biological activity of various substituted isoxazole derivatives 
 The biological activity of substituted isoxazoles3 has made them a focus of medicinal 
chemistry over the years. Isoxazoles are potent, selective agonists at human cloned dopamine 
D4 receptors4 and  exhibit GABAA antagonist,5 analgesic,6 antiinflammatory,6 ulcerogenic,6 
antimicrobial,7 antifungal,7 COX-2 inhibitory,8 antinociceptive,9 and anticancer10 activity. 
 
Cushman M. et al11 have designed benzo[d]isoxazole and oxazolidine-2-one derivatives and 
evaluated as a new series of potent HIV-1 non-nucleoside reverse transcriptase inhibitors 
with anti-HIV activity. The most promising compound in this series was ADAM (Figure 2), 
with EC50 values of 40 μM (vs HIV-1RF) and 20 μM(vs HIV-1IIIB). Methyl 5-((Z)-5- 
(methoxycarbonyl)-1- (3-methoxy-7-methylbenzo [d] isoxazole-5-yl) pent-1-enyl-2-
methoxy-3-methylbenzoate also inhibited HIV-1 reverse transcriptase with an IC50 of 0.91 
μM. ADAM 4 has an antiviral EC50 of 0.6 μM in CEM-SS cells and a plasma half-life of 51.4 
min. 
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Figure 2 
 
HIV-1 is the etiological agent of AIDS, one of the world’s most serious health problems with 
about 33 million people infected worldwide in 2007. The reverse transcriptase (RT) of HIV-1 
is an essential enzyme in HIV replication and has been a key target in anti-AIDS drug 
discovery. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine, 
delavirdine, and efavirenz have been approved by the Food and Drug Administration (FDA) 
for the treatment of AIDS.12 They are very useful drugs in combination therapy with 
nucleoside analogues (NRTIs) and protease inhibitors (PIs)13-14 for the treatment of AIDS. 
Recently, the NNRTI etravirine was approved by the FDA for treatment of antiretroviral 
drug-resistant HIV infections. The cytotoxicities of the newly synthesized ADAMs were 
determined along with their abilities to inhibit the cytopathic effect of HIV-1 in cell culture. 
The inhibition of HIV-1 RT by the ADAMs, and their metabolic stabilities in rat plasma were 
also investigated. 
 
Liljefors T. et al15 have synthesized a series of 4-aryl-5-(4-piperidyl)-3-isoxazololes and 
evaluated for GABAA antagonists. The meta-phenyl-substituted compounds and the para-
phenoxy-substituted compound (Figure 3) all display high affinities (Ki = 10-70 nM) and 
antagonist potencies in the low nanomolar range (Ki = 9-10 nM).  
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Figure 3 
 
Shvets N. et al16 were demonstrated that the 2,3,5-substituted perhydropyrrolo[3,4-
d]isoxazole-4,6-dione (Figure 4) derivatives have potent antibacterial activity. The reaction 
involved the cycloaddition reaction of N-methyl-C-arylnitrones with N-substituted 
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maleimides. Most of the compounds exhibited high activity against Enterococcus faecalis 
(ATCC 29212) and Staphylococcus aureus (ATCC 25923). 
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H3C H3C CH3CH3
R= p-Et2NC6H4 R= 4-BzO-3-MeOC6H3
 
Figure 4 
 
Due to the exceptional anticonvulsant activity displayed by substituted aniline enaminones, 
related pyridine derivatives17 and phenothiazines, the further investigation of various 
aromatic heterocycles was undertaken and found that the isoxazoles are important 
heterocycles for the treatment of convulsant diseases. The reaction of cyclic 1,3-diketo esters 
with  aminoisoxazole derivatives led to a series of potent anti-maximal electroshock 
analogues. Sodium channel binding studies, as well as evaluations against pentylenetetrazol, 
bicuculline, and picrotoxin on isoxazole were all negative, leading to an unknown mechanism 
of action. X-ray diffraction patterns of a representative of the 3-amino series (Figure 5) 
unequivocally display the existence of intramolecular hydrogen bonding of the nitrogen to the 
vinylic proton in the cyclohexene ring, providing a pseudo three ring structure. 
 
HN N
O
OH3C
CO2R
R1
R = CH3, C2H5
R1= H, CH3
 
Figure 5 
 
Giovannoni M. P. et al18 have synthesized a number of arylpiperazinylalkylpyridazinones and 
tested for their analgesic activity. They were observed that many of the tested molecules, at 
the dose of 20 mg kg-1 p.o., showed high antinociceptive activity, in particular, substituted 
lead (Figure 6) a compound which was able to reduce the number of abdominal constrictions 
by more than 50% in writhing test. They were investigated the mechanism of action of this 
compound, which shown that it carries out its analgesic action through the inhibition of 
reuptake of noradrenaline.  
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Figure 6 
 
Christian Peifer et al19 have reported the discovery of isoxazole (Figure 7) as a potent dual 
inhibitor of p38α (IC50= 0.45 μM) and CK1δ (IC50= 0.23 μM). Among the synthesized 
isoxazoles, selected compounds were profiled over 76 kinases and evaluation of their cellular 
efficacy showed 18 (CKP138) to be a highly potent and dual-specific inhibitor of CK1δ and 
p38α. 
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Figure 7 
 
In 2006, Johnson & Johnson Pharmaceutical Research & Development20, has been reported 
the synthesis of a series of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole 
(Figure 8) derivatives using substituted salisaldehydes and ethyl 4-bromocrotonate. Among 
the synthesized isoxazoles, some of which proved to be the most potent α2-adrenoceptor 
blockers with potent serotonin (5-HT) reuptake inhibiting activity. Serotonin is one of the 
important monoamine for human body and the deficit of 5-HT mainly lead to the depression 
 
O
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N
N
R1
R2
R1, R2= H, OMe, NHAr
 
Figure 8 
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Carr J. B. et al21 have been synthesized a series of highly substituted isoxazoles (Figure 9) 
and screened for anthelmintic activity at doses ranging from 16 to 500 mg/kg orally against 
the rat roundworm, Nlppostrongjlus Erazikensis. They were found that the newly synthesized 
isoxazole derivatives have potent anthelmintic activity. 
 
O
N
R2 R1
R1= Cl, Br, OH, CH3SO3, CH3CONH2
R2= H, Br, Cl
 
Figure 9 
 
? Biologically active isoxazoles containing alkyl, amide and sulfone groups 
Isoxazoles bearing sulfones and carboxamide moieties demonstrated to have 
significant pharmacological applications. For examples, COX-2 selective inhibitor, 
valdecoxib (Figure 10)22 are currently prescribed for the treatment of arthritis and 
inflammatory diseases. These COX-2 inhibitors exhibited anti-inflammatory activity with 
reduced gastrointestinal side effects. Moreover, oxacillin (Figure 10)23 and its derivatives are 
useful compounds because of their narrow spectrum anti biotic properties. 23 
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O
N
O
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R R''
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Cloxacillin
Dicloxacillin
Flucloxacillin
 
Figure 10 
 
Some N-phenyl and N-benzyl-substituted amido (Figure 11) analogs of COX-2 selective 
tricyclic non-steroidal anti-inflammatory drugs have been synthesized by Balsamo A. and 
coworkers24 with the aim to obtain information on the structural requirements for the COX-
inhibitory activity. The newly synthesized compounds were tested in vitro for their inhibitory 
properties only towards COX-2 enzyme by measuring prostaglandin E2 (PGE2) production 
on activated J774.2 macrophages. Some of the new compounds showed a modest activity, 
with percentage inhibition values near 30% at a concentration of 10 μM. The biological data 
was indicates that the N-phenyl-substituted amides present in isoxazole moiety with steric 
hindrances may prevent a good interaction with COX-2 active site. 
Chapter 3                                                                                                     Library of Trifunctionalized Isoxazoles  
  
 
Studies on Bioactive Heterocycles 
   
87
 
O
N
O
N
H
Ph
SO2Me
O
N
O
N
H
SO2Me
Ph
 
Figure 11 
 
Aldo Balsamo et al24 have reported several heteroaromatic analogs of (2-aryl-1-
cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors (Figure 12), in which 
the cyclopentene moiety was replaced by pyrazole, thiophene or isoxazole ring, were 
synthesized, in order to verify the influence of the different nature of the central core on the 
COX inhibitory properties of these kinds of molecules. Among the compounds tested, only 
the 3-(p-methylsulfonylphenyl) substituted thiophene derivatives, showed a certain COX-2 
inhibitory activity, accompanied by an appreciable COX-2 versus COX-1 selectivity. Only 
one of the 1-(p-methylsulfonylphenyl) pyrazole compounds displayed a modest inhibitory 
activity towards both type of isoenzymes, while the pyrazole 1-(p-aminosulfonylphenyl) 
substituted proved to be significantly active only towards COX-1. All the isoxazole 
derivatives were inactive on both COX isoforms. 
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Figure 12 
 
Habeeb A. G. et al25 were also reported the synthesis of 4,5-diphenyl-4-isoxazolines (Figure 
13) possessing a variety of substituents (H, F, MeS, MeSO2) at the para-position of one of 
the phenyl rings and evaluated as analgesic and selective COX-2 inhibitory anti-
inflammatory agents. Although the 4,5-phenyl-4-isoxazolines (Figure 13), which do not have 
a methyl at C3, exhibited potent analgesic and anti-inflammatroy activities, those compounds 
evaluated  were not selective inhibitors of COX-2. In contrast, 2,3-dimethyl-5-(4-
methylsulfonylphenyl)-4-phenyl-4-isoxazoline exhibited excellent analgesic and anti-
inflammatory activities, and it was a potent and selective COX-2 inhibitor (COX-1, IC50) 258 
μM; COX-2, IC50) 0.004 μM).  
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Figure 13 
 
A fluoro substituent at the para position of the 4-phenyl ring was also a selective (SI =3162) 
but less potent (IC50 =0.0316 μM) inhibitor of COX-2 than 2,3-dihydro-2,3-dimethyl-5-(4-
(methylsulfonyl)phenyl)-4-phenylisoxazole. A molecular modeling for 4-(4-fluorophenyl)-
2,3-dihydro-2,3-dimethyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole showed that the S 
atom of the MeSO2 substituent is positioned about 6.46 Å  inside the entrance to the COX-2 
secondary pocket (Val523) and that a C3 Me (2,3-dihydro-2,3-dimethyl-5-(4-
(methylsulfonyl)phenyl)-4-phenylisoxazole, 4-(4-fluorophenyl)-2,3-dihydro-2,3dimethyl-5-
(4-(methylsulfonyl)phenyl)-4-phenylisoxazole) central isoxazoline ring substituent is crucial 
to selective inhibition of COX-2 for this class of compounds. 
 
Talley J. J. et al26 have synthesized sodium salt of N-[[(5-Methyl-3-phenylisoxazol-4-yl)- 
phenyl]sulfonyl]propanamide, parecoxib sodium (Figure 14) and evaluated as a potent and 
selective inhibitor of COX-2 for parenteral administration. 
 
O
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CH3
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R= CH3, CH2CH3, CH2CH2CH3
 
Figure 14 
 
Among the most potent and selective COX-2 inhibitors that have been identified is the 
isoxazole sulfonamide valdecoxib (Figure 10). In addition, sulfonamide valdecoxib 
possesses exceptional anti-inflammatory activity in vivo.27 Talley et al have developed an 
injectable COX-2 inhibitor with a water-soluble prodrug of sulfonamide valdecoxib that 
would undergo biotransformation in vivo.  
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Moreover, the 3-substituted phenyl-5-isoxazolecarboxaldehydes28 has been identified as 
activated aldehydes for the generation of isoxazole-based combinatorial libraries on solid 
phase through automation. Three highly functionalized isoxazole-based libraries (Figure 15) 
comprising of  compounds each have been synthesized in parallel format using Baylis 
Hillman reaction, Michael addition, reductive amination and alkylation reactions. With an 
objective of lead generation all the three libraries were evaluated for their antithrombin 
activity in vivo. All the compounds obtained were evaluated for their antithrombotic activity 
in vivo.  Swiss mice (20–25 g, from CDRI animal colony) were used in a group of at least 10 
animals each. Thrombosis was induced by infusion of a mixture of 15 mg collagen and 5 mg 
adrenaline in a volume of 100 mL into the tail vein of each mouse. The compounds were 
administered at 30 μmol/kg by oral route 1 h prior to the thrombotic challenge. The 
antithrombotic effects of these compounds were assessed by the percentage protection 
offered by these agents to mice from death or paralysis following thrombotic challenge using 
aspirin as a standard. 
 
N
O
N R NH2
O
R1
R2
R= CH2Ph, (CH2)4NH2
R1=H, 4CH3, 2Cl
R2=H, 4CN, 4Br
 
Figure 15 
 
Pruitt J. R. et al29 have evaluated trisubstituted isoxazoles for their in vitro and in vivo 
antithrombotic efficacy. They were compared to trisubstituted isoxazolines (Figure 16) for 
Factor Xa selectivity and potency. They were also compared in an arterio-venous (A-V) shunt 
model of thrombosis. Factor Xa (fXa) catalyzes the production of thrombin from prothrombin 
and sits at the junction of the intrinsic and extrinsic pathways of the coagulation cascade. It 
has recently been suggested that fXa inhibitors may be more effective as antithrombotic 
agents than direct inhibitors of thrombin and may have less bleeding risk, leading to a better 
safety-efficacy ratio. 
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Figure 16 
 
Some of the biological activities described to isoxazole derivatives includes PAF antagonist, 
hypolipidemic, nootropic, immunomodulator, antiobesity and CNS modulation.30 The 
substituted isoxazoles, are also considered to be important synthons due to their versatility 
towards chemical transformations to useful synthetic intermediates such as 1,3-dicarbonyl, 
1,3-iminocarbonyl and γ-amino alcohols. The significance of this class of molecules gets 
further impetus due to their involvement as intermediates in the synthesis of various natural 
products.31  
 
3.3       Synthesis of functionalized isoxazoles using various synthetic approaches. 
 Isoxazoles can be synthesized by various methods, which are described as under. 
 
Tweedie S. R. et al.32 have synthesized a palladium-catalyzed couplings of heteroaryl amines 
with aryl halides using sodium phenolate as the stoichiometric base (Figure 17). 
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Figure 17 
 
Yavari I. et al.33 were synthesized isoxazole derivatives (Figure 18) through the reaction of 
activated acetylenes and alkyl 2-nitroethanoates in the presence of triphenylphosphine. 
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Figure 18 
Chapter 3                                                                                                     Library of Trifunctionalized Isoxazoles  
  
 
Studies on Bioactive Heterocycles 
   
91
 
Burkhart D. J. et al.34 have synthesized the 4-acetyl-5-methyl-3-isoxazoyl carboxylate 
(Figure 19) by the reaction of α-halo oxime with 1,4-diketone in presence of base. Further, 
the isoxazole smoothly lithiated at the 5-methyl position and followed by quenched the anion 
with a variety of electrophiles such as alkyl halides, aldehyde, TMSCl and Me3SnCl in good 
to excellent yields. 
 
NEtO2C
Cl
OH
O
O
NaOEt / EtOH N
O
OEtO2C
 
Figure 19 
 
Suzuki K. et al.35 have synthesized functionalized isoxazole derivatives (Figure 20) by 
cyclocondensation of C-chlorooximes with cyclic 1,3-diketones in the presence of base. 
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Figure 20 
 
Lauten M. et al.36 have synthesized highly substituted isoxazole derivatives (Figure 21) by 
the reaction of N-acetoacetyl derivatives and hydroxyl amine hydrochloride in methanol 
using sodium acetate. 
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O
H
O
X
R
O
N X
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X=N(CH3)2
 
Figure 21 
 
Kislyi V. P. et al.37 were prepared 4-amino-5-benzoyl (acetyl) isoxazole-3-carboxamides 
(Figure 22) by the cyclization of α-hydroxyimino nitriles o-alkylated with bromo 
acetophenones (bromoacetone) in presence of lithium salt.  
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Figure 22 
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Holzer W. et al.38 have synthesized 1,3-disubstituted 4-benzoyl-5-hydroxypyrazoles with 
phosphorusoxytrichloride affords the corresponding 4-benzoyl-5-chloropyrazoles. Reaction 
of the latter with hydroxylamine leads to oximes, which can be cyclized to novel 3-phenyl-
6H-pyrazolo [4, 3-d] isoxazoles (Figure 23) by treatment with sodium hydride in 
dimethylformamide. 
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Figure 23 
 
Bourbeau M. P. et al.39 have synthesized series of 4-alkyl-5-aminoisoxazoles (Figure 24) in 
high yield by nucleophilic addition of lithiated alkyl nitriles to α-chlorooximes. The scope 
and limitations of this reaction were examined by varying the nature of the nitrile and 
chloride oxime. 
 
R Cl
N
HO
R' CN
tBuLi
-78 oC
15 min
N O
NH2
R1
R
R= aryl, heteroaryl, alkyl
R1 = alky, aryl, benzyl  
Figure 24 
 
Recentyl, Dong D. and coworkers40 have developed an efficient and divergent synthesis of 
highly substituted isoxzoles using cyclopropyl oximes (Figure 25). Under Vilsmeier 
conditions (POCl3/CH2Cl2), substituted isoxazoles were synthesized from 1-carbamoyl, 1-
oximyl cyclopropanes via sequential ring-opening, chlorovinylation, and intramolecular aza-
cyclization. 
 
R NHAr
ON
HO
POCl3 
CH2Cl2
rt
N
OArHN
ClH2CH2C R
R = Me, Ph  
Figure 25 
 
Duan H. et al.41 have reported a catalytic cascade synthesis of isoxazoline-N-oxide (Figure 
26) through proline-catalyzed nitroalkene activation. A large substrate scope was obtained 
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with good to excellent yields. Mechanistic studies were revealed that intramolecular 
cyclization as the rate-determining step, giving only trans isomers in all cases. 
 
NO2
Ph
OAc
20% Proline, NaOAc
DMSO, rt, 10 h
N+ O
--O
Ph Ph
 
Figure 26 
 
Daidone G. et al.42 were obtained N-(5-methylisoxazol-3-yl)-2-aminobenzamide derivatives 
(Figure 27) starting from the 2-nitroaroyl chlorides and 3-amino-5-methylisoxazole in 
presence of stannous chloride and hydrochloric acid.  
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Figure 27 
 
In 1995, Junjuppa H. et al43 have synthesized some novel isoxazole fused estrone (Figure 28) 
derivatives via α-oxoketene dithioacetal.  
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H H
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SMe
 
Figure 28 
 
Moreover, 10,11-Dihydro-11-[bis(methylthio)methylene]dibenzoxepin-10-one (I) has been 
utilized as a useful three carbon synthon for the efficient regiospecific annulation of a 
isoxazole derivatives (Figure 29) by Junjappa H. and coworkers.44 The reaction involves 
cyclocondensation of I with hydroxylamine in EtOH/NaOEt gave 72% fused isoxazoles. 
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Figure 29 
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Kuettel S. et al45 have synthesized 4-(3-phenylisoxazol-5-yl)morpholine derivatives (Figure 
30) by two synthetic routes, in which substituted acetophenones were reacted with carbon 
disulfide and methyl iodide in the presence of sodium hydride to give 4-phenoxyphenyl-2,2-
bis(methylthio)vinylketones, followed by in situ cyclization of the resulting N,S-acetals with 
hydroxylamine. 
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S S XHN
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X= N-Boc
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X
 
Figure 30 
 
Mahata P. K. et al46 have synthesized 3-dimethoxymethyl-5-(methylthio) isoxazole 
derivatives (Figure 31) with mask or unmask aldehyde functionality by cyclocondensation 
reaction of 1,1-dimethoxy-4,4-bis(methylthio)but-3-en-2-one as three carbon synthon with 
hydroxylamine in alcohol. 
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Figure 31 
 
Dieter R. K. et al47 have demonstrated that α-oxoketene dithioacetals derived from various 
aliphatic or aromatic ketones afforded oximes, upon treatment with hydroxylamine in ethanol 
at reflux. They were further converted the oximes into isoxazoles upon treatment with 
Amberlyst 15 ion exchange resin (Figure 32). 
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Figure 32 
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? Synthesis of functionalized isoxazoles using combinatorial chemistry approach. 
Recently, Tu S. J. et al48 have developed a series of new polycyclic-fused isoxazole 
[5,4-b]pyridines (Figure 33) through a one-pot tandem reaction under microwave irradiation 
in water without any use of additional reagent or catalyst. The synthetic protocol represents a 
green one and makes this methodology suitable for library synthesis in drug discovery efforts.  
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Figure 33 
 
Laborde E. et al49 have developed an efficient three-component, two-step “catch and release” 
solid-phase synthesis of 3,4,5-trisubstituted isoxazoles (Figure 34). The reaction involves a 
base-promoted condensation of a 2-sulfonyl acetonitrile derivative 1 with an isothiocyanate 2 
and in situ immobilization of the resulting thiolate anion 3 on Merrifield resin. Reaction of 
the resin-bound sulfonyl intermediate 4 with hydroxylamine, followed by release from the 
resin and intramoleculer cyclization, afforded 3,5-diamino-4-(arylsulfonyl)-isoxazoles 5. 
However, this methodology has some drawback such as; long reaction time, isolation of 
product and high reaction temperature.  
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Figure 34 
 
In 2008, Waldo J. P. et al50 have reported solution phase synthesis of a diverse library of 
highly substituted isoxazoles (Figure 35). The reaction involved iodocyclization of o-
methyloximes of 2-alkyn-1-ones affords 4-iodoisoxazoles, which undergo various palladium-
catalyzed reactions to yielded 3,4,5-trisubstituted isoxazoles. The palladium-catalyzed 
processes have been adapted to parallel synthesis utilizing commercially available boronic 
acid, acetylene, styrene, and amine sublibraries. Accordingly, a diverse 51-member library of  
3,4,5-trisubstituted isoxazoles has been generated. 
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Figure 35 
 
Kurth M. J. et al51 have constructed a library of 3-Aryl-4,5-dihydroisoxazole-5-carboxamides 
(Figure 36). They were investigated the reaction order (nitrile oxide 1,3-dipolar 
cycloaddition followed by amide formation, or vice versa) both experimentally and 
computationally to determine which route would result in the highest yields, minimize 
purification efforts, and give higher 1,3-dipolar cycloaddition regioselectivity.  
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Figure 36 
 
In addition, Taddei M. et al.52 have developed libraries of substituted isoxazole through in- 
situ generation of polymer-bound enaminones (Figure 37). The synthetic protocol makes use 
of commercially available aniline cellulose, a low-cost and versatile biopolymer, under very 
mild conditions. This new support allowed carrying out reactions in polar solvents under both 
conventional heating and MW irradiation without degradation of the polymer. The reaction 
between cellulose-bound enaminones and hydroxylamine to afford the target heterocycles in 
high yields directly in solution is the key step. The support can be conveniently recycled. 
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Figure 37 
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3.4 CURRENT RESEARCH WORK 
 
The isoxazole nucleus is present in a wide range of biologically interesting molecules, which 
show anti HIV, analgesic, anti-inflammatory, antibacterial, hypoglycemic, sedative-hypnotic 
activities.3-21 As we discussed, the remarkable biological potential of the sulfone group and 
carboxamide group bearing isoxazole scaffolds have attracted many chemists to synthesize 
this class of molecules. Thus, continuous efforts have been devoted to the development of 
more general and versatile synthetic methodologies for this class of compounds. Many 
research groups have been synthesized isoxazole derivatives using various methods. 
However, the existing methods suffered with some drawbacks such as; long reaction time, 
product isolation, etc. Thus, the practical synthesis of structurally diverse isoxazole based 
small molecules is of great significance. 
 
Nowadays, a great deal of effort has been focused on the field of green chemistry in adopting 
methods and processes. As a part of this “green” concept, toxic and/or flammable organic 
solvents are replaced by alternative non-toxic and nonflammable media. In this context, many 
efforts have been made to use aqueous media. Among alternative green solvents, water has 
been the solvent of choice for a variety of transformations. On the other hand; functionalized 
ketene dithioacetals are versatile intermediates in organic synthesis for the construction of 
substituted heterocycles. Given the importance of sulfone and carboxamide groups containing 
isoxazoles, and our ongoing interest on the synthesis various bioactive heterocycles using 
novel ketene dithioacetals starting from acetoacetanilides, encouraged us to utilized these 
ketene dithioacetals for the construction of small molecule library of 3-methyl-5-
(methylsulfonyl)-N-arylisoxazole-4-carboxamide derivatives in aqueous medium. The newly 
synthesized compounds were characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy 
and elemental analysis. The biological screening of the synthesized compounds is under 
process. The chemical purity of all the synthesized compounds was examined by UPLC. 
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3.5 RESULTS AND DISCUSSION 
 
 Various substituted 3-oxo-N-arylbutanamide were prepared by refluxing substituted 
amines and ethyl acetoacetate in toluene with a catalytic amount of NaOH or KOH (Scheme 
1). The reaction mixtures were refluxed for 12-15 h. The synthesized acetoacetanilides were 
further converted to 2-(bis(methylthio)methylene)-3-oxo-N-arylbutanamide 1a-w through the 
reaction with carbon disulfide, base and followed by methylation.  
 
Scheme 1: Synthesis of various acetoacetanilides  
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O O
N
H
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          Refulx
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R
 
 
 
Scheme 2: Water mediated synthesis of isoxazoles containing methyl, sulfone and 
carboxamide groups 
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Under the optimized condition (described in chapter 3), the various  ketene dithioacetals were 
reacted with hydroxyl amine hydrochloride 2 and potassium hydroxide to furnished 
isoxazoles in excellent yields using water as a solvent. (Scheme 2, Table 1). The synthesized 
compounds were characterized by spectral data. In the 1H NMR of isoxazole 3b a 
characteristic singlet for amide proton appeared at δ 9.19 and hydrogen of methylthio group 
displayed a singlet at δ 2.63. 
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Table 1: 3-mehtyl, 5-methylthio, 4-carboxamide substituted isoxazoles. 
 
Entry R Time h Yield % mp ºC 
3a Ph 2.5 94 135-137 
3b 4-CH3Ph 2.8 92 141-142 
3c 4-OCH3Ph 3.0 92 128-130 
3d 4-FPh 3.2 90 142-144 
3e 2-OCH3Ph 2.6 88 136-138 
3f 2-CH3 3.0 87 133-135 
3g 4-ClPh 2.9 89 145-147 
3h 4-EtPh 3.3 90 147-148 
3i 4-NO2Ph  2.5 87 149-151 
3j 3-Cl,4-FPh 3.4 88 134-136 
3k 5-Cl,2-OCH3Ph 3.6 90 151-153 
3l 2,5-diClPh 2.8 89 142-144 
3m 2,5-diCH3Ph 2.9 98 136-138 
3n 4-Cl,2-CH3Ph 3.0 87 137-139 
3o 3,4-diFPh 3.2 91 146-148 
3p 2-ClPh 3.1 94 142-144 
3q 2-FPh 3.3 96 140-142 
3r 4-BrPh 3.5 95 151-153 
3s 3,4-diClPh 2.8 90 137-139 
3t 3-NO2Ph 3.2 88 125-127 
3u 3-CH3Ph 3.0 94 130-132 
3v 2,3-diCH3Ph 3.7 85 138-140 
3w 2-OCH3,4-NO2Ph 2.8 96 124-126 
 
 
As we described the significant utility of sulfone group in medicinal chemistry and to develop 
library of isoxazole functionalized with alkyl, carboxamide and sulfone groups, we next 
planned to oxidize the sulfides to sulfones. With the optimized condition in hand for 
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oxidation, all the isoxazoles were oxidized to make sulfone group containing isoxazole 
derivatives and the results are gather in table 2. 
 
 
Table 2: 3-mehtyl, 5-sulfone, 4-carboxamide functionalized library of isoxazoles. 
 
Entry R Time min Yield % mp ºC 
OPMS-1 Ph 60 94 186-188 
OPMS-2 4-CH3Ph 50 95 192-194 
OPMS-3 4-OCH3Ph 60 93 188-190 
OPMS-4 4-FPh 55 91 191-193 
OPMS-5 2-OCH3Ph 65 94 184-186 
OPMS-6 2-CH3 55 96 179-181 
OPMS-7 4-ClPh 60 92 185-187 
OPMS-8 4-EtPh 65 95 192-194 
OPMS-9 4-NO2Ph  60 93 196-198 
OPMS-10 3-Cl,4-FPh 55 92 188-190 
OPMS-11 5-Cl,2-OCH3Ph 55 91 195-197 
OPMS-12 2,5-diClPh 60 90 188-190 
OPMS-13 2,5-diCH3Ph 55 91 181-183 
OPMS-14 4-Cl,2-CH3Ph 50 88 187-189 
OPMS-15 3,4-diFPh 65 89 189-191 
OPMS-16 2-ClPh 60 93 191-192 
OPMS-17 2-FPh 55 87 182-184 
OPMS-18 4-BrPh 65 85 162-164 
OPMS-19 3,4-diClPh 60 82 155-157 
OPMS-20 3-NO2Ph 60 90 164-166 
OPMS-21 3-CH3Ph 65 94 185-187 
OPMS-22 2,3-diCH3Ph 60 92 188-190 
OPMS-23 2-OCH3,4-NO2Ph 55 97 172-174 
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The chemical purity of all the newly synthesized compounds was examined using UPLC. 
Among all the final compounds, compound OPMS 12 has shown less than 95% chemical 
purity and other shown more than 95% chemical purity (Figure 38). The 1H NMR of 
compound OPMS-1 displayed a characteristic singlet for amide proton at δ 9.88 and two 
singlets for methyl and mehtylthio hydrogen, respectively, at δ 2.69 and 3.33. The overall 
study indicates that this is the simple and facile methodology to introduce sulfone and 
caboxamide group to isoxazole scaffold in excellent yield and chemical purity. 
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Figure 38: Chemical purity of trifunctionalized isoxazoles using UPLC 
 
In ketene dithioacetal system the carbonyl carbon and β-carbon atoms regarded as hard and 
soft electrophilic centers, since the carbonyl carbon is adjacent to the hard-base oxygen while 
the β-carbon is flanked by the soft-base methylthio groups. Thus, the nucleophile of 
hydroxylamine hydrochloride attack on β-carbon of systems and formed heterocyclic product 
by removal of methylthio group as good leaving group (Figure 39).   
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Figure 39: Mechanism for the formation of Isoxazole. 
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3.6 CONCLUSION 
 
In Summary, we have synthesized solution-phase library of isoxazoles functionalized with 
methyl, sulfone and carboxamide moieties in two steps with excellent yield and chemical 
purity for medicinally interesting molecules. Water was emerged as an efficient and green 
solvent in the condensation reaction of various ketene dithioacetals with hydroxyl amine 
hydrochloride. Further, the facile synthesis of isoxazole containing sulfone group was 
achieved via oxidation of sulfide to sulfone. SPB was more efficient and effective oxidizing 
agent for oxidation of sulfide to sulfone in aqueous medium. This procedure offers a good 
scope for the synthesis of a wide variety of isoxazoles containing caboxamide and sulfone in 
two steps.  
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3.7 EXPERIMENTAL SECTION 
 
 Melting points were determined in open capillaries and are uncorrected. Thin-layer 
chromatography was accomplished on 0.2-mm precoated plates of silica gel G60 F254 
(Merck). Visualization was made with UV light (254 and 365nm) or with an iodine vapor. IR 
spectra were recorded on a FTIR-8400 spectrophotometer using DRS prob. 1H (400 MHz) 
and 13C (100 MHz) NMR spectra were recorded on a Bruker AVANCE II spectrometer in 
CDCl3. Chemical shifts are expressed in δ ppm downfield from TMS as an internal standard. 
Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 mass 
spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary evaporator. 
Chemical purity was determined on Waters Acquity UPLC with PDA Detector using Acquity 
BEH C18, 50 × 2.1, 1.7µm column at 210-400nm. 
 
? Gradient Program for UPLC: (Same as chapter 2) 
? General synthesis of 3-oxo-N-arylbutanamide AAA 1-23. 
 A mixture containing the primary amine (10 mmol), ethyl acetoacetate (10 mmol), 
and catalytic amount of sodium or potassium hydroxide lie (10 %) was reflux at 110 oC for 
the approximately 12-15 h. The reaction was monitored by TLC. After completion of 
reaction, the solvent was removed under vaccuo and the solid or oil was crystallized from 
methanol which afforded pure products.  
 
? General procedure for the synthesis of trisubstituted isoxzoles 3a-w. 
To a well stirred solution of hydroxyl amine hydrochloride (15 mmol), potassium 
hydroxide (15 mmol) in water (25 mL) was added suspension of various ketene dithioacetals 
1a-w and refluxed the resulting mixture for appropriate time (Table 1) with constant stirring. 
After completion of the reaction, the reaction mixture was allowed to come to room 
temperature and add cold water (50 mL). The separated suspension was filtered, washed with 
water (2 × 50 mL), dried and crystallized from methanol to afford analytically pure products 
which were used for next step without further purification. 
 
? General procedure for the oxidation of sulfide to sulfones OPMS 1-23. 
The appropriate compound 3a-w (6 mmol) in water (15 mL) was added sodium per 
borate (18 mmol) and the resulting mixture was then heated to reflux for appropriate time 
(Table 2). The mixture was cooled to room temperature and extracted with ethyl acetate (2 × 
15 mL). The organic layer was washed with water (2× 20 mL) and dried over magnesium 
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sulphate. The solvent was evaporated at room temperature and product was isolated by 
crystallization technique in excellent yield. 
 
3-methyl-5-(methylsulfonyl)-N-phenylisoxazole-4-carboxamide (OPMS-1): White solid; 
Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3207, 2922, 1647, 1496, 1406, 1207 cm-1;  1H NMR: 
δ 2.69(s, 3H, CH3), 3..33 (s, 3H, CH3), 7.09-7.15 (q, 1H, ArH), 7.66-7.73 (t, 2H, ArH), 7.75-
7.97 (t, 2H, ArH), 9.88 (s, 1H, NH); 13C NMR: δ 12.47, 40.97, 111.18, 121.41, 122.76, 
132.52, 132.24, 140.19, 159.75, 169.74; MS (m/z): 280 (M+); Anal. Calcd for C12H12N2O4S: 
C, 51.42; H, 4.32; N, 9.99; Found: C, 51.29; H, 4.24; N, 9.89.  
 
N-(4-methylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-2): 
White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3275, 2822, 1687, 1526, 1406, 1284 cm-
1; 1H NMR: δ 2.32 (s, 3H, CH3), 2.69 (s, 3H, CH3), 3.32 (s, 3H, CH3), 7.13-7.16 (q, 2H, 
ArH), 7.52-7.56 (t, 2H, ArH), 9.79 (s, 1H, NH); 13C NMR: δ 12.43, 25.99, 40.59, 111.38, 
124.74, 124.95, 132.59, 137.43, 138.16, 138.24, 142.32, 159.47, 159.98, 169.05, 169.96; MS 
(m/z): 294 (M+); Anal. Calcd for C13H14N2O4S: C, 53.05; H, 4.79; N, 9.52; Found: C, 53.06; 
H, 4.65; N, 9.44. 
 
N-(4-methoxyphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-3): 
White solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3319, 3034, 1663, 1514, 1423, 1251 cm-
1; MS (m/z): 310 (M+); Anal. Calcd for C13H14N2O5S: C, 50.31; H, 4.55; N, 9.03; Found: C, 
50.27; H, 4.43; N, 9.09. 
 
N-(4-fluorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-4): 
White solid; Rf 0.36 (6:4 hexane-EtOAc); IR (KBr): 3210, 2921, 1675, 1547, 1458, 1284, 
1105 cm-1; MS (m/z): 298 (M+); Anal. Calcd for C12H11FN2O4S: C, 48.32; H, 3.72; N, 9.39; 
Found: C, 48.21; H, 3.60; N, 9.31. 
 
N-(2-methoxyphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-5): 
White solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3266, 2741, 1674, 1529, 1444, 1124 cm-
1; MS (m/z): 310 (M+); Anal. Calcd for C13H14N2O5S: C, 50.31; H, 4.55; N, 9.03; Found: C, 
50.29; H, 4.44; N, 9.07. 
 
N-(2-methylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-6): 
White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3314, 2844, 1714, 1629, 1481, 1224 cm-
Chapter 3                                                                                                     Library of Trifunctionalized Isoxazoles  
  
 
Studies on Bioactive Heterocycles 
   
105
 
1; MS (m/z): 294 (M+); Anal. Calcd for C13H14N2O4S: C, 53.05; H, 4.79; N, 9.52; Found: C, 
53.03; H, 4.67; N, 9.45. 
 
N-(4-chlorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-7): 
White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3214, 2787, 1841, 1681, 1482, 1124 cm-
1; MS (m/z): 314 (M+); Anal. Calcd for C12H11ClN2O4S: C, 45.79; H, 3.52; N, 8.90; Found: C, 
45.71; H, 3.43; N, 8.82.  
 
N-(4-ethylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-8): 
White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3334, 2781, 1681, 1481, 1242 cm-1; MS 
 (m/z): 308 (M+); Anal. Calcd for C14H16N2O4S: C, 54.53; H, 5.23; N, 9.08; Found: C, 54.41; 
H, 5.11; N, 8.98. 
 
N-(4-nitrophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-9): 
White solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3215, 2741, 1658, 1511, 1411, 1174 cm-
1; 13C NMR: δ 13.24, 40.41, 113.38, 125.51, 127.43, 132.39, 135.06, 136.40, 141.56, 144.50, 
164.49, 171.75; MS (m/z): 325 (M+); Anal. Calcd for C12H11N3O6S: C, 44.31; H, 3.41; N, 
12.92; Found: C, 44.20; H, 3.29; N, 12.81. 
 
N-(3-chloro-4-fluorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide 
(OPMS-10): White solid; Rf 0.54 (7:3 hexane-EtOAc); IR (KBr): 3210, 2754, 1711, 1629, 
1511, 1124 cm-1; MS (m/z): 332 (M+); Anal. Calcd for C12H10ClFN2O4S: C, 43.32; H, 3.03; 
N, 8.42; Found: C, 43.19; H, 2.90; N, 8.44. 
 
N-(5-chloro-2-methoxyphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide 
(OPMS-11): White solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3114, 2914, 1619, 1577, 
1481, 1141 cm-1; MS (m/z): 344 (M+); Anal. Calcd for C13H13ClN2O5S: C, 45.29; H, 3.80; N, 
8.13; Found: C, 45.16; H, 3.71; N, 8.08. 
 
N-(2,5-dichlorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-
12): White solid; Rf 0.51 (7:3 hexane-EtOAc); IR (KBr): 3210, 2754, 1681, 1229, 1581, 1142 
cm-1; MS (m/z): 349 (M+); Anal. Calcd for C12H10Cl2N2O4S: C, 41.28; H, 2.89; N, 8.02; 
Found: C, 41.19; H, 2.76; N, 7.92. 
 
N-(2,5-dimethylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-
13): White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3110, 2741, 1617, 1529, 1311, 1124 
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cm-1; MS (m/z): 308 (M+); Anal. Calcd for C14H16N2O4S: C, 54.53; H, 5.23; N, 9.08 Found: 
C, 54.44; H, 5.10; N, 8.97. 
 
N-(4-chloro-2-methylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide 
(OPMS-14): White solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3224, 2871, 1658, 1519, 
1311, 1121 cm-1; MS (m/z): 328 (M+); Anal. Calcd for C13H13ClN2O4S: C, 47.49; H, 3.99; N, 
8.52; Found: C, 47.38; H, 3.87; N, 8.39. 
 
N-(3,4-difluorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-
15): White solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3147, 2871, 1611, 1531, 1321, 1124 
cm-1; MS (m/z): 316 (M+); Anal. Calcd for C12H10F2N2O4S: C, 45.57; H, 3.19; N, 8.86; 
Found: C, 45.44; H, 3.07; N, 8.72. 
 
N-(2-chlorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-16): 
White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3221, 2851, 1895, 1684, 1371, 1118 cm-
1; MS (m/z): 314 (M+); Anal. Calcd for C12H11ClN2O4S: 45.79 H, 3.52; N, 8.90; Found: C, 
45.84; H, 3.43; N, 8.85. 
 
N-(2-fluorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-17): 
White solid; Rf 0.35 (6:4 hexane-EtOAc); IR (KBr): 3247, 2851, 1678, 1499, 1281, 1245 cm-
1; MS (m/z): 298 (M+); Anal. Calcd for C12H11FN2O4S: C, 48.32; H, 3.72; N, 9.39; Found: C, 
48.21; H, 3.61; N, 9.27. 
 
N-(4-bromophenyl)-3-methyl-5-(methylsulfonyl) isoxazole-4-carboxamide (OPMS-18): 
White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3277, 2811, 1581, 1448, 1227 cm-1; MS 
(m/z): 359 (M+); Anal. Calcd for C12H11BrN2O4S: C, 40.13; H, 3.09; N, 7.80; Found: C, 
40.11; H, 3.07; N, 7.68. 
 
N-(3,4-dichlorophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-
19): White solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3182, 2841, 1675, 1458, 1368, 1147 
cm-1; MS (m/z): 349 (M+); Anal. Calcd for C12H10Cl2N2O4S: C, 41.28; H, 2.89; N, 8.02; 
Found: C, 41.14; H, 2.75; N, 8.11. 
 
N-(3-nitrophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-20): 
White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3265, 2835, 1679, 1428, 1221 cm-1; MS 
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(m/z): 325 (M+); Anal. Calcd for C12H11N3O6S: C, 44.31; H, 3.41; N, 12.92; Found: C, 44.22; 
H, 3.30; N, 12.82. 
 
N-(3-methylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-21): 
White solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3243, 2813, 1685, 1477, 1118 cm-1; MS 
(m/z): 294 (M+); Anal. Calcd for C13H14N2O4S: C, 53.05; H, 4.79; N, 9.92; Found: C, 52.92; 
H, 4.66; N, 9.84. 
 
N-(2,3-dimethylphenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide (OPMS-
22): White solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3274, 2817, 1688, 1478, 1311, 1264 
cm-1; MS (m/z): 308 (M+); Anal. Calcd for C14H16N2O4S: C, 54.53; H, 5.23; N, 9.08; Found: 
C, 54.45; H, 5.21; N, 8.98. 
 
N-(2-methoxy,4-nitrophenyl)-3-methyl-5-(methylsulfonyl)isoxazole-4-carboxamide 
(OPMS-23): White solid; Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3157, 2872, 1765, 1668, 
1348, 1274 cm-1; MS (m/z): 355 (M+); Anal. Calcd for C13H13N3O7S: C, 43.94; H, 3.69; N, 
11.83; Found: C, 43.81; H, 3.55; N, 11.71. 
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1H NMR spectrum of 3a 
 
 
 
1H NMR spectrum of 3b 
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Expanded 1H NMR spectrum of 3b  
 
 
1H NMR spectrum OPMS-1 
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1H NMR spectrum of OPMS-2 
 
 
13C NMR of compound OPMS-2 
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13C NMR spectrum OPMS-9 
 
 
Mass spectrum of 3h 
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Mass spectrum of 3i 
 
 
Mass spectrum of 3k 
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Mass spectrum of OPMS-1 
 
 
Mass spectrum OPMS-3 
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Mass spectrum of OPMS-10 
 
 
IR spectrum of OPMS-1 
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IR spectrum of OPMS-3 
 
 
Chemical purity of OPMS-2 
 
Chapter 3                                                                                                     Library of Trifunctionalized Isoxazoles  
  
 
Studies on Bioactive Heterocycles 
   
116
 
Chemical purity of OPMS-6 
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4.1 INTRODUCTION 
 
Flavonoids are a group of polyphenolic compounds, which are widely distributed 
through out the plant kingdom. To date about 3000 varieties of flovonoids are known.1 
Flavonoids occur as aglycones, glycosides and methylated derivatives. The flavonoid 
aglycone consists of a benzene ring (A) condensed with a sixmembered ring (C), which in the 
2-position carries a phenyl ring (B) as a substituent (Figure 1). Six-member ring condensed 
with the benzene ring is either a γ-pyrone (chromenols 3 and chromenones 4) or its 
dihydroderivative (1, 2). The position of the benzenoid substituent divides the flavonoid class 
into flavonoids (1-4) and isoflavonoids (5, 6). Chromenols (1) differ from chromenones (4) 
by hydroxyl group the 3-position and C2-C3 double bonds.2  
 
O
O
OH
O
O
O
O
O
O
O
O
OH
O
O
A C
B
Ph Ph
R R
1 2
3 4
5 6
Flavonoids
Isoflavonoids R= H, OH  
Figure 1 
 
Many flavonoids possess low toxicity in mammals and some of them are widely used in 
medicine for maintenance of capillary integrity.3 Concerning the chromenone moiety, besides 
forming the basic nucleus of an entire class of natural products, i.e. flavones,4 it also forms 
the important component of pharmacophores for a large number of molecules of medicinal 
significance.5 Consequently, considerable attention is being devoted to isolation from natural 
resources, chemistry and synthesis of chromenone derivatives, and evaluation of their 
biological activity with emphasis on their potential medicinal applications.5–8 
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4.2     Biological activity of various chromenone derivatives. 
In recent decades, chromenone and its derivatives have attracted considerable 
attention from medicinal and synthetic organic chemists because of a wide range of 
biological activities displayed by this class of compounds which is described below. The 
corresponding 2-substituted-3-nitro chromenones are molecules of current interest as they 
have potent biological activity. It is well recognized that incorporation of nitro group into the 
chromenone skeleton have significant biological activity.9,10  
 
Vasselin A. D. et al11 have synthesized a new series of fluoro, methoxy and amino substituted 
isoflavones (Figure 2) and demonstrated as potent antitumor agents. The substituted 
isoflavones were synthesized using palladium catalyzed coupling methodologies to construct 
the central aryl carbon-carbon single bond. The new isoflavone derivatives were tested for in 
vitro activity in human breast (MDA-MB-468 and MCF-7) and colon (HT29 and HCT-116) 
cancer cell lines. Low micromolar GI50 values were obtained in a number of cases, with the 
MDA-MB-468 cell line being the most sensitive overall. This study is suggesting that 
isoflavone derivatives can act as substrates for CYP1A1 bioactivation. 
 
O
O
R1
R
R= F, OMe, diF, diOMe
R1= NO2, OMe, diOMe  
Figure 2 
 
Chen S. F. et al9 have developed a series of nitrocoumarin and nitrochromene derivatives 
(Figure 3) and shown to inhibit the phosphatidylinositol-specific phospholipase C(PLC) 
(ICW C 10 pg/mL) isolated from human melanoma. The inhibition of PLC by nitrocoumarin 
was time-dependent and irreversible. The inhibition of PLC was shown to interfere with 
inositide metabolism in whole cells in a manner consistent with their proposed mode of 
activity.  
 
O
NO2
N
X= O, NH, NMe
X
O
NO2
R= Aryl
NH
R
 
Figure 3 
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Dauzonne D. et al10 have synthesized some novel flavone-8-acetic acid derivatives and 
evaluated for reversible inhibitors of aminopeptidase N(APN/CD13) activity. The cell surface 
APN/CD13, overexpressed in tumor cells, plays a critical role in angiogenesis. In this 
context, they have tested a series of novel flavone-8-acetic acid derivatives and found that the 
2’, 3-dinitroflavone-8-acetic acid proved to be the most efficient and exhibited an IC50 of 25 
µM which is 2.5 times higher than that of bestatin, the natural known inhibitor of 
APN/CD13. The presence of other substituents such as OMe groups at the 3 or 4 position of 
the A phenyl group, or the existence of steric constraints, did not improve selectivity and 
potency. The results were indicated that derivatives, which bear a CH2COOH group in the 8-
position and two NO2 substituents in both 2’ and 3 positions (Figure 4), inhibited efficiently 
APN activity and this to the same extent as bestatin. Deletion or replacement of the NO2 
group in the 2’-position gave compounds with a lesser degree of potency against APN 
activity whereas the presence of an electron-donating methoxy group in the ortho or para 
position of the nitro substituent led to slightly lowered inhibitory effects. 
 
O
NO2
O2N
O
HOOC
A
 
Figure 4 
 
Balbi A. et al,13 have synthesized some chromenone derivatives (Figure 5) having nitro 
group and amine linkage at 3 and 2 positions, respectively, and demonstrated that they were 
potent stabilization agents for oligonucleotides. The newly synthesized chromenones having 
tri or pentamethylenamine linkers were tested and the Tm data and thermodynamic parameters 
for complex formation confirmed the ability of chromone (c-pyrone) derivatives to stabilize 
strongly the 7-mer/8-mer complementary complex. Moreover, benzochromone derivatives 
showed the capacity of stabilizing this 7-mer/8-mer complementary complex. The effect of 
all these chromenones on the stability of the oligonucleotide complexes (ΔΔG at 37 ºC 
ranged from -1.2 to -2.0 kcal/mol) was shown to be comparable to the effect of one 
nucleotide base pair and similar to the effect (ΔΔG at 37 ºC ranged from -1.5 to -2.0 
kcal/mol) found for acridine oligonucleotide conjugates, which served as a reference in this 
study.   
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R= N(CH3)2, NH(CH2)NH2
R1= H, 4-NO2Ph, iPr
 
Figure 5 
 
Cantello C. C. et al14 have synthesized some substituted 4-hydroxy-3-nitrocoumarins and 
found these compounds possess potent antiallergic activity (Figure 6). The antiallergic 
activity was measured by the homocytotropic antibody-antigen induced passive cutaneous 
anaphylaxis reaction in the rat.    
 
O
OH
NO2
O
R= H, Me, Halo, NH2, NO2, OH, OMe
R
 
Figure 6 
 
The design and synthesis of a small library of 8-amidoflavone, 8-sulfonamidoflavone, 8-
amido-7-hydroxyflavone (Figure 7) and heterocyclic analogs of flavopiridol was reported by 
Georg G. I. and coworker.15 The potential activity of these compounds as kinase inhibitors 
was evaluated by cytotoxicity studies in MCF-7 and ID-8 cancer cell lines and inhibition of 
CDK2-Cyclin A enzyme activity in vitro. The antiproliferative and CDK2- Cyclin A 
inhibitory activity of these analogs was significantly lower than the activity of flavopiridol. 
They were carried out molecular docking simulations for those molecules and these studies 
suggested a different binding orientation inside the CDK2 binding pocket for these analogues 
compared to flavopiridol. 
 
O
O
R= alkyl or aryl
OH
NHS
O
O R
Cl
 
Figure 7 
 
Griffin R. J. et al16 have synthesized a diverse range of chromen-2-one, chromen-4-one and 
pyrimidoisoquinolin-4-one derivatives and evaluated for inhibitory activity against the DNA 
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repair enzyme DNAdependent protein kinase (DNA-PK), with a view to elucidating 
structure-activity relationships for potency and kinase selectivity. DNA-PK inhibitory activity 
varied widely over the series of compounds evaluated (IC50 values ranged from 0.19 to >10 
µM), with excellent activity being observed for the 7,8-benzochromenone and pyrimido[2,1-
a]isoquinolinone templates. They have revealed a very constrained structure-activity 
relationship at the 2-position of the benzopyranone and pyrimido[2,1-a]-isoquinolin-4-one 
pharmacophore, with only a 2-morpholino or 2-(2’-methylmorpholino) group being tolerated 
at this position. More detailed biological studies conducted with the most potent inhibitor 
NU7163 demonstrated ATP-competitive DNA-PK inhibition, with a Ki value of 24 nM, and 
compound (Figure 8) exhibited selectivity for DNA-PK compared with the related enzymes 
ATM, ATR, mTOR, and PI 3-K (p110alpha). This study was identify these structural classes 
as novel DNA-PK inhibitors and delineated initial structure activity relationships against 
DNA-PK. 
 
O
X
N
X, Y= O or S
Y
 
Figure 8 
 
Dauzonnel D. et al17 have synthesized some new 3-aminoflavones (Figure 9) using various 
aromatic aldehydes. They have also demonstrated these chromenones possess potent 
cytotoxic activity in vitro. Those results in the 3-aminoflavones series indicated that the 4’-
methoxy group was important for cytotoxic activity. Moreover, they were observed that the 
flavone analogs bearing 3-amino of 3-nitro group have potent cytotoxic activity. Methoxy 
groups on the 6 and 7 positions of flavonoids also appear to be important for antiproliferative 
activity. 
  
O
O
NH2
R
R1
R= H, OMe, Halo, Me
R1= H, OMe, NO2,Me  
Figure 9 
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Chen K. et al18 have studied three-dimensional quantitative structure-activity relationship 
(3D-QSAR) for flavone (Figure 10) template in GABAA receptors. A reasonable 
pharmacophore model was built through CoMFA, CoMSIA, and HQSAR analyses and 
electrostatic potential calculations. A plausible binding mode for flavonoids with GABAA 
receptors was rationalized on the basis of commonly recognized binding site and the specific 
S1 and S2 subsites relating to substituent positions.  
 
O
O
R
R1
R, R1= H, OMe, Halo, Me, NO2  
Figure 10 
 
In 2008,19 several fused chromenones (Figure 11) have been synthesized and found useful in 
the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 
channels found in T cells. These chromenone derivatives were also useful in the prevention 
of autoimmune and inflammatory diseases, including multiple sclerosis. 
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X
R6
R1= H, Me, alkyl, aryl
R2= H, OMe, Halo, Me,alkyl
R3= H, Me, Halo, alkyl
R4= H, Me, R5= H, Me, alkyl, NO2, aryl, halo,
R6= H, Me, alkyl, aryl, X= N, S, O
O
R2
R1
R5
R4
R3
 
Figure 11 
 
Lewin C. et al20 have synthesized several aminoflavones and examined its antiproliferative 
activity, activation of apoptosis and inhibition of tubulin assembly. These flavones mostly 
contained 5,6,7,8-tetra- or 5,7-dioxygenated groups on A ring. Among them, flavones having 
5-hydroxy-6,7,8-trimethoxy substitution pattern on the A-ring exhibited promising 
antiproliferative activity (Figure 12). 
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Figure 12 
 
A new series of flavonoid derivatives have been designed, synthesized and evaluated as 
potent AChE inhibitors by Hua Y. and coworkers.21 Most of them showed more potent 
inhibitory activities to AChE than rivastigmine. The most potent inhibitor isoflavone 
derivative (Figure 13) inhibit AChE with an IC50 of 4 nM and showed high BChE/AChE 
inhibition ratio (4575-fold), superior to donepezil (IC50 = 12 nM, 389-fold). They were also 
performed molecular docking studies to explore the detailed interaction with AChE. 
 
O
O
MeO
MeO
R, R1= H, Me, iPr
N
R
R1
 
Figure 13 
 
In search for a new antibacterial agent with improved antimicrobial spectrum and potency, 
Shingare M. S. et al22 have designed and synthesized a series of novel 3-((Z)-2-(4-
nitrophenyl)-2-(1H-tetrazol-5-yl) vinyl)-4H-chromen-4-ones (Figure 14) by convergent 
synthetic approach. All the synthesized compounds were assayed for their in vitro 
antibacterial activities against gram-negative and gram-positive bacteria. They were 
performed preliminary structure activity relationship to elucidate the essential structure 
requirements for the antimicrobial activity. Amongst the synthesized chromenones, few 
compounds were found to possess activity against methicillin resistant S. aureus in addition 
to the activity against other bacterial strains such as E. faecalis, S. pneumoniae, and E. coli. 
 
O
O
R= H, Me, Halo, OMe, NO2, OH, disub, trisub.
NO2
N
N N
NH
R
 
Figure 14 
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Moreover, a new series of quinoxaline fused chromenones have been synthesized and 
evaluated for antibacterial and antifungal activities.23 The results of the antimicrobial 
screening showed the compound (Figure 15) being the most effective among the various 
treatments in antimicrobial screening. However, other molecules showed moderate activity 
against the microorganisms tested. 
 
O
O2N
O
NH
HN
OMe
OMe
 
Figure 15 
 
4.3 Synthesis of various chromenone derivatives. 
Numerous methods have been developed for the synthesis of substituted chromenone 
molecules. The two most important methods for the synthesis of chromenone derivatives are 
due to Perkin W. H.24 and Pechmann V25. The naturally occurring chromenones26 have been 
obtained either (i) by the closure of the lactonic ring with the necessary substitutents in the 
benzene nucleus, or (ii) by the introduction of the aliphatic acid and its anhydride on an o-
hydroxy aldehyde with the intermediate formation of the o-hydroxy cinnamic acid (Perkin’s 
method) and the action of malic acid on phenols in the presence of sulphuric acid 
(Pechmann’s method) have been very convenient methods for the synthesis of naturally 
occurring chromenones. The o-hydroxy cinnamic acids have also been prepared by other 
methods and them easily lactonize to chromenones. 
 
The phenols have been used by Ruhemann S.27 and Simonis H.28 for the synthesis of 
chromone derivatives. Ruhemann condensed sodium phenolates with ethyl chloro fumarate, 
ethyl phenyl propiolate and ethyl β-chloro crotonate and treated the intermediate products, 
thus obtained, with con. H2SO4 or better with PCl5 and AlCl3 whereby the desired chromones 
were obtained (Figure 16). 
 
O R
HOOC
O R
O
R= Me, Ph, COOH
 
Figure 16 
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The only attempt at synthesizing chromones from o-hydroxy acid was made by Kostanecki S. 
V.,29a who condensed ethyl o-methoxy benzoate with acetone and acetophenone and obtained 
the chromones on heating the intermediate β-diketones with HCl (Figure 17). 
 
O
R= Me, Ph
OMe
O
OEt
OMe
O
RCH3COR
O
O
R
 
Figure 17 
 
The o-hydroxy acetophenones have been largely used for the synthesis of chromone 
derivatives. Kostanecki29b et al have condensed o-hydroxy acetophenones with aldehydes 
giving rise to chalkones, the dibromides of which on treatment with alkali form chromones 
(Figure 18). 
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O R
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Figure 18 
 
Moreover, Kostanecki29c et al have synthesized chromenones by the reaction of esters with o-
methoxy acetophenones and the resulted intermediate β-diketones then heated with 
hydroiodic acid (Figure 19). 
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O R
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Figure 19 
 
Spath E.30 et al have condensed o-hydroxy phenyl benzyl ketones with ethyl formate and the 
intermediate oxymethylene ketones gave isoflavones on ring closure with HCl (Figure 20).  
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O
HCO2Et
O
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O
O
Ph Ph
CH2OH
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Figure 20 
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Nagai W. N.31a and Tahara Y.31b et al have utilized resacetophenone and phenol for the 
synthesis of chromenones in the presence of sodium acetate and acetic anhydride (Figure 
21). However, this method was further developed by Robinson32 et al and used by them in 
synthesizing a large number of chromones and chromonols occurring in nature by heating 
various o-hydroxy aryl ketones with the anhydrides and the corresponding sodium salts of 
aliphatic and aromatic acids.  
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Figure 21 
 
Recently, Alfredo C. et al33 have synthesized flavones via a microwave assisted, One-Pot 
Sonogashira-carbonylation-annulation reaction starting from 2-iodo phenol and acetylene 
(Figure 22). They were observed that palladium complexes of 1,3,5,7-tetramethyl-2,4,8-
trioxa-6-phenyl-6-phosphaadamantane are shown to be effective catalytic systems facilitating 
the sequential application of a microwave-assisted Sonogashira and carbonylative annulation 
reaction.    
 
CO
Me3Si C CH I
OH O
O
DBU, Ph2pentadienone Pd,
DMF, 4h, 50 oC
 
Figure 22 
 
In addition, Zhen Y. et al34 have developed a Pd-catalyzed copper-free carbonylative 
Sonogashira coupling reaction to synthesize alkynyl ketones and flavones from terminal 
alkynes and aryl iodides using water as a solvent (Figure 23).  The reaction was carried out at 
room temp under balloon pressure of CO with Et3N as a base.  The developed method was 
successfully applied to the synthesis of flavones. 
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I
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Et3N, PdCl3, PPh3
H2O, 6 min, rt
 
Figure 23 
 
In 2002, Rao V. K. et al35 have demonstrated the utility of o-hydroxy benzoylacetone for the 
synthesis of some substituted chromenones, chelating agents and related materials. The 
synthesis of 3-nitro chromenone was achieved by the reaction of o-hydroxy 
nitroacetophenone and ethyl orthoformate using pyridine (Figure 24).  
 
O
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NO2
OH
CH(OEt)3
Pyridine NO2
 
Figure 24 
 
Chen S. F. et al9 have synthesized 4-(3-nitro-2H-chromen-2-yl)morpholine (Figure 25) with 
the reaction of salisaldehyde and 4-((Z)-2-nitrovinyl)morpholine refluxing in morpholine. 
The synthesized chromenes further substituted at 2-position with various primary and 
secondary amines and evaluated as potent phospholipase C inhibitors.  
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Figure 25 
 
In 1976, Ellis G. P. et al36 have first synthesized some substituted 3-nitro chromones by the 
reaction of nitroacetophenone and acetic formic anhydride (Figure 26).  
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Figure 26 
 
In addition, et al37 have utilized substituted 2-hydroxy-ω-nitroacetophenone and chromenone-
3-carbaldehyde for the synthesis of various 2-substituted-3-nitro chromenones in good yields 
(Figure 27).  
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Figure 27 
 
Balbi A. et al13 have synthesized substituted 2-amino-3-nitro chromenone derivatives starting 
from various phenols and ethyl 2-(dimethylcarbamoyl) acetate followed by POCl3 mediated 
cycliczation and nitration (Figure 28). The synthesized chromenones were evaluated as 
potent stabilizing agents for oligonucleotides. 
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NMe2
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NO2Me2N
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O OEt
iPr
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MeiPr
POCl3, PhCl, 5h
H2SO4, HNO3, 
0 oC, 30 min, rt
 
Figure 28 
 
In 1995, Dauzonne D. et al38 have described an efficient synthesis of 3-nitrochromones. The 
reaction of 2-hydroxy-2-nitroacetophenone with acetic formic anhydride and sodium formate 
without external heating or cooling gave an almost quantitative yield of 3-nitrochromone 
(Figure 29). 
 
O
O
NO2
OH
O
NO2R
AcOCHO
RPyridine
R= H, NO2  
Figure 29 
 
Moreover, Dauzonne D. et al10 have synthesized flavone-8-acetic acid using 3-allyl-2-
hydroxybenzaldehyde 1 and 1-((Z)-2-chloro-2-nitrovinyl) benzene 2. Further, the product 3 
was treated with PCC in DCM for 19 h then reaction of 4 with DBU afforded 2-aryl-3-nitro 
chromenone 5. Compound 5 on reaction with ruthenium chloride, sodium hypoiodate in 
acetonitrile and CTC afforded product 6 which on reduction gave the target molecule 7 
(Figure 30).   
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Figure 30 
 
Recently, an efficient route to a new class of tetrahydrochromeno[2,3-b]carbazoles and 
tetrahydrochromeno[3,2-f]indazoles has been developed by Tsoleridis A. et al.39 The 
cycloaddition reactions of chromones 1 and pyrazole-o-quinodimethane 2 were more 
regioselective giving only cycloadducts 3 (Figure 31).  
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Figure 31 
 
Hu W. et al40 have synthesized, and examined crystal and molecular structure of 3-chloro-
3,6-dinitro-2,2- dimethyl-4-chromanone 3, the first 3-chloro-3-nitro-4-chromanone by 
nitrating its corresponding 4-chromanone 1 at the 3 position and then chlorinating the 
nitration product 2. They were observed that the nitro group at the 6 position conjugates with 
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the benzene ring. The pyranone ring has a half-chair conformation; the chloro group occupies 
the pseudoequatorial position, and the nitro group occupies the pseudoaxial position. The 2 
and 3 positions are essentially antiperiplanar, minimizing steric interaction (Figure 32). 
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Figure 32 
 
Recently, Rao H. S. et al51a have developed a combinatorial library of the 2-alkylamino-3-
nitro 4-alkylsufanyl-4H-chromenes (Figure 33). They were demonstrates the reaction of 
nitroketene N,S-acetals and substituted salisaldehydes afforded the nitrochromenes in the 
presence of base with excellent yields. Further, they have replaced the C4 methylthio group 
with various thiols to obtained substituted chromenones in good yields. 
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R1= H, Me, OMe, Halo, NO2, OH;   R2= Aryl, Alkyl  
Figure 33 
 
? Nitro group in various chemical transformation reactions. 
Nitro group can be converted to amine functionality using various reducing agents. As 
we described above,10 the 3-nitroflavone-8-acetic acid on reaction with palladium and carbon 
at 20 oC for 16 h gave 3-aminoflavone-8-acetic acid by reduction of nitro group (Figure 34).   
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NH2H2, Pd/C
THF, 20 oC, 16h
 
Figure 34 
 
Fringuelli F. et al41 have utilized 3-nitrocoumarins as dienophiles in the Diels-Alder reaction 
in water. They were described new approach to the Synthesis of nitrotetrahydrobenzo[c]- 
chromenones and dihydrodibenzo[b,d]furans (Figure 35). The reactions of 8-hydroxy-3-
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nitrocoumarins with various diene were investigated in aqueous medium, in organic solvent 
and under solventless conditions. The reactions performed in water occurred in 
heterogeneous phase but were faster than those executed organic solvents. 
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Figure 35 
Vinokurov V. G. et al42 have synthesized 6,7,8,13-tetrahydro[l]benzopyrano-[4,3-b][l,4]- 
benzodiazepine-6,8-dione by the condensation of 3-nitro-4-chlorocoumarin and anthranilic 
acid. Thus, the obtained amides were reduced to N-(3-amino-4-coumarinyl)anthranilic acid 
amides and further cyclized in the presence of catalytic amount of hydrochloric acid to 
diazepines (Figure 36). 
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Figure 36 
 
Junjappa H. et al43 have developed a novel highly regioselective synthesis of substituted 
quinoxalines (Figure 37) through POCl3 mediated heteroannulation of nitroketene N,S-
arylaminoacetals. The 3-chloro-2-(methylthio)quinoxalines further substituted with various 
nucleophiles. 
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Figure 37 
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A new synthesis of 2-substituted[1]benzopyrano[3,4-d]imidazol-4(3H)-ones, starting from 3-
nitrocoumarin N-functionalized amidines 3, has been developed by Trimarco P. et al.44 When 
the 3-nitro-amidines 3 were treated with NaBH4 in the presence of 10% palladium on 
charcoal, 2-substituted [1]benzopyrano[3,4-d]imidazol-4(3H)-ones 4 were produced. 
Structure elucidation of compounds 4 revealed that they exist as one of the three possible 
tautomeric structures (Figure 38).  
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4.4 CURRENT RESEARCH WORK 
 
The chromenone and its derivatives have attracted considerable interest to medicinal 
and synthetic organic chemists because of a wide range of biological activities. As we 
mentioned, the corresponding 2-substituted-3-nitro chromenones are molecules of current 
interest as they have potential biological activity. Moreover, Chromenones bearing nitro 
group at C3, afford the possibility of further modifications through which, one can generate, a 
large number of pharmacologically important compounds. Given the biological significance 
of 2,3-substituted chromenones, several routes are reported in the literature for the synthesis 
of substituted chromenone via [4+2] annulation,45 [5+1] addition,36,46 [4+1+1] addition 
reaction,47 or electrophilic substitution reactions over the preconstructed chromone motifs. 
However, these potentially useful methods have not been thoroughly explored. Further more, 
the existing few examples are rather limited in scope and suffer from several practical 
disadvantages such as extremely vigorous conditions or low yields.48 Therefore, developing a 
simple and effective method to synthesize 2-substituted-3-nitro chromenones via readily 
available starting material is essential. 
 
In chapter 1, we have demonstrates the utility of ω-nitro acetophenone for the synthesis of 
nitro functionalized pyrimidine derivatives. Nowadays, functionalized ketene dithioacetals 
are versatile intermediates in organic synthesis for the synthesis of substituted heterocycles 
(Chapter 2). These studies motivated us to utilize the 2HNA as a versatile synthon to make 
new nitro ketene dithioacetals and to study its utility for the synthesis of novel NO2 group 
functionalized chromenones. The newly synthesized compounds were characterized by IR, 
Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. In addition the newly 
synthesized 2-methylthio-3-nitro-4H-chromen-4-one was confirmed by X-Ray diffraction 
technique. The detail study of X-Ray crystallography is described in chapter 6. The biological 
screening of the newly synthesized compounds is under process.  
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4.5 RESULTS AND DISCUSSION 
 
The reaction of 2HNA 1 with carbon disulfide in the presence of base and followed 
by methylation with methyl iodide, to our surprise, the product isolated was not the expected 
2 but was characterized as 2-methylthio-3-nitro-4H-chromen-4-one 3. In addition the 
structure of 3 was confirmed unequivocally by the analysis of single crystal X-Ray 
diffraction technique (Chapter 6). 
 
 
Scheme 1: Synthesis of novel 2-methylthio-3-nitro-4H-chromen-4-one (3) through 
intramoleculer heteroannulation of 2. 
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Having discovered a facile synthesis of chromenone 3, we next planned to optimize the 
reaction condition using various bases and solvents (Table 1). The yield of desired product 3 
was poor when strong bases such as, NaOi-Pr and NaOMe were used in THF and DMF 
(Table 1, entry 1-4). However, the reaction of 1 with KF in THF and DMF did not improve 
the yield and the reaction needed longer time (Table 1, entry 7,8). It was found that the 
reaction proceeded smoothly in the presence of K2CO3 and THF to furnish the product 3 in 
excellent yield (Table 1, entry 5). 
 
Further, to develop facile route for 2-substituted-3-nitro chromenones through nucleophilic 
substitution of 2-methylthio group, we carried out the reaction of compound 3 with various 
amines. Extensive literature survey revealed, the elimination of methylthio group from 
aromatic or heterocyclic moieties required more drastic conditions.49-52 It is important to note 
that nucleophilic displacement at C2 possessing methylthio group for C-N bond formation 
required either oxidation of sulfide to sulfone then reaction with nucleophiles or transition 
metal catalysts.43,49a However, our studies revealed that elimination of methylthio group by 
various amines in the chromenone 3 was simple and required neither oxidation nor transition 
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metal catalysts. This can be explained by the fact that the adjacent electron-withdrawing 
effect of nitro and carbonyl groups makes the labile methylthio moiety a good leaving group. 
 
Table 1: Optimization of the reaction condition for the synthesis of 3. 
 
Entry Base(2 equiv) Solvent Time h Yield (%) 
1 NaOi-Pr THF 1.5 52 
2 NaOi-Pr DMF 1.7 48 
3 NaOMe THF 2.0 64 
4 NaOMe DMF 2.3 60 
5 K2CO3 THF 1.5 88 
6 K2CO3 DMF 1.5 80 
7 KF THF 3.0 68 
8 KF DMF 3.2 66 
 
 
 
Scheme 2: Reaction of chromenone 3 with primary alkyl/aryl and secondary amines. 
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Thus, under the optimized condition, the reaction of primary alkyl/aryl amines with 
chromenone 3 in isopropyl alcohol afforded substituted 2-aryl/alkylamine-3-nitro-4H-
chromenones FPMS 1-23 in excellent yields (Table 2, Scheme 2). However, the reaction of 
various secondary amines with chromenone was conducted using dioxane as solvent which 
afforded chromenones FPMS 24-29 with good to excellent yields (Table 3, Scheme 2).  
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Table 2: Synthesis of 2-aryl/alkylamine-3-nitro-4H-chromen-4-ones FPMS 1-23. 
 
Entry R Yield % mp oC Purity % 
FPMS-1 Ph 97 220-222 97.89 
FPMS-2 3-CH3Ph 95 165-167 95.49 
FPMS-3 4-OCH3Ph 94 174-176 97.75 
FPMS-4 2-FPh 94 186-188 95.56 
FPMS-5 3,4-diClPh 95 185-187 98.91 
FPMS-6 4-CH3Ph 92 155-157 95.56 
FPMS-7 4-FPh 97 160-162 99.73 
FPMS-8 3,4-diFPh 92 191-193 94.89 
FPMS-9 4-EtPh 95 210-312 92.78 
FPMS-10 2-OCH3,4-NO2Ph 88 188-190 94.88 
FPMS-11 3-Cl,4-FPh 92 154-156 91.37 
FPMS-12 3-BrPh 93 182-184 96.78 
FPMS-13 4-NO2Ph 96 177-179 96.24 
FPMS-14 2,3-diCH3Ph 95 181-183 94.99 
FPMS-15 2-OCH3Ph 91 170-172 96.65 
FPMS-16 2,4-diCH3Ph 91 185-187 98.80 
FPMS-17 4-ClPh 90 161-163 93.38 
FPMS-18 3-OCH3Ph 94 167-168 93.56 
FPMS-19 3-NO2Ph 93 172-174 95.82 
FPMS-20 2-ClPh 92 151-153 96.71 
FPMS-21 CH3 96 186-188 94.70 
FPMS-22 Cyclo propyl 97 196-198 95.52 
FPMS-23 Furfuryl 96 178-180 94.07 
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Table 3: Synthesis of novel chromenones FPMS 24-30. 
 
Entry N  Yield % mp 
oC Purity % 
FPMS-24 
N
 
93 133-135 99.49 
FPMS-25 
N
O  
94 136-138 97.54 
FPMS-26 
N
NMe  
97 126-128 96.77 
FPMS-27 
N
NEt  
93 132-134 96.17 
FPMS-28 N
Me
Me  
95 141-143 95.68 
FPMS-29 N
 
96 124-126 96.10 
FPMS-30 N
 
91 142-144 97.03 
 
 
 
The plausible mechanism for the formation of chromenone 4 from 1 may involve initial 
formation of nitroketene dithioacetals 2 and followed by intramoleculer heteroannulation 
(Scheme 3). The o-hydroxy group appears to undergo nucleophilic attack on suitably located 
β-C atom, which mainly activated by the presence of nitro group at the α-position of ketene 
dithioacetals and followed by elimination of methylthio group 3 to furnish the corresponding 
chromenone in good yields (scheme 1). The mechanism for the direct nucleophilic addition 
with chromenone involves activation of C2 which is triggered by NO2 and carbonyl groups 
present at C3. The excellent electron-withdrawing effect of nitro and carbonyl groups create 
the C2═C3 bond as polarized push-pull alkene with electron delocalizing from methylthio to 
nitro group. Due to this polarization effect, the C2 exhibits electrophilic characteristics. In 
addition, the C2 is adjacent to oxygen and methylthio groups which are electronegative (El-ve) 
atom and good leaving group (GL), respectively 4. As a result of these entire affects the C2 
act as hard electrophile, which resulted in facile C-N bond formation with various 
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nucleophiles through elimination of the methylthio group 5 and furnished novel 2-substituted 
chromenones 6. 
 
Scheme 3: Proposed mechanism for the formation of novel chromenone. 
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4.6 CONCLUSION 
 
In summary, we have developed a novel synthetic strategy for the synthesis of 2-
substituted 3-nitro-4H-chromen-4ones through [5+1] heteroannulation of readily accessible 
2-hydroxy-ω-nitro acetophenone with carbon disulfide and followed by straightforward 
nucleophilic addition through elimination of methylthio with various amines. The direct C-N 
bond formation reaction at C2 was achieved by the presence of nitro functionality at C3 
position of chromenone. The newly developed methodology allows direct access to 2-
substituted-3-nitro chromenone in excellent yield and high chemical purity. The presence of 
nitro functionality further makes them useful substrates for various transformations for 
biological interest.  
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4.7 EXPERIMENTAL SECTION 
 
The solvents and chemicals were analytical grade. THF was distilled over 
sodium/benzophenone prior to use and anhydrous K2CO3 was used. Analytical thin layer 
chromatography (TLC) was performed on 0.2-mm precoated plates of Silica Gel 60 F254 
precoated plates. 1H (400 MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO, 
and TMS was used as an internal reference on a Bruker AVANCE II spectrometer. Mass 
spectra were determined using direct inlet probe on a GCMSQP2010 mass spectrometer. 
Chemical purity was determined on Waters Acquity UPLC with PDA Detector using Acquity 
BEH C18, 50 × 2.1, 1.7µm column at 210-400nm. Melting points were measured in open 
capillaries and are uncorrected. 
 
? Gradient Program for UPLC 
Mobile Phase: A - 10 mM Ammonium dihydrogenphosphate, 
 B – Acetonitrile 
 
Entry Time Flow %A %B 
1 Initial 0.2 mL 90 10 
2 5.0 0.2 mL 10 90 
3 5.1 0.2 mL 90 10 
4 6.0 0.2 mL 90 10 
 
 
? General method for the synthesis of substituted ω-nitro acetophenone:   
To a suspension of substituted 4-hydroxycoumarin (26 mmol) in glacial acetic acid 10 ml 
was added slowly a solution of con. HNO3 (2.20 mL) in glacial acetic acid 2 ml. the reaction 
mixture was then heated to 80 ºC at which a vigorous reaction starts. The reaction mix was 
cooled in ice-cold water to keep the reaction mix under control. After completion of the 
reaction, crushed ice was added to the reaction mixture. The separated substituted 3-nitro-4-
hydrxycoumarin was filtered and washed with water and dry it in oven. The product of 
substituted 3-nitro-4-hydroxycouamarin (12 mmol) was dissolved in sodium hydroxide 
solution (5%, 75 mL) and the reaction mixture was kept at rt for 24 h. insoluble material was 
filtered and the clear filtrate acidified with con. HCl. The separated product was filtered and 
washed with water. It is crystallized from methanol.  
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? A typical procedure for the synthesis of 2-(methylthio)-3-nitro-4H-chromen-4-one  
To a well-stirred suspension of K2CO3 (55 mmol) in dry THF (15 mL) at 0-5 ºC was 
added CS2 (27.5 mmol) diluted with 10 mL THF along with substituted 2-hydroxy-ω-
nitroacetophenone (27.5 mmol) over a period of 30 min. After completion of the addition, the 
reaction mixture was stirred at 0-5 ºC for 30 min and rt for 30 min. Appearance of orange 
yellow solid in the reaction medium indicated the formation of disodium salt. To this 
reaction, a solution of methyl iodide (55 mmol) in THF (7 mL) was added dropwise within 
15 min at 0-5 ºC. The mixture was allowed to warm to room temperature and stirred for 5-6 
h, and then poured onto crushed ice under stirring. The separated solid was collected by 
filtration, washed with water (2 × 100 mL) then hexane, dried in vacuo and crystallized from 
chloroform to furnish the analytically pure products in excellent yield which were used for 
next step without further purification. 
 
2-(methylthio)-3-nitro-4H-chromen-4-one (3): Yellow solid; Rf 0.41 (6:4 hexane-EtOAc); 
Yield 98 %; purity 98.91%; mp 185-187 °C; IR (KBr): 3088, 1656, 1512, 1448, 1366, 1321, 
1222, 989; MS m/z: 237(M+); 1H NMR (400 MHz): δ 3.13(s, 3H, CH3), 7.56-7.61(t, 1H, 
ArH), 7.79(d, J = 8.8Hz, 1H, ArH), 7.85-7.91(t, 1H, ArH), 8.11(d, J = 8.6 Hz, 1H, ArH); 
Anal. Calcd. for C10H7NO4S: C, 50.63; H, 2.97; N, 5.90%. Found: C, 50.57; H, 2.90; N, 
5.84%. 
 
? General procedure for the reaction of various alkyl/aryl amines with 
chromenone 3. 
To a solution of various amines (1.15 mmol) in isopropyl alcohol (5 mL) was added 
suspension of 3 (1.05 mmol) and reflux the resulting mixture for 45-60 min. After completion 
of the reaction, the reaction mixture was allowed to come to room temperature then cooled it 
at 0-5 ºC in ice bath. The separated suspension was filtered, washed with water (20 mL), 
dried in vacuo and crystallized from methanol to afford analytically pure products. 
 
3-nitro-2-(phenylamino)-4H-chromen-4-one (FPMS-1): Creamish solid; Rf 0.51 (6:4 
hexane-EtOAc); IR (KBr): 3439, 3377, 1645, 1510, 1213, 1093; MS m/z: 282(M+); 1H NMR 
(400 MHz): δ 7.24(d, J = 0.76Hz, 1H, ArH), 7.40-7.55(m, 6H, ArH), 7.61-7.66 (t, 1H, ArH), 
8.29(dd, J = 7.92Hz, 1H, ArH), 11.65(s, 1H, NH); 13C NMR (100 MHz): 88.17, 116.84, 
118.21, 122.19, 125.00, 125.76, 125.87, 126.93, 128.96, 134.18, 134.88, 151.01, 158.83, 
167.32, Anal. Calcd. for C15H10N2O4: C, 63.83; H, 3.57; N, 9.93%. Found: C, 63.77; H, 3.50; 
N, 9.86%. 
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2-(m-tolylamino)-3-nitro-4H-chromen-4-one (FPMS-2): White solid; Rf 0.52 (6:4 hexane-
EtOAc); IR (KBr): 3389, 3105, 1685, 1478, 1233, 1124, 985; MS m/z: 296(M+); Anal. Calcd. 
for C16H12N2O4: C, 64.86; H, 4.08; N, 9.46%. Found: C, 64.79; H, 4.01; N, 9.40%. 
 
2-(4-methoxyphenylamino)-3-nitro-4H-chromen-4-one (FPMS-3): Creamish solid; Rf 
0.49 (6:4 hexane-EtOAc); IR (KBr): 3274, 3160, 1698, 1491, 1171, 1024; MS m/z: 312(M+); 
13C NMR (100 MHz): 55.33, 87.64, 117.58, 118.51, 122.18, 125.79, 126.66, 134.88, 149.37, 
154.56, 167.54, Anal. Calcd. for C16H12N2O5: C, 61.54; H, 3.87; N, 8.97%. Found: C, 61.49; 
H, 3.82; N, 8.93%. 
 
2-(2-fluorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-4): White solid; Rf 0.51 (6:4 
hexane-EtOAc); IR (KBr): 3591, 3300, 1658, 1512, 1435, 1402, 1288; MS m/z: 300(M+); 
Anal. Calcd. for C15H9FN2O4: C, 60.01; H, 3.02; N, 9.33%. Found: C, 59.89; H, 3.04; N, 
9.21%. 
 
2-(3,4-dichlorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-5): Yellowish solid; Rf 
0.50 (6:4 hexane-EtOAc); IR (KBr): 3287, 3087, 1696, 1436, 1296, 1114; MS m/z: 351(M+); 
Anal. Calcd. for C15H8Cl2N2O4: C, 51.31; H, 2.30; N, 7.98%. Found: C, 51.19; H, 2.18; N, 
7.86%. 
 
2-(p-tolylamino)-3-nitro-4H-chromen-4-one (FPMS-6): Pale yellow solid; Rf 0.50 (6:4 
hexane-EtOAc); IR (KBr): 3419, 3115, 1665, 1489, 1265, 1214, 1174; MS m/z: 296(M+); 
Anal. Calcd. for C16H12N2O4: C, 64.86; H, 4.08; N, 9.46%. Found: C, 64.79; H, 4.01; N, 
9.40%. 
2-(4-fluorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-7): Creamish solid; Rf 0.51 
(6:4 hexane-EtOAc); IR (KBr): 3468, 3160, 1666, 1590, 1375, 1232, 1188; MS m/z: 
300(M+); Anal. Calcd. for C15H9FN2O4: C, 60.01; H, 3.02; N, 9.33%. Found: C, 59.89; H, 
3.04; N, 9.21%. 
 
2-(3,4-difluorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-8): White solid; Rf 0.48 
(6:4 hexane-EtOAc); IR (KBr): 3337, 3027, 1696, 1590, 1417, 1392, 1258, 1172; MS m/z: 
318(M+); Anal. Calcd. for C15H8F2N2O4: C, 56.61; H, 2.53; N, 8.80%. Found: C, 56.49; H, 
2.41; N, 8.68%. 
 
2-(4-ethylphenylamino)-3-nitro-4H-chromen-4-one (FPMS-9): Yellowish solid; Rf 0.51 
(6:4 hexane-EtOAc); IR (KBr): 3328, 3120, 1676, 1500, 1385, 1242, 1088; MS m/z: 
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310(M+); Anal. Calcd. for C17H14N2O4: C, 65.80; H, 4.55; N, 9.03%. Found: C, 65.69; H, 
4.41; N, 8.91%. 
 
2-(2-methoxy,4-nitrophenylamino)-3-nitro-4H-chromen-4-one (FPMS-10): Yellow solid; 
Rf 0.48 (6:4 hexane-EtOAc); IR (KBr): 3389, 3360, 1693, 1507, 1473, 1312, 1288; MS m/z: 
357(M+); Anal. Calcd. for C16H11N3O7: C, 53.79; H, 3.10; N, 11.76%. Found: C, 53.67; H, 
2.94; N, 11.62%. 
 
2-(3-chloro,4-fluorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-11): White solid; Rf 
0.51 (6:4 hexane-EtOAc); IR (KBr): 3467, 3068, 1714, 1530, 1477, 1392, 1198; MS m/z: 
334(M+); Anal. Calcd. for C15H8ClFN2O4: C, 53.83; H, 2.41; N, 8.37%. Found: C, 53.71; H, 
2.28; N, 8.25%. 
 
2-(3-bromophenylamino)-3-nitro-4H-chromen-4-one (FPMS-12): Creamish solid; Rf 0.53 
(6:4 hexane-EtOAc); IR (KBr): 3472, 3116, 1694, 1526, 1485, 1337, 1174; MS m/z: 
361(M+); Anal. Calcd. for C15H9BrN2O4: C, 49.89; H, 2.51; N, 7.76%. Found: C, 49.77; H, 
2.37; N, 7.62%. 
 
2-(4-nitrophenylamino)-3-nitro-4H-chromen-4-one (FPMS-13): Yellowish solid; Rf 0.51 
(6:4 hexane-EtOAc); IR (KBr): 3357, 3071, 1695, 1541, 1351, 1237, 1108; MS m/z: 
327(M+); Anal. Calcd. for C15H9N3O6: C, 55.05; H, 2.77; N, 12.84%. Found: C, 54.91; H, 
2.64; N, 12.72%. 
 
2-(2,3-dimethylphenylamino)-3-nitro-4H-chromen-4-one (FPMS-14): White solid; Rf 
0.51 (6:4 hexane-EtOAc); IR (KBr): 3392, 3070, 1681, 1470, 1335, 1221, 1108; MS m/z: 
310(M+); Anal. Calcd. for C17H14N2O4: C, 65.80; H, 4.55; N, 9.03%. Found: C, 65.67; H, 
4.42; N, 8.89%. 
 
2-(2-methoxyphenylamino)-3-nitro-4H-chromen-4-one (FPMS-15): Creamish solid; Rf 
0.50 (6:4 hexane-EtOAc); IR (KBr): 3368, 3170, 1657, 1413, 1271, 1224; MS m/z: 312(M+); 
Anal. Calcd. for C16H12N2O5: C, 61.54; H, 3.87; N, 8.97%. Found: C, 61.48; H, 3.83; N, 
8.91%. 
 
2-(2,4-dimethylphenylamino)-3-nitro-4H-chromen-4-one (FPMS-16): White solid; Rf 
0.52 (6:4 hexane-EtOAc); IR (KBr): 3424, 3187, 1697, 1584, 1335, 1231, 1192; MS m/z: 
310(M+); Anal. Calcd. for C17H14N2O4: C, 65.80; H, 4.55; N, 9.03%. Found: C, 65.68; H, 
4.42; N, 8.88%. 
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2-(4-chlorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-17): Yellowish solid; Rf 0.53 
(6:4 hexane-EtOAc); 3487, 3018, 1734, 1680, 1577, 1439, 1108; MS m/z: 316(M+); Anal. 
Calcd. for C15H9ClN2O4: C, 56.89; H, 2.86; N, 8.85%. Found: C, 56.84; H, 2.81; N, 8.78%. 
 
2-(3-methoxyphenylamino)-3-nitro-4H-chromen-4-one (FPMS-18): White solid; Rf 0.51 
(6:4 hexane-EtOAc); IR (KBr): 3416, 3117, 1671, 1541, 1427, 1224; MS m/z: 312(M+); 
Anal. Calcd. for C16H12N2O5: C, 61.54; H, 3.87; N, 8.97%. Found: C, 61.48; H, 3.83; N, 
8.91%. 
 
2-(3-nitrophenylamino)-3-nitro-4H-chromen-4-one (FPMS-19): Yellow solid; Rf 0.50 
(6:4 hexane-EtOAc); IR (KBr): 3471, 3301, 1699, 1513, 1322, 1230, 1047; MS m/z: 
327(M+); Anal. Calcd. for C15H9N3O6: C, 55.05; H, 2.77; N, 12.84%. Found: C, 54.88; H, 
2.69; N, 12.75%. 
 
2-(2-chlorophenylamino)-3-nitro-4H-chromen-4-one (FPMS-20): Yellow solid; Rf 0.53 
(6:4 hexane-EtOAc); IR (KBr): 3420, 3310, 1788, 1687, 1514, 1490, 1170; MS m/z: 
316(M+); Anal. Calcd. for C15H9ClN2O4: C, 56.89; H, 2.86; N, 8.85%. Found: C, 56.81; H, 
2.72; N, 8.78%. 
 
2-(methylamino)-3-nitro-4H-chromen-4-one (FPMS-21): Yellow solid; Rf 0.49 (6:4 
hexane-EtOAc); IR (KBr): 3357, 3147, 1689, 1523, 1272, 1130, 1017; MS m/z: 220(M+); 1H 
NMR (400 MHz): δ 3.33(d, J = 5.16Hz, 3H, CH3), 7.35(d, J = 8Hz, 1H, ArH), 7.41-7.45(t, 
1H, ArH), 7.63-7.67(t, 1H, ArH), 8.28(dd, J = 7.88Hz, 1H, ArH), 10.06(s, 1H, NH); Anal. 
Calcd. for C10H8N2O4: C, 54.55; H, 3.66; N, 12.72%. Found: C, 54.49; H, 3.61; N, 12.75%. 
 
2-(cyclopropylamino)-3-nitro-4H-chromen-4-one (FPMS-22): Yellow solid; Rf 0.52 (6:4 
hexane-EtOAc); IR (KBr): 3315, 3170, 1698, 1517, 1401, 1373, 1270; MS m/z: 232(M+); 
Anal. Calcd. for C11H8N2O4: C, 56.90; H, 3.47; N, 12.06%. Found: C, 56.78; H, 3.35; N, 
11.98%. 
2-(furan-2-ylamino)-3-nitro-4H-chromen-4-one (FPMS-23): Yellow solid; Rf 0.51 (6:4 
hexane-EtOAc); IR (KBr): 3320, 3240, 1788, 1587, 1314, 1280, 1170; MS m/z: 272(M+); 
Anal. Calcd. for C13H8N2O5: C, 57.36; H, 2.96; N, 10.29%. Found: C, 57.24; H, 2.84; N, 
10.17%. 
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? General procedure for the reaction of various secondary amines with 
chromenone 3: 
To a solution of various secondary amines (1.15 mmol) in dioxane (5 mL) was added 
suspension of 3 (1.05 mmol) and reflux the resulting mixture for 75-80 min. After completion 
of the reaction, the reaction mixture was allowed to come to room temperature then add water 
20 mL and extracted with chloroform (2 × 10 mL). The separated organic layer was dried 
over MgSO4 and evaporated under reduced pressure to afforded analytically pure products. 
 
3-nitro-2-(piperidin-1-yl)-4H-chromen-4-one (FPMS-24): Reddish brown solid; Rf 0.27 
(4:6 hexane-EtOAc); IR (KBr): 3061, 1662, 1591, 1508, 1492, 1421, 1178; MS m/z: 
274(M+); 13C NMR (100 MHz): 22.82, 24.83, 48.09, 87.32, 117.16, 121.56, 125.65, 134.07, 
151.46, 158.20, 168.89, Anal. Calcd. for C14H14N2O4: C, 61.31; H, 5.14; N, 10.21%. Found: 
C, 61.27; H, 5.09; N, 10.17%. 
 
2-morpholino-3-nitro-4H-chromen-4-one (FPMS-25): Reddish brown solid; Rf 0.28 (4:6 
hexane-EtOAc); MS m/z: 276(M+); IR (KBr): 3074, 1681, 1574, 1443, 1403, 1167; Anal. 
Calcd. for C13H12N2O5: C, 56.52; H, 4.38; N, 10.14%. Found: C, 56.48; H, 4.39; N, 10.17%.  
 
2-(4-methylpiperazin-1-yl)-3-nitro-4H-chromen-4-one (FPMS-26): Brown solid; Rf 0.26 
(4:6 hexane-EtOAc); IR (KBr): 3049, 1679, 1587, 1463, 1280, 1140; MS m/z: 289(M+); 
Anal. Calcd. for C14H15N3O4: C, 58.13; H, 5.23; N, 14.53%. Found: C, 58.10; H, 5.18; N, 
14.58%. 
 
2-(4-ethylpiperazin-1-yl)-3-nitro-4H-chromen-4-one (FPMS-27): Reddish solid; Rf 0.25 
(4:6 hexane-EtOAc); IR (KBr): 2932, 1682, 1574, 1325, 1248, 1109; MS m/z: 303(M+); 1H 
NMR (400 MHz): δ 1.11-1.14(t, 3H, CH3), 2.48-2.52(q, 2H, CH2), 2.62-2.64(t, 4H, CH2), 
3.60-3.63(t, 4H, CH2), 7.31(d, J = 8.28Hz, 1H, ArH), 7.38-7.42(t, 1H, ArH), 7.61-7.66(t, 1H, 
ArH), 8.23(dd, J = 7.84Hz, 1H, ArH); Anal. Calcd. for C15H17N3O4: C, 59.40; H, 5.65; N, 
13.85%. Found: C, 59.37; H, 5.59; N, 13.81%. 
 
2-(dimethylamino)-3-nitro-4H-chromen-4-one (FPMS-28): Reddish brown solid; Rf 0.24 
(4:6 hexane-EtOAc); IR (KBr): 3071, 1688, 1495, 1326, 1105, 1030; MS m/z: 234(M+); 
Anal. Calcd. for C11H10N2O4: C, 56.41; H, 4.30; N, 11.96%. Found: C, 56.29; H, 4.18; N, 
11.83%. 
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3-nitro-2-(1H-pyrrol-1-yl)-4H-chromen-4-one (FPMS-29): Brown solid; Rf 0.25 (4:6 
hexane-EtOAc); IR (KBr): 3022, 1679, 1571, 1430, 1221, 1109; MS m/z: 256(M+); Anal. 
Calcd. for C13H8N2O4: C, 60.94; H, 3.15; N, 10.93%. Found: C, 60.81; H, 3.02; N, 10.81%. 
 
3-nitro-2-(pyrrolidin-1-yl)-4H-chromen-4-one (FPMS-30): Reddish solid; Rf 0.25 (4:6 
hexane-EtOAc); IR (KBr): 3019, 1697, 1572, 1483, 1237, 1103; MS m/z: 260(M+); Anal. 
Calcd. for C13H12N2O4: C, 60.00; H, 4.65; N, 10.76%. Found: C, 59.91; H, 4.58; N, 10.68%. 
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1H NMR spectrum of compound 3  
 
 
 
1H NMR spectrum of compound FPMS 01 
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1H NMR spectrum of compound FPMS 21 
 
 
 
1H NMR spectrum of FPMS 27 
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13C NMR spectrum of compound FPMS-1 
 
 
 
Expanded 13C NMR spectrum of compound FPMS-1 
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13C NMR spectrum of compound FPMS-3 
 
 
13C NMR spectrum of compound FPMS-24 
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Mass spectrum of compound 3 
 
 
Mass spectrum of compound FPMS-1 
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Mass spectrum of compound FPMS-27 
 
 
 
Mass spectrum of compound FPMS-21 
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IR spectrum of compound 3  
 
 
 
IR spectrum of compound FPMS 01  
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IR spectrum of compound FPMS 04 
 
 
IR spectrum of compound FPMS-24 
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Synthesis, Characterization and Anti-Viral 
Screening of Novel 3-amino-4,5-dihydro-6-
methyl-4-oxo-N-aryl-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide Derivatives. 
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5.1 INTRODUCTION 
 
Biaryls and heterobiaryls have attracted significant attention from the scientific 
community because of their relevance in medicinal chemistry. Heterobiaryls frequently can 
be observed in numerous bioactive small molecules, and in particular, heterobiaryls fused 
with various heterocycles, such as pyrazole, pyridine, and pyrimidine, have been used as key 
pharmacophores.1 As shown in Figure 1, a blockbuster drug, sildenafil citrate (1),2 and a 
potent anticancer agent (2),3 contain heterobiaryls fused with privileged heterocycles as core 
skeletons. In addition, 1H-pyrazolo[3,4-b]pyridine is recognized as a privileged substructural 
motif of drug-like molecules and potential drugs. Compound 3, which contains the 
heterobiaryl pyrazolopyridine substructure, stimulates soluble guanylate cyclase via a nitric 
oxide independent regulatory site and induces vasodilation.4 6-Aryl pyrazolo[3,4-b]pyridines 
are also reported as potentinhibitors of glycogen synthase kinase-3 (4).5 These examples 
emphasize the importance of pyrazol-fused heterobiaryls, as well as pyrazolopyridines, as 
key pharmacophores in bioactive small molecules.  
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5.2 Biological activity of several fused pyrazolopyridine and pyrazolopyrimidine 
derivatives. 
 
Several diverse biological activities have been reported for condensed 
polyazaaromatic ring systems which are described as below. 
 
Mitogen-activated protein kinases (MAP) are a family of praline-directed serine/threonie 
kinases that activate their substrates by dual phosphorylation. The kinases are activated by a 
variety of signals including nutritional and osmotic stress, UV light, growth factors, 
endotoxin and inflammatory cytokines. One group of MAP kinases is the p38 kinase group 
that includes various isoforms (ex. p38α, p39β, p38γ and p38δ). The p38 kinases are 
responsible for phosphorylating and activating transcription factors as well as other kinases, 
and are activated by physical and chemical stress, pro-inflammatory cytokines and bacterial 
lipopolysaccharide. More importantly, the products of the p38 phosphorylation have been 
shown to mediate the production of inflammatory cytokines, including TNF and IL-1, and 
cyclooxygenae-2. Each of these cytokines has been implicated in numerous disease states and 
conditions. The inhibition of these cytokines by inhibition of the p38 kinases of benefit in 
controlling, reducing and alleviating many of this disease states. In this context, some novel 
substituted pyrazolopyridones (Figure 2) have been synthesized and found potent for the 
treatment of disease associated with p38 MAP kinase.6 
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Figure 2 
 
Recently, Yassin F. A.7 has synthesized some pyrazolopyridine derivatives (Figure 3) and 
evaluated for their antimicrobial activity.  
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Echevarri A. et al8 have developed three series of 4-anilino-1H-pyrazolo[3,4-b]pyridine-5-
carboxylic esters to study potential anti-Leishmania activity. These compounds were obtained 
by a condensation reaction of 4-chloro-1H-pyrazolo[3,4-b]pyridine with several aniline 
derivatives. Some of them were also obtained by an alternative pathway involving a 
Mannich-type reaction. They were determined the hydrophobic parameter, log P, by shake-
flask methodology, and using the Hansch-Fujita addictive hydrophobic fragmental constants. 
Among them, compound (Figure 4) shown most promising activity (IC50) 0.39 and 0.12 íM.  
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Figure 4 
 
Green N. J. et al9 have studied structure-activity relationship of a series of dipyrazolo[3,4-
b:3’,4’-d]pyridin-3-ones binding to the immune regulatory protein B7.1. The interaction of 
co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an 
important role in the activation of naive T cells. Consequently, agents that disrupt these 
interactions should have applications in treatment of transplant rejection as well as 
autoimmune diseases. They have identified several leads that prevented the interaction of 
B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the 
dihydrodipyrazolopyridinone (Figure 5), was subsequently shown to bind the V-like domain 
of human B7.1 at equimolar stoichiometry. 
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Phosphodiesterase 9A (PDE9A) is one member of the wide family of phosphodiesterases 
(PDE). These kinds of enzymes modulate the levels of the cyclic nucleotides 5’-3’ cylic 
adenosine monophosphate (cAMP) and 5’-3’ cyclic guanosine monophosphate (cGMP). 
These cyclic nucleotides (cAMP and cGMP) are important second messengers and therefore 
play a central role in cellular signal transduction cascades. Each of them reactivates inter alia, 
but not exclusively, protein kinases. The protein kinase activated by cAMP is called protein 
kinase A (PKA), and the protein kinase activated by cGMP is called protein kinase G (PKG). 
Activated PKA and PKG are able in turn to phosphorylate a number of cellular effector 
proteins. It is possible in this way for the second messengers cAMP and c GMP to control a 
wide variety of physiological processes in a wide variety of organs. However, the cyclic 
nucleotides are also able to act directly on effector molecules. Thus, it is known, for example, 
the cGMP is able to act directly on ion channels and thus is able to influence the cellular ion 
concentration. The phosphodiesterases are a control mechanism for controlling the activity of 
cAMP and cGMP and thus in turn for the corresponding physiological processes. Thus, 
several phyrazolopyrimidones (Figure 6) have been synthesized and found potent PDE 
inhibitors.10 
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Fossa P. et al11 have synthesized substituted pyrazolopyridine and pyrazolopyrimidine 
derivatives and demonstrated its molecular modeling studies and pharmacological activity of 
selective A1 receptor antagonists (Figure 7). They were applied an approach combining 
pharmacophore mapping, molecular alignment, and pseudoreceptor generation to derive a 
hypothesis of the interaction pathway between a set of A1 AR antagonists taken from a 
model of the putative A1 receptor. The pharmacophore model consists of seven features and 
represents an improvement of the N6-C8 model, generally reported as the most probable 
pharmacophore model for A1 AR agonists and antagonists. It was used to build up a 
pseudoreceptor model able to rationalize the relationships between structural properties and 
biological data. All the synthesized compounds were tested for their affinity toward A1, A2a, 
and A3 AR, showing interesting antagonistic activity and A1 selectivity. 
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Figure 7 
 
Moreover, pyrazolopyrimidinones and their salts are also (Figure 8) important heterocycles 
due to their application for the treatment of impotency.12 Pyrazolopyrimidones are also useful 
in the treatment of such diseases and adverse conditions as angina, hypertension, congestive 
heart failure, reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, 
chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and gut motility (Figure 8).13 
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Das S. K. et al14 have designed, synthesized and evaluated several dual PPAR α/γ agonists 
with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and 
benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia. 
Among them, compounds (Figure 9) were found to possess a potent dual PPAR α/γ agonist 
property. It significantly reversed diabetic hyperglycemia while improving overall lipid 
homeostasis in preclinical animal models. 
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Voelter W. et al15 have developed a simple high-yielding procedure for the synthesis of 
pyrazolopyrimidinones (Figure 10). They have also demonstrated its considerable utility for 
the production of intermediates for potential phosphodiesterase inhibitors. 
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Figure 10 
 
Dumaitre B. et al16 have synthesized a series of 6-phenylpyrazolo[3,4-d]pyrimidones for 
inhibitors of cGMP specific (type V) phosphodiesterase. Enzymatic and cellular activity as 
well as in vivo oral antihypertensive activity is evaluated. They have found that a n-propoxy 
group at the 2-position of the phenyl ring is necessary for activity. This position can 
accommodate many unrelated groups. Amino derivatives were very potent but lacked 
metabolic stability. Substitution by carbon-linked small heterocycles provided both high 
levels of activity and stability. Cellular activity very often correlated with in vivo activity. 
Among the compounds, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonamidophenyl)-1,5-
dihydropyrazolo[3,4-d]pyrimidin-4-one and 1-ethyl- 3-methyl-6-(2-propoxy-5-(4-
methylthiazol-2-yl)phenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one (Figure 11) 
displayed outstanding in vivo activities at 5 mg/kg/os and good metabolic stabilities.  
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Synthesis of sildenafil analogues (Figure 12) from anacardic acid and their 
phosphodiesterase-5 inhibition activity have been reported by Rao S. A. and coworkers.17 
Anacardic acid (6-pentadecylsalicylic acid), a major component of cashew nut shell liquid, 
consists of a heterogeneous mixture of monoenes, dienes, and trienes. The enes mixture of 
anacardic acid was hydrogenated to a saturated compound. Using saturated anacardic acid as 
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a starting material, analogues of sildenafil [a potent phosphodiesterase-5 (PDE5) inhibitor 
and an orally active drug for the treatment of erectile dysfunction] were synthesized, to 
observe the effect of the pentadecyl side chain on PDE5 inhibition. 
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Figure 12 
 
Magedov I. V. et al18 have synthesized some 4-aza-2,3-didehydro podophyllotoxin analogues 
(Figure 13). They were implementing a bioisosteric replacement of the 
methylenedioxybenzene subunit with a pyrazole moiety to afford tetracyclic 
dihydropyridopyrazoles. Libraries of these structurally simple analogues were prepared by a 
straightforward one-step multicomponent synthesis and demonstrated to display 
antiproliferative properties in a number of human cancer cell lines. These new heterocycles 
potently induce apoptosis in cancerous Jurkat cells even after a short 24 h exposure. The ease 
of synthesis and encouraging biological activities make the presented library of 
dihydropyridopyrazoles promising new leads in anticancer drug design. 
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Claudia M. et al19 have synthesized a series of ethyl-4-amino-1-(2-chloro-2-phenylethyl)-6-
oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylates (Figure 14) as potential A1 
adenosine receptor (A1 AR) ligands.  Binding affinities of these compounds were determined 
for adenosine A1, A2A and A3 receptors.  Among these, two molecules showed good affinity 
(Ki = 299 μM and 517 μM) and selectivity towards A1 AR, whereas some showed good 
affinity for A2A AR (Ki = 290 μM), higher than towards A1 AR (Ki = 1000 μM).  The only 
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arylamino derivatives of the series displayed high affinity (Ki = 4.6 nM) and selectivity for 
A3 AR.   
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Figure 14 
 
 
5.3 Various synthetic approaches for substituted pyrazolopyridines and 
pyrazolopyrmidines.  
 
Condensed polyazaaromatic ring systems are present in a variety of biologically 
active compounds (both naturally-occurring and synthetic). Although a large number of 
methods for their synthesis have been documented in the literature, many of them require 
multistep procedures using intermediates which are not readily available. Among them, few 
methods are discussed here.  
 
Adamo M. F. A. et al20 have described the preparation of two novel heterocyclic nuclei 
isoxazolopyridone and pyrazolopyridone (Figure 15) starting from NO2 substituted 
isoxazole, arylaldehydes and nitro methane. The syntheses were modular in nature and fast to 
execute. The title compounds were obtained pure without intervention of chromatography. 
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Sayed G. L. et al21 have prepared bifunctional pyrazolopyridine (2) derivatives by the 
reaction of 2-(2,4-dinitrophenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (1) with p-
methoxybenzaldehyde, malononitrile in the presence of ammonium acetate (Figure 16). 
Further, compound 2 was used as the key intermediate to prepare the pyrazolo-pyrido-
pyrimidine derivatives through its reaction with formic acid, formamide-formic acid-DMF, 
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ammonium thiocyanate or reaction with triethyl orthoformate followed by cyclization with 
hydrazine hydrate. 
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Attaby F. A. et al22 have synthesized some pyrazolopyridone derivatives (Figure 17). The 
reaction of α-β unsaturated nitrile derivatives with S-methylisothiourea was afforded the 
propene derivatives 1. Cyclization of 1 using ethanolic hydrochloric acid afforded the 
pyridine derivatives in good yields. This on reactions with hydrazine hydrate and of 
phenylhydrazine afforded the corresponding pyrazolopyridine derivatives 2.  
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Junjappa H. et al23 have developed a novel process for the synthesis of substituted N-
methylpyrazolopyridones (Figure 18). The pyrazolopyridones were prepared by alkylation of 
the pyridones with dimethyl sulphate, followed by heating the mixture of N-methyl products 
with methyl iodide. Treatment of the pyridones (1) with hydrazine in refluxing propanol 
yielded the respective pyrazolo-[4,3-c]pyridone (2) derivatives in excellent yields. 
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Moreover, a variety of novel α-cyanoketene S,S-acetals, were readily prepared by the reaction 
of cyanoacetanilides or cyanothioacetamide with carbon disulfide, followed by alkylation, 
react smoothly with nucleophiles to afford variously substituted methylthio derivatives of 
pyrazolepyridine (Figure 19).24 
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Additionally, a novel and efficient method for the synthesis of substituted 4-alkylthio-N-
arylsulphonylamino-2-pyridons via the reaction of ketene-S,S-acetals with N-
cyanoacetoarylsulfonylhydrazides has been developed by Elgemeie G. H. and coworkers.25 
The arylsulfonylamino-pyrazolo[3,4-c]pyridine-2(1H)-ones have also been prepared from the 
reaction of 4-alkylthio-N-arylsulfonylamino-2-pyridones with hydrazines (Figure 20).  
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Figure 20 
 
Lacova M. et al26 have developed one-pot and facile preparations of 6-(2-hydroxy-5-R-
benzoyl)-4-methyl-2-aryl-pyrazolo[3,4-b]pyridines (Figure 21), using the reaction of 3-
formyl chromones 1 with 5-amino-1-aryl-pyrazoles 2. An enamine-intermediate 2-ethyloxy-
6-R-3-(3-methyl-1-phenylpyrazol-5-ylaminomethylene)chroman-4-one 3 was isolated at 
lower temperatures. They were observed that reactions under microwave irradiation 
proceeded significantly faster and with high yields. 
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Figure 21 
 
Abass M. has synthesized several fused pyrazolopyrimidones (Figure 22) with quinolone 
scaffold. He has described the synthesis of amino-ester, its hydrolysis and chloroacetylatio, 
which were utilized for the synthesis of pyrazoloyridones.27 
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Hassanein E. M. et al28 have synthesized some pyrazolopyridone derivatives via the reaction 
of compound 1 with ketene dithioacetal 2, yielded compound 3 in good yields (Figure 23). 
Further, the reaction of 3 with hydrazine afforded pyrazolopyridones 4 in high yield. 
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A mild one-step synthetic method to access privileged pyrazolearylpyrazole[3,4-b]pyridines 
(Figure 24) from indole-3-carboxaldehyde derivatives and a variety of aminopyrazoles has 
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been developed by Park S. B. and coworker.29 This novel method constructs heterobiaryls 
with the wide scope of substrate generality and excellent regioselectivity via indole ring 
opening.  
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Rodrigues L. M. et al30 have synthesized some pyrazolopyridine derivatives (Figure 25). The 
reaction of N-substituted-5-amino-4-cyanopyrazoles with malononitrile occurs with 
formation of 6-substituted pyrazole[3,4-b]pyridines respectively.  
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Figure 25 
Recently, Yao H. et al31 have developed a synthesis of indeno[2’,1’:5,6]pyrido[2,3-
d]pyrazoles by the three-component reaction of aldehyde, 5-amino-3-methyl-1-phenyl- 
pyrazole and 1,3-indenedione in the presence of SDS in aqueous media (Figure 26).  
 
N
HN
N
Ph
N
N
Ph
H2N
O
O
Ar CHO
SDS, H2O
90 oC
Ar O
 
Figure 26 
 
Li J. R. et al32 have developed synthesis of pyrazolopyrimidinones under microwave 
irradiation (Figure 27). They have demonstrated that the direct reaction of o-
aminopyrazocarbonitriles and carbonyl compounds afforded pyrazolopyrimidinones under 
microwave irradiation with high yields. 
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Mekheimer R. et al33 have synthesized some benzoannulated pyrazolopyridones 2 by the 
reaction of 1 with hydrazine hydrate (Figure 28).  
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Swett L. R. et al34 have synthesized two isomeric pyrazolopyridones (Figure 29) which were 
identified as their tetrahydropyrazolopyridine derivatives by the reaction of 5-amino-1,3-
dimethylpyrazole with ethyl acetoacetate.  
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5.4 CURRENT RESEARCH WORK 
 
The pyrazolopyridine and pyrazolpyrimidine derivatives have considerable chemical 
and pharmacological importance because of a broad range of biological activities displayed 
by these classes of molecules. As we demonstrated, the tremendous biological potential of 
pyrazolopyridine derivatives encouraged us to synthesize some pyrazolopyridine derivatives. 
Various methodologies have been described for the synthesis of pyrazolopyridone 
derivatives. However, the existing methods are suffer with some drawbacks, such as; yield, 
time, product isolation, isomer formation.  
 
During the course of our ongoing interest on the synthesis of various heterocyclic compounds 
using ketene dithioacetals, we observed that ketene dithioacetals are versatile intermediate for 
the synthesis of pyrazolopyridone derivatives. Thus, to synthesized target molecules, the 
reaction of various ketene dithioacetals with cyanoacetamide in the presence of base was 
afforded pyridones. Further, the pyridones on reaction with hydrazine hydrated in isopropyl 
alcohol furnished the novel pyrazolopyridone derivatives in excellent yields. The synthesized 
compounds were characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental 
analysis. All the synthesized compounds were evaluated for in vitro anti-viral activity against 
HIV-1 IIIB and ROD strains.  
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5.5 RESULTS AND DISCUSSION 
 
Initially, the reaction of 2-(bis(methylthio)methylene)-3-oxo-N-phenylbutanamide (1a) with 
cyanoacetamide 2 was carried out using sodium methoxide in methanol. The reaction of 1a 
with 2 in sodium methoxide was afforded the product 3a in 75 % yield with long reaction 
time (Table 1). To optimize the reaction condition for the synthesis of compound 3a, various 
sodium alkoxides were utilized in respective alcohol. As a result, we found the reaction of 1a 
with 2 was faster and afforded the pyridone 3a in good yield in the presence of sodium 
isopropoxide and isopropyl alcohol.  
 
Scheme 1: Synthesis of substituted pyrazolopyridones using ketene dithioacetals. 
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Table 1: Reaction of 1a with 2 using various bases. 
 
Entry Base Time h Yield % 
1 NaOMe 7 75 
2 NaOEt 6 82 
3 NaOiPr 4 88 
 
 
The resulting pyridones 3a-w were further reacted with hydrazine hydrate in isopropyl 
alcohol to afford the pyrazolopyridone derivatives in excellent yield with short reaction time. 
The results are gathered in table 2. The synthesized compounds were confirmed by IR, Mass, 
1H and 13C NMR spectroscopy and elemental analysis. All the synthesized compounds were 
evaluated for their in vitro anti-viral activity using HIV-1 IIIB and ROD strains. 
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Table 2: Synthesis of various pyrazolpyridones PPMS 1-23. 
 
Entry R Time min Yield % mp oC 
PPMS-1 Ph 50 96 312-314 
PPMS-2 4-CH3Ph 65 95 > 320 
PPMS-3 4-OCH3Ph 40 96 > 320 
PPMS-4 4-FPh 45 97 > 320 
PPMS-5 2-OCH3Ph 55 88 > 320 
PPMS-6 2-CH3 65 89 > 320 
PPMS-7 4-ClPh 60 91 > 320 
PPMS-8 4-EtPh 45 93 > 320 
PPMS-9 4-NO2Ph  50 95 > 320 
PPMS-10 3-Cl,4-FPh 60 85 > 320 
PPMS-11 5-Cl,2-OCH3Ph 65 87 > 320 
PPMS-12 2,5-diClPh 70 88 > 320 
PPMS-13 2,5-diCH3Ph 60 89 > 320 
PPMS-14 4-Cl,2-CH3Ph 70 83 > 320 
PPMS-15 3,4-diFPh 75 92 > 320 
PPMS-16 2-ClPh 75 84 > 320 
PPMS-17 2-FPh 60 85 > 320 
PPMS-18 4-BrPh 55 92 > 320 
PPMS-19 3,4-diClPh 60 94 > 320 
PPMS-20 3-NO2Ph 55 84 > 320 
PPMS-21 3-CH3Ph 65 88 > 320 
PPMS-22 2,3-diCH3Ph 65 89 > 320 
PPMS-23 2-OCH3,4-NO2Ph 70 91 > 320 
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In mechanism, the cyanoacetamide on the treatment with base generate an anion at active 
methylene group which attack on β carbon of ketene dithioacetal. The amine nucleophile 
attack on carbonyl carbon and form sodium salt of pyridine moiety by removal of methylthio 
and water molecule. The sodium salt on acidification affords pyridone. The binucleophile 
hydrazine hydrate on reaction with pyridone form pyrazolopyridone. 
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Figure 30: Proposed mechanism for the formation of pyrazolopyridone. 
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5.6 ANTI-VIRAL SCEREENING 
 
Antiviral activity was examined by Tetrazolim-based colorimetric (MTT) assay35 using the 
human T-lymphotropic virus type I (HTLV-I)-transformed MT-4 cell line7. The method is 
based on HIV-induced cytopathogenic effect (CPE) and measures the degree of cell killing 
on HIV infection. The replication of HIV in MT-4 cells was monitored 5 days after infection. 
Stock solutions of compounds were made in DMSO (generally at 10 mg/ ml). Final DMSO 
concentration in the test should not exceed 1% (v/v). Nevirapine was used as reference 
standard. 
 
? Materials and reagents 
• ‘Complete medium’: RPMI-1640 medium with 20 mM HEPES buffer, supplemented 
with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine, 0.1% sodium bicarbonate and 
20 μg/ml gentamicin. 
• Virus stock (see Steps 1–13)  
• A solution of 30 ml Triton X-100 and 2 ml methanesulfonic acid or 2 ml concentrated 
hydrochloric acid in 500 ml isopropanol. 
 
? Equipments 
• Titertek multidrop dispenser (ThermoFisher Scientific) 
• Biomek 3000 robot (Beckman) 
• Microplate washer (Biotek EL404, Beun-de Ronde and Serlabo) 
• Multiskan Ascent reader (ThermoFisher Scientific) 
• An invert light microscope (magnification: ocular ×10 and objective × 20) 
 
? Reagent setup 
MTT 7.5mg/ml of MTT in PBS was prepared as follows: put 10 g MTT (powder) in a 
2-liter bottle, add 1.333 ml of PBS and cover the bottle with tin foil (to protect against light). 
Sonicated it until MTT was dissolved. The solution was filtered over an easy flow filter (0.22 
mm cellulose acetate membrane for tissue culture applications) under reduced pressure and 
stored it in dark-brown plastic bottles (±150 ml). The bottles of cleared MTT were placed 
inside a -20 oC freezer. 
 
 (Note: Do not fill the bottles completely as the aqueous solution will expand during the 
freezing process) 
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? Preparation of the stock solution of test compounds 
DMSO, water, buffer solutions (e.g., PBS) and, a mixture of these solvents were used 
as solvents to make homogeneous aliquots (solution, suspension or emulsion) of the test 
compounds. 
 
? Growing virus stock 
1|  The quality of the cells was examined by microscopically. 
2|  Placed the 300,000 number of cells per ml of final culture in a 50-ml tube. 
3|  PBS was added to the tube to obtain a final volume of 40 ml. 
4|  Pellet the cells by centrifugation (5 min, 220g at room temperature).  
5|  The cells were resuspended by adding the required volume of an adequate culture in 
the complete medium. 
6|  The required volume of virus stock was added to the cell suspension.  
7|  The treated cells were transferred in an appropriate culture flask. 
8|  Incubated at 37 oC, 5% CO2 (≥95% relative humidity (RH)). 
9|  The cell culture was inspected microscopically everyday for the presence of 
cytopathogenic effect. 
10|  The content of the culture flask was transferred to a 50-ml tube. 
11|  The cells were pellet by centrifugation (5 min, 220g). 
12|  Carefully labeled the required number of cryotubes. 
13|  Dispensed the supernatant (virus stock) in aliquots of 0.5 or 1 ml in cryotubes.  
 
? Titration of virus stock 
14|  The infected MT-4 cells were cultivated in a humidified atmosphere (≥95% RH) at 37 
oC and 5% CO2 in air. Subcultivated the cells every 3 to 4 d. Seed the cells at 6×105 
cells per ml before starting the experiment.  
15|  96-well microtiter plates were filled with 100 ml of complete medium. 
16|  Virus stock was added in 25-μl volume to the six middle cups (2B–G) of the 
microtiter plate. The actual volume in the cups 2B–G was 125 μl. 
17|  The wells 2B–G were diluted using the Biomek 3000 robot or a multichannel pipette.  
18|  The exponentially growing MT-4 cells were centrifuged for 5 min at 220g and 
discarded the supernatant by pouring into bleach solution. 
19|  Resuspended the cells at 6×105 cells per ml in complete medium in a flask that was 
connected to an autoclaved dispensing cassette of a Titertek multidrop dispenser. 
20|  Dispensed 50 ml of cell suspension to the microtiter plate wells. 
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21|  The microtiter plates were incubated in a humidified atmosphere (≥95% RH) at 37 oC 
and 5% CO2 in air for 5 d. 
22|  After the 5-d incubation, the cells were examined by microscopically for eventual 
HIV-induced CPE. A well was scored positive if any trace of CPE was observed. The 
50% cell culture infective dose (CCID50) value was calculated using the Reed and 
Muench method36. The calculation is as follows: M ¼ inv log{x1 + [(x2 _ x1)((y1 _ 
50) / y1 _ y2)]} where y1 ¼ percent of wells scored positive closest to, but higher 
than, 50% at a certain virus dilution, y2 ¼ percent of wells scored positive closest to, 
but lower than, 50% at a certain virus dilution, x1 ¼ the log(dilution of the virus 
where y1 was observed), x2 ¼ the log(dilution of the virus where y2 was observed) 
and M ¼ dilution of virus stock for 1 CCID50 
 
? Assessing the anti-HIV activity and cytotoxicity of compounds 
23|  The MT-4 cells were cultivated in a humidified atmosphere (≥95% RH) at 37 oC and 
5% CO2. Subcultivated the cells every 3–4 d, seeding at 6×105 cells per ml. 
24|  96-well microtiter plates were filled with 100 ml of complete medium. 
25|  The stock solutions of compounds were added in 25-ml volumes to the six middle 
cups of the second column of the microtiter plate (2B–G). The actual volume in the 
cups 2B–G was 125 μl. 
26|  50 ml of HIV was added at 100–300 CCID50 and medium, respectively. 
27|  The exponentially growing MT-4 cells were centrifuged for 5 min (220g) and 
discarded the supernatant. 
28|  Resuspended the MT-4 cells at 6×105 cells per ml in complete medium in a flask 
which was connected with an autoclavable dispensing cassette of a Titertek multidrop. 
29|  50 ml of cell suspension was dispensed to the microtiter plate wells.  
30|  The plates were incubated at 37 oC in a humidified atmosphere of 5% CO2 in air. 
31|  Five days after infection, the viability of HIV and mock infected cells was examined 
spectrophotometrically by the MTT method. 
 
? MTT assay 
32|  The 20 ml of MTT (7.5 mg/ml) solution (warmed to 37 oC) was added to each well of 
the microtiter plates using the Titertek multidrop dispenser. 
33|  The trays were incubated at 37 oC in a CO2 incubator for 1 h. 
34|  A constant volume of medium was removed (e.g., 150 ml) from each cup using a 
multichannel pipette or a microplate washer (Biotek EL404, a double, aspiration and 
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dispensing, 96-channel washer) without disturbing the MT-4 cell clusters containing 
the formazan crystals. 
35|  Lyse the cells (and infectious virus) and solubilize the formazan crystals by adding 
100 ml of the acidified Triton X-100 isopropanol solution to each cup using the 
microplate washer (or a multichannel pipette). 
36|  The formazan crystals were completely dissolved by placing the plates on a vibrating 
platform shaker for 10 min. 
37|  The absorbance was examined in an eight-channel computer-controlled Multiskan 
Ascent reader and stacker at two wavelengths (540 and 690 nm). Subtract the 
absorbance measured at 690 nm from the absorbance at 540 nm to eliminate the 
effects of scattering by cell debris.  
38|  Calculated the 50% cytotoxic concentration (CC50) and 50% inhibitory concentration 
(IC50); CC50 is the concentration of compound that reduced the absorbance (OD540) 
of the mock-infected control sample by 50%.  
 
Calculated the protection achieved by the compounds in HIV-infected cells using the 
formula: ((ODT)HIV _ (ODC)HIV) / ((ODC)mock _ (ODC)HIV)× 100.  
 
where (ODT)HIV is the OD measured with a given concentration of the test compound in the 
HIV-infected cells; (ODC)HIV is the OD measured for the control untreated, HIV-infected 
cells, which stands for 100% infection-related CPE; and (ODC)mock is the OD measured for 
the control untreated, mock-infected cells, which stands for 0% infection-related CPE. The 
concentration achieving 50% protection according to the above formula is defined as IC50. 
The OD ratio, defined as (ODC)mock/(ODC)HIV, should be at least 5. The OD ratio is low when 
either the cells are not in optimal condition or when not enough virus is added.  
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Table 3: The in-vitro anti-viral activity against HIV-1 IIIB and ROD strains using MTT method. 
 
Code Name Strain Exp.no. IC50(µg/ml) CC50(µg/ml) SI 
Max Prot 
(%) 
Appr. 
Average 
IC50(µg/ml) 
Average 
CC50(µg/ml) 
SD SI Remarks 
PPMS-01 IIIB P3.4842 >101 =101 <1 8 1      
  P3.4848 >125 >125 X1 0 1 >94.70 ≥94.70  ≤1  
 ROD P3.4843 >94.7 =94.7 <1 9 1      
  P3.4849 >125 >125 X1 0 1 >94.70 ≥94.70  ≤1  
PPMS-02 IIIB P3.4842 >125 >125 X1 12 1     Cryst. 
  P3.4848 >125 >125 X1 9 1 >125.00 >125.00  X1 observ. at 
 ROD P3.4843 >125 >125 X1 4 1     125 µg/ml 
  P3.4849 >125 >125 X1 1 1 >125.00 >125.00  X1  
PPMS-03 IIIB P3.4842 >88.8 =88.8 <1 11 1   19.78  Cryst. 
  P3.4848 >113 =113 <1 0 1 >103.93 91.87  <1 observ. at 
 ROD P3.4843 >73.8 =73.8 <1 2 1   19.78  125 µg/ml 
  P3.4849 >125 >125 X1 0 1 >103.93 91.87  <1  
PPMS-04 IIIB P3.4842 >89 =89 <1 8 1   18.27  Cryst. 
  P3.4848 >107 =107 <1 4 1 >100.98 100.98  <1 observ. at 
 ROD P3.4843 >83.9 =83.9 <1 6 1   18.27  25 µg/ml 
  P3.4849 >124 =124 <1 14 1 >100.98 100.98  <1  
PPMS-05 IIIB P3.4842 >125 >125 X1 16 1     Cryst. 
  P3.4848 >125 >125 X1 2 1 >125.00 >125.00  X1 observ. at 
 ROD P3.4843 >125 >125 X1 6 1     125 µg/ml 
  P3.4849 >125 >125 X1 0 1 >125.00 >125.00  X1  
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PPMS-06 IIIB P3.4842 >83.3 =83.3 <1 12 1   6.76  Cryst. 
  P3.4848 >92.7 =92.7 <1 0 1 >92.73 92.73  <1 observ. at 
 ROD P3.4843 >96.1 =96.1 <1 11 1   6.76  125 µg/ml 
  P3.4849 >98.8 =98.8 <1 10 1 >92.73 92.73  <1  
PPMS-07 IIIB P3.4842 >92.6 =92.6 <1 8 1   9.80   
  P3.4848 >110 =110 <1 0 1 >109.50 98.70  <1  
 ROD P3.4843 >93.5 =93.5 <1 6 1   9.80   
  P3.4849 >125 >125 X1 1 1 >109.50 98.70  <1  
PPMS-08 IIIB P3.4842 >125 >125 X1 10 1     Cryst. 
  P3.4848 >125 >125 X1 10 1 >125.00 >125.00  X1 observ. at 
 ROD P3.4843 >125 >125 X1 3 1     25 µg/ml 
  P3.4849 >125 >125 X1 5 1 >125.00 >125.00  X1  
PPMS-09 IIIB P3.4842 >56.8 =56.8 <1 8 1   23.60  Cryst. 
  P3.4848 >103 =103 <1 0 1 >99.83 77.10  <1 observ. at 
 ROD P3.4843 >71.5 =71.5 <1 7 1   23.60  25 µg/ml 
  P3.4849 >125 >125 X1 3 1 >99.83 77.10  <1  
PPMS-10 IIIB P3.4842 >31.4 =31.4 <1 11 1   15.42  Cryst. 
  P3.4848 >57.2 =57.2 <1 6 1 >36.30 36.30  <1 observ. at 
 ROD P3.4843 >20.4 =20.4 <1 19 1   15.42  125 µg/ml 
  P3.4849 >36.2 =36.2 <1 23 1 >36.30 36.30  <1  
MMS-11 IIIB P3.4842 >75.5 =75.5 <1 9 1   9.92   
  P3.4848 >73.1 =73.1 <1 3 1 >69.60 69.60  <1  
 ROD P3.4843 >54.8 =54.8 <1 6 1   9.92   
  P3.4849 >75 =75 <1 5 1 >69.60 69.60  <1  
PPMS-12 IIIB P3.4842 >51.1 =51.1 <1 8 1   15.02  Cryst. 
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  P3.4848 >68 =68 <1 0 1 >66.95 66.95  <1 observ. at 
 ROD P3.4843 >61.8 =61.8 <1 7 1   15.02  125 µg/ml 
  P3.4849 >86.9 =86.9 <1 13 1 >66.95 66.95  <1  
PPMS-13 IIIB P3.4842 >55.6 =55.6 <1 10 1   7.46   
  P3.4848 >63.1 =63.1 <1 0 1 >58.55 58.55  <1  
 ROD P3.4843 >49.5 =49.5 <1 3 1   7.46   
  P3.4849 >66 =66 <1 2 1 >58.55 58.55  <1  
PPMS-14 IIIB P3.4842 >75 =75 <1 5 1   6.12  Cryst. 
  P3.4848 >68.6 =68.6 <1 5 1 >68.65 68.65  <1 observ. at 
 ROD P3.4843 >60.4 =60.4 <1 2 1   6.12  25 µg/ml 
  P3.4849 >70.6 =70.6 <1 3 1 >68.65 68.65  <1  
PPMS-15 IIIB P3.4842 >100 =100 <1 16 1   1.67   
  P3.4848 >100 =100 <1 0 1 >99.03 99.03  <1  
 ROD P3.4843 >97.1 =97.1 <1 27 1   1.67   
  P3.4849 >125 >125 X1 24 1 >99.03 99.03  <1  
PPMS-16 IIIB P3.4842 >58.7 =58.7 <1 11 1   8.99  Cryst. 
  P3.4848 >65.9 =65.9 <1 7 1 >62.65 62.65  <1 observ. at 
 ROD P3.4843 >52.6 =52.6 <1 3 1   8.99  25 µg/ml 
  P3.4849 >73.4 =73.4 <1 13 1 >62.65 62.65  <1  
PPMS-17 IIIB P3.4842 >98.9 =98.9 <1 8 1   8.55  Cryst. 
  P3.4848 >101 =101 <1 0 1 >92.88 92.88  <1 observ. at 
 ROD P3.4843 >82.9 =82.9 <1 15 1   8.55  25 µg/ml 
  P3.4849 >88.7 =88.7 <1 0 1 >92.88 92.88  <1  
PPMS-18 IIIB P3.4842 >116 =116 <1 13 1   11.82  Cryst. 
  P3.4848 >94.6 =94.6 <1 9 1 >108.20 108.20  <1 observ. at 
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 ROD P3.4843 >114 =114 <1 7 1   11.82  5 µg/ml 
  P3.4849 >125 >125 X1 13 1 >108.20 108.20  <1  
PPMS-19 IIIB P3.4842 >78.1 =78.1 <1 14 1   6.53   
  P3.4848 >74 =74 <1 0 1 >71.08 71.08  <1  
 ROD P3.4843 >62.9 =62.9 <1 2 1   6.53   
  P3.4849 >69.3 =69.3 <1 2 1 >71.08 71.08  <1  
PPMS-20 IIIB P3.4842 >106 =106 <1 5 1     Cryst. 
  P3.4848 >125 >125 X1 7 1 >106.00 ≥106.00  ≤1 observ. at 
 ROD P3.4843 >106 =106 <1 7 1     25 µg/ml 
  P3.4849 >125 >125 X1 4 1 >106.00 ≥106.00  ≤1  
PPMS-21 IIIB P3.4842 >80.1 =80.1 <1 6 1   5.85   
  P3.4848 >67.2 =67.2 <1 0 1 >72.05 72.05  <1  
 ROD P3.4843 >68.3 =68.3 <1 2 1   5.85   
  P3.4849 >72.6 =72.6 <1 3 1 >72.05 72.05  <1  
PPMS-22 IIIB P3.4842 >50.8 =50.8 <1 8 1   11.09   
  P3.4848 >67.7 =67.7 <1 6 1 >57.85 57.85  <1  
 ROD P3.4843 >46 =46 <1 7 1   11.09   
  P3.4849 >66.9 =66.9 <1 10 1 >57.85 57.85  <1  
PPMS-23 IIIB P3.4844 >116 =116 <1 5 1   21.57  Cryst. 
  P3.4848 >86.7 =86.7 <1 0 1 >102.20 102.20  <1 observ. at 
 ROD P3.4845 >125 =125 <1 8 1   21.57  25 µg/ml 
  P3.4849 >81.1 =81.1 <1 5 1 >102.20 102.20  <1  
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5.7 CONCLUSION 
 
In summary, we have described the synthesis substituted pyrazolopyridone derivatives in 
excellent yields. The reaction of various ketene dithioacetals with cyanoacetamide was 
afforded the pyridone derivatives with good yields in the presence of base. Sodium 
isopropoxide was found as an efficient base for the synthesis of pyridones. The pyridones 
were further reacted with hydrazine hydrate to furnished pyrazolopyridones in excellent 
yields with short reaction time. Unfortunately, the synthesized compounds were found 
inactive against HIV-1 IIIB and ROD strains. 
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5.8 EXPERIMENTAL SECTION 
 
The solvents and chemicals were analytical grade. Analytical thin layer 
chromatography (TLC) was performed on 0.2-mm precoated plates of Silica Gel 60 F254 
precoated plates. 1H (400 MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO, 
and TMS was used as an internal reference on a Bruker AVANCE II spectrometer. Mass 
spectra were determined using direct inlet probe on a GCMSQP2010 mass spectrometer. IR 
spectra were recorded on a FTIR-8400 spectrophotometer using DRS prob. Melting points 
were measured in open capillaries and are uncorrected. 
 
? General procedure for the synthesis of pyridones 3a-w. 
To a well stirred mixture of cyanoacetamide (10 mmol) and sodium isopropoxide (10 
mmol) in isopropyl alcohol was added the solution of ketene dithioacetals 1a-w (10 mmol) in 
isopropyl alcohol within 10-15 min. The resulting reaction mixture was further stirred at rt 
for 15 min. Then, reflux the reaction mixtures for 4-5 h on water bath. After completion of 
the reaction, the solvent was evaporated under vacuuo and the resulting solid was treated with 
dilute HCl solution. Thus, the obtained solid was filtered, wash with water and dried at rt to 
afford analytically pure products. The solid products were used for next step without further 
purification.  
 
? General procedure for the synthesis of pyrazolopyridones PPMS 1-23. 
The mixture of substituted pyridones 3a-w (5 mmol) and hydrazine hydrate (10mmol) 
in isopropyl alcohol was refluxed for appropriate time on water bath (Table 2). After 
completion of the reaction, solid product was appeared in the reaction. Cool the reaction 
mixture upto rt and filter the separated product washed with iPA and dried at rt to furnished 
analytically pure products. 
 
3-amino-4,5-dihydro-6-methyl-4-oxo-N-phenyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-1): Creamish solid; IR (KBr): 3367, 3138, 2897, 1667, 1494, 1342, 
1159, 854 cm-1; 1H NMR: δ 2.59 (s, 3H, CH3), 5.60 (s, 2H, NH2), 7.06-7.71 (m,  5H, ArH), 
9.93 (s, 1H, NH), 11.15 (s, 1H, NH), 11.68 (s, 1H, NH); 13C NMR: δ 18.60, 94.71, 110.01, 
119.45, 123.07, 125.62, 128.76, 139.20, 148.51, 159.93, 163.53; MS (m/z): 283 (M+); Anal. 
Calcd for C14H13N5O2: C, 59.36; H, 4.63; N, 24.72; Found: C, 59.29; H, 4.54; N, 24.64. 
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3-amino-4,5-dihydro-6-methyl-4-oxo-N-p-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-2): Creamish solid; IR (KBr): 3425, 3369, 2899, 1664, 1506, 1354, 
1157, 839 cm-1; 1H NMR: δ 2.22 (s, 3H, CH3), 2.51 (s, 3H, CH3), 5.16 (s, 2H, NH2), 7.17 (d, 
J = 8.16, 2H, ArH), 7.51 (d, J = 7.4, 2H, ArH), 10.16 (s, 1H, NH), 11.02 (s, 1H, NH), 11.78 
(s, 1H, NH); MS (m/z): 297 (M+); Anal. Calcd for C15H15N5O2: C, 60.60; H, 5.09; N, 23.56; 
Found: C, 60.49; H, 5.01; N, 23.49. 
 
3-amino-4,5-dihydro-N-(4-methoxyphenyl)-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-
7-carboxamide (PPMS-3): Creamish solid; IR (KBr): 3379, 3024, 2902, 1651, 1516, 1332, 
1166, 954 cm-1; 1H NMR: δ 2.58 (s, 3H, NH), 3.78 (s, 3H, OCH3), 5.78 (s, 2H, NH2), 6.85 (d, 
J = 8.92, 2H, ArH), 7.57 (d, J = 8.88, 2H, ArH), 10.39 (s, 1H, NH), 11.00 (s, 1H, NH), 11.94 
(s, 1H, NH); 13C NMR: δ 14.49, 55.14, 95.11, 113.83, 121.10, 132.29, 148.51, 155.36, 
159.85, 164.93; MS (m/z): 313 (M+); Anal. Calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 
22.35; Found: C, 57.41; H, 4.74; N, 22.29. 
 
3-amino-N-(4-fluorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-4): Creamish solid; IR (KBr): 3347, 3104, 2842, 1681, 1496, 1331, 
1152, 857 cm-1; 1H NMR: δ 2.54 (s, 3H, CH3), 5.18 (s, 2H, NH2), 7.14 (d, J = 8.92, 2H, ArH), 
7.66 (d, J = 8.12, 2H. ArH), 10.24 (s, 1H, NH), 11.07 (s, 1H, NH), 11.82 (s, 1H, NH); MS 
(m/z): 301 (M+); Anal. Calcd for C14H12FN5O2: C, 55.81; H, 4.01; N, 23.25; Found: C, 55.74; 
H, 3.94; N, 23.19. 
 
3-amino-4,5-dihydro-N-(2-methoxyphenyl)-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-
7-carboxamide (PPMS-5): Creamish solid; IR (KBr): 3309, 3014, 2908, 1671, 1563, 1287, 
1246, 927 cm-1; MS (m/z): 313 (M+); Anal. Calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 
22.35; Found: C, 57.43; H, 4.73; N, 22.26. 
 
3-amino-4,5-dihydro-6-methyl-4-oxo-N-o-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-6): Creamish solid; IR (KBr): 3406, 3115, 2902, 1660, 1514, 1280, 
1178, 952 cm-1; MS (m/z): 297 (M+); Anal. Calcd for C15H15N5O2: C, 60.60; H, 5.09; N, 
23.56; Found: C, 60.51; H, 5.02; N, 23.48. 
 
3-amino-N-(4-chlorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-7): Creamish solid; IR (KBr): 3330, 3142, 2830, 1688, 1489, 1241, 
1118, 827 cm-1; MS (m/z): 317 (M+); Anal. Calcd for C14H12ClN5O2: C, 52.92; H, 3.81; N, 
22.04; Found: C, 52.84; H, 3.74; N, 21.96. 
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3-amino-N-(4-ethylphenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-8): Creamish solid; IR (KBr): 3324, 3143, 2812, 1675, 1532, 1298, 
1114, 897 cm-1; MS (m/z): 311 (M+); Anal. Calcd for C16H17N5O2: C, 61.72; H, 5.50; N, 
22.49; Found: C, 61.64; H, 5.44; N, 22.41. 
 
3-amino-4,5-dihydro-6-methyl-N-(4-nitrophenyl)-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-9): Creamish solid; IR (KBr): 3369, 3020, 2897, 1685, 1573, 1494, 
1157, 854 cm-1; MS (m/z): 328 (M+); Anal. Calcd for C14H12N6O4: C, 51.22; H, 3.68; N, 
25.60; Found: C, 51.19; H, 3.61; N, 25.49. 
 
3-amino-N-(3-chloro-4-fluorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-10): Creamish solid; IR (KBr): 3341, 3158, 2957, 1687, 
1471, 1282, 1206, 956 cm-1; MS (m/z): 335 (M+); Anal. Calcd for C14H11ClFN5O2: C, 50.09; 
H, 3.30; N, 20.86; Found: C, 50.01; H, 3.21; N, 20.81. 
 
3-amino-N-(5-chloro-2-methoxyphenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-11): Creamish solid; IR (KBr): 3317, 3142, 2870, 1671, 
1418, 1266, 1107, 897 cm-1; MS (m/z): 347 (M+); Anal. Calcd for C15H14ClN5O3: C, 51.81; 
H, 4.06; N, 20.14; Found: C, 51.76; H, 3.94; N, 20.09. 
 
3-amino-N-(2,5-dichlorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-12): Creamish solid; IR (KBr): 3347, 3031, 2810, 1681, 
1546, 1322, 1183, 974 cm-1; MS (m/z): 352 (M+); Anal. Calcd for C14H11Cl2N5O2: C, 47.75; 
H, 3.15; N, 19.89; Found: C, 47.69; H, 3.04; N, 19.81. 
 
3-amino-4,5-dihydro-6-methyl-N-(2,5-dimethylphenyl)-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-13): Creamish solid; IR (KBr): 3358, 3108, 2920, 1698, 
1543, 1248, 1198, 854 cm-1; MS (m/z): 311 (M+); Anal. Calcd for C16H17N5O2: C, 61.72; H, 
5.50; N, 22.49; Found: C, 61.62; H, 5.45; N, 22.40. 
 
3-amino-N-(4-chloro-2-methylphenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-14): Creamish solid; IR (KBr): 3342, 3017, 2902, 1616, 
1471, 1236, 1087, 874 cm-1; MS (m/z): 331 (M+); Anal. Calcd for C15H14ClN5O2: C, 54.30; 
H, 4.25; N, 21.11; Found: C, 54.14; H, 4.18; N, 21.08. 
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3-amino-N-(3,4-difluorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-15): Creamish solid; IR (KBr): 3369, 3124, 2837, 1685, 
1426, 1212, 1106, 854 cm-1; MS (m/z): 319 (M+); Anal. Calcd for C14H11F2N5O2: C, 52.67; 
H, 3.47; N, 21.94; Found: C, 52.59; H, 3.41; N, 21.87. 
 
3-amino-N-(2-chlorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-16): Creamish solid; IR (KBr): 3369, 3124, 2802, 1657, 1566, 1432, 
1216, 874 cm-1; MS (m/z): 317 (M+); Anal. Calcd for C14H12ClN5O2: C, 52.92; H, 3.81; N, 
22.04; Found: C, 52.86; H, 3.76; N, 21.96. 
 
3-amino-N-(2-fluorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-17): Creamish solid; IR (KBr): 3352, 3124, 2922, 1658, 1506, 1323, 
1066, 827 cm-1; MS (m/z): 301 (M+); Anal. Calcd for C14H12FN5O2: C, 55.81; H, 4.01; N, 
23.25; Found: C, 55.71; H, 3.93; N, 23.17. 
 
3-amino-N-(4-bromophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-18): Creamish solid; IR (KBr): 3369, 3104, 2824, 1657, 1416, 1232, 
1096, 924 cm-1; MS (m/z): 362 (M+); Anal. Calcd for C14H12BrN5O2: C, 46.43; H, 3.34; N, 
19.34; Found: C, 46.36; H, 3.28; N, 19.29. 
 
3-amino-N-(3,4-dichlorophenyl)-4,5-dihydro-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-19): Creamish solid; IR (KBr): 3298, 2949, 2810, 1678, 
1511, 1336, 1174, 852 cm-1; MS (m/z): 352 (M+); Anal. Calcd for C14H11Cl2N5O2: C, 47.75; 
H, 3.15; N, 19.89; Found: C, 47.68; H, 3.05; N, 19.80. 
 
3-amino-4,5-dihydro-6-methyl-N-(3-nitrophenyl)-4-oxo-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-20): Creamish solid; IR (KBr): 3391, 2902, 2802, 1692, 1596, 1473, 
1176, 974 cm-1; MS (m/z): 328 (M+); Anal. Calcd for C14H12N6O4: C, 51.22; H, 3.68; N, 
25.60; Found: C, 51.17; H, 3.58; N, 25.51. 
 
3-amino-4,5-dihydro-6-methyl-4-oxo-N-m-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PPMS-21): Creamish solid; IR (KBr): 3364, 2927, 1674, 1533, 1281, 1112, 
873 cm-1; MS (m/z): 297 (M+); Anal. Calcd for C15H15N5O2: C, 60.60; H, 5.09; N, 23.56; 
Found: C, 60.52; H, 4.98; N, 23.49. 
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3-amino-4,5-dihydro-6-methyl-N-(2,3-dimethylphenyl)-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-22): Creamish solid; IR (KBr): 3288, 3038, 2992, 1698, 
1584, 1224, 1186, 854 cm-1; MS (m/z): 311 (M+); Anal. Calcd for C16H17N5O2: C, 61.72; H, 
5.50; N, 22.49; Found: C, 61.64; H, 5.44; N, 22.41. 
 
3-amino-4,5-dihydro-N-(2-methoxy-4-nitrophenyl)-6-methyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PPMS-23): Creamish solid; IR (KBr): 3375, 3024, 2802, 1684, 
1516, 1395, 1236, 894 cm-1; MS (m/z): 358 (M+); Anal. Calcd for C15H14N6O5: C, 50.28; H, 
3.94; N, 23.45; Found: C, 50.21; H, 3.87; N, 23.39. 
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1H NMR spectrum of compound PPMS-1 
 
 
Expanded 1H NMR spectrum of compound PPMS-1 
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1H NMR spectrum of compound PPMS-2 
 
 
1H NMR spectrum of compound PPMS-3 
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Expanded 1H NMR spectrum of compound PPMS-3 
 
 
 
1H NMR spectrum of compound PPMS-4 
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13C NMR spectrum of compound PPMS-1 
 
 
 
Expanded 13C NMR spectrum of compound PPMS-1 
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13C NMR spectrum of PPMS-3 
 
 
 
Mass spectrum of compound PPMS-8 
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Mass spectrum of compound PPMS-10 
 
 
 
IR spectrum of compound PPMS-2 
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IR spectrum of compound PPMS-3 
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X-Ray Diffraction Study of 3,4-dihydro-6-(2-
hydroxyphenyl)-5-nitro-4-phenylpyrimidin-
2(1H)-one and 2-(methylthio)-3-nitro-4H-
chromen-4-one 
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6.1 Crystal and Molecular Structure of 3,4-dihydro-6-(2-hydroxy phenyl)-5-
nitro-4-phenylpyrimidin-2(1H)-one 
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? Growth and Characterization of 3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-
phenylpyrimidin-2(1H)-one. 
Dihydropyrimidines, especially NO2 functionalized pyrimidine finds applications in 
medicinal chemistry due to their important pharmacological and therapeutic properties1-3. 
Due to the medicinal properties of pyrimidine derivatives, the crystal growth of organic 
material compound 4 has been carried out.  
 
 
6.2 Procedure for the development of single crystals. 
In the present study, the pure, single spot (on TLC) compound was taken in glacial 
acetic acid and heated with stirring till it dissolved. A small quantity of charcoal was added 
for decolorizing. The solution was then heated to boiling and immediately filtered while hot 
in corkable 50 ml conical flask using Whatmann filter paper. The flask was corked and kept 
for several days. The crystals thus grown by thin film evaporation technique were isolated 
and washed with chilled methanol. The constitution of 3,4-dihydro-6-(2-hydroxyphenyl)-5-
nitro-4-phenylpyrimidin-2(1H)-one was supported by IR, 1H & 13C NMR and Mass spectral 
studies. 
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Figure 1: Photographs of the grown crystal of DHPM 4 
 
 
 
Good quality single crystals with maximum dimension 0.2 cm X 0.2 cm were obtained. 
Figures 1 show the types of crystals grown. The crystals were lemon yellow in color. 
 
6.3 SINGLE CRYSTAL X-RAY DIFFRACTION ANALYSIS 
 
Single crystal X-ray diffraction is the most common experimental method for 
obtaining a detailed picture of a small molecule that allows resolution of individual atoms. It 
is performed by analyzing the diffraction of x-rays from an ordered array of many identical 
molecules. Many molecular substances, including proteins, polymers and other solidify in to 
crystals under the proper conditions. When solidifying in to the crystalline state, these 
individual molecules typically adapted as one of only a few possible orientations. A crystal is 
a three dimensional array of those molecules that are held together by Van der Waals and 
noncovalent bonding. The smallest representative unit of this crystal is referred to as the unit 
cell. Understanding the unit cell of these arrays simplifies the understanding of a crystal as a 
whole. 
 
? Single Crystal X-ray Diffraction and Structure Determination 
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 A single crystal of suitable size was chosen for X-ray diffraction studies. The data 
were collected at room temperature on a DIPLabo Image Plate system with graphite 
monochromated radiation MoKα. Each exposure of the image plate was set to a period of 400 
s. Thirty-six frames of data were collected in the oscillation mode with an oscillation range of 
5˚ and processed using Denzo.4 The reflections were merged with Scalepack. All the frames 
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could be indexed using a primitive monoclinic lattice. The structure was solved by direct 
methods using SHELXS-975. Least-squares refinement using SHELXL-975 with isotropic 
displacement parameters for all the non-hydrogen atoms converged the residual to 0.1402. 
Subsequent refinements were carried out with anisotropic thermal parameters for the non-
hydrogen atoms. After eight cycles of refinement the residuals converged to 0.0470. The 
hydrogen atoms were fixed at chemically acceptable positions and were allowed to ride on 
their parent atoms. The details of crystal data and refinement are given in Table 1. The bond 
lengths and bond angles of all the non-hydrogen atoms (Table 2) are in good agreement with 
the standard values6. Figure 1 represents the ORTEP7 diagram of the molecule with thermal 
ellipsoids drawn at 50% probability. 
 
In the title compound C16H13N3O4, the heterocyclic ring adopts a flattened boat conformation, 
with a puckering amplitude8 Q=0.3833(2)Å, θ=106.2(3)˚ and Φ=352.1(3)˚. The phenyl ring 1 
(C7-C8-C9-C10-C11-C12) adopts an axial conformation with the heterocyclic ring whereas 
the phenyl ring 2 (C18-C19-C20-C21-C22-C23) adopts an equatorial conformation, as 
indicated by the dihedral angle values of  39.38(8)˚ and 81.12(1)˚ respectively. The nitro 
group C6-C5-N15-O17 is almost coplanar with the pyrimidine ring as indicated by the 
torsion angle value of 12.6(3)˚. The carbonly group C2=O14 is oriented in +anti-periplanar 
conformation, as indicated by the torsion angle value of 163.58(1)˚ for C6-N1-C2-O14. The 
hydroxyl group of phenyl ring 1 makes an angle of 121.74(2)° with the C11 and 119.25(2)° 
with the C7 atoms. The observed bond length of O13 atom of hydroxyl group with C12 was 
1.343(2). The hydrogen atom H13 of hydroxyl group makes intramolecular hydrogen bond 
with O14 of heterocyclic ring with the bond length 2.799(2)Å and bond angle 172˚. The bond 
lengths N15-O16, N15-O17, N1-C6, N1-C2, N3-C2, N3-C4 are comparable with other 
reported compounds.9 The  structure exhibits intermolecular hydrogen bonds of the type N-
H…O and O-H…O, which bind the molecules into one-dimensional polymeric chains. The 
observed hydrogen bonds are listed in Table 3. The packing of the molecules down b-axis is 
shown in the Figure 2. 
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Figure 2: ORTEP of the molecule with thermal ellipsoids drawn at 50% probability. 
 
 
 
Figure 3: Packing of the molecules when viewed down the b-axis. The dashed lines 
represent the hydrogen bonds. 
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Table 1: Experimental details and other measurement data  
 
Empirical formula C16H13N3O4
Formula weight 311.29 
Temperature 293 k 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21/c 
Cell dimensions a = 11.1070(10)Å 
 b = 8.8210(4)Å 
 c = 15.1110(13)Å 
 β=106.193(2)˚ 
Volume 1421.76(2)Å3
Z 4 
Density (calculated) 1.454 Mg/m3
Absorption coefficient 0.107 mm-1
F000 648 
Crystal size 0.270 x 0.250 x 0.230 mm 
Theta range for data collection 2.70 to 25.03˚ 
Index ranges -13<=h<=13, -9<=k<=9, -17<=l<=17 
Reflections collected 4326 
Independent reflections 2351 
Absorption correction  None 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2351 / 0 / 209 
Goodness-of-fit on F2 1.023 
Final R indices [I > 2σ(I)] R1 = 0.0470, wR2 = 0.1344 
R indices (all data) R1 = 0.0526, wR2 = 0.1422 
Extinction coefficient 0.045(8) 
Largest diff. peak and hole 0.238 and -0.265 e.Å-3
Deposition number CCDC 743221 
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Table 2: Various Bond lengths (Å) and Bond angles (˚) 
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Atoms Length (Å) Atoms Length (Å) 
N1-C2 1.376(2) C9-C10 1.380(3) 
N1-C6 1.382(2) C10-C11 1.377(3) 
C2-O14 1.239(2) C11-C12 1.388(3) 
C2-N3 1.332(2) C12-O13 1.343(2) 
N3-C4 1.460(2) N15-O17 1.223(2) 
C4-C5 1.513(2) N15-O16 1.229(2) 
C4-C18 1.528(2) C18-C23 1.381(3) 
C5-C6 1.352(2) C18-C19 1.386(3) 
C5-N15 1.435(2) C19-C20 1.384(3) 
C6-C7 1.477(2) C20-C21 1.383(4) 
C7-C8 1.387(3) C21-C22 1.371(4) 
C7-C12 1.407(2) C22-C23 1.382(3) 
C8-C9  1.376(3)   
Atoms Angle(˚) Atoms Angle(˚) 
C2-N1-C6 123.67(1) C8-C9-C10 119.27(2) 
O14-C2-N3 123.97(1) C11-C10-C9 120.69(2) 
O14-C2-N1 120.70(1) C10-C11-C12 120.57(2) 
N3-C2-N1 115.32(1) O13-C12-C11  121.74(2) 
C2-N3-C4 122.82(1) O13-C12-C7 119.25(2) 
N3-C4-C5 106.58(1) C11-C12-C7 118.98(2) 
N3-C4-C18 112.46(1) O17-N15-O16  122.50(1) 
C5-C4-C18 113.67(1) O17-N15-C5 120.23(1) 
C6-C5-N15 121.88(1) O16-N15-C5 117.21(1) 
C6-C5-C4 120.65(1) C23-C18-C19 118.20(2) 
N15-C5-C4 117.36(1) C23-C18-C4 119.40(2) 
C5-C6-N1 116.27(1) C19-C18-C4 122.40(2) 
C5-C6-C7 130.54(1) C20-C19-C18 120.9(2) 
N1-C6-C7 113.19(1) C21-C20-C19 119.9(2) 
C8-C7-C12 119.16(2) C22-C21-C20 119.6(2) 
C8-C7-C6 118.23(1) C21-C22-C23 120.3(2 
C12-C7-C6 122.36(1) C18-C23-C22 121.1(2) 
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C9-C8-C7 121.31(2)   
 
 
 
 
 
 
Table 3: Geometry of intermolecular hydrogen interactions 
 
Atoms Length (Å) Angle(˚) Symmetry codes 
N1-H1…O14  2.892(2) 170 2-x,1-y,-2 
O13-H13…O14 2.799(2) 172 x,1+y,z 
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6.4 Crystal and Molecular Structure of 2-(methylthio)-3-nitro-4H-chromen-4-
one 
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6.5 Procedure for the development of single crystals. 
In the present study, the pure, single spot (on TLC) compound was taken in 
chloroform and heated with stirring till it dissolved. A small quantity of charcoal was added 
for decolorizing. The solution was then heated to boiling and immediately filtered while hot 
in corkable 50 ml conical flask using Whatmann filter paper. The flask was corked and kept 
for several days. The crystals thus grown by thin film evaporation technique were isolated 
and washed with chilled methanol. The constitution of 2-(methylthio)-3-nitro-4H-chromen-4-
one was supported by IR, 1H & 13C NMR and Mass spectral studies. 
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Figure 1: Photograph of the grown crystals of compound 2 
 
 
Good quality single crystals with maximum dimension 1.0 cm X 0.2 cm were obtained. 
Figures 1 show the types of crystals grown. The crystals were yellowish in color. 
 
6.6 Single Crystal X-ray Diffraction and Structure Determination 
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 A single crystal of the title compound with dimensions 0.30 x 0.25 x 0.25 mm was 
chosen for the X-ray diffraction study. The data were collected on a DIPLabo Image Plate 
system equipped with a normal focus, 3KW sealed X-ray source (graphite monochromated 
MoKα). The crystal to detector distance was fixed at 120 mm with the detector area of 441 x 
240 mm2. Thirty six frames of data were collected at room temperature by the oscillation 
method. Each exposure of the image plate was set to 400 seconds. Successive frames were 
scanned in steps of 5º per minute with an oscillation range of 5º. Image processing and data 
reduction were done using Denzo.4 The reflections were merged with Scalepack.13 All the 
frames could be indexed using a monoclinic lattice. Absorption correction was not applied. 
The structure was solved by direct methods using SHELXS-97.14 Least-squares refinement 
using SHELXL-9715 with isotropic temperature factors for all the non-hydrogen atoms 
converged the residual R1 to 0.0528. Subsequent refinements were carried out with 
anisotropic thermal parameters for non-hydrogen atoms and isotropic temperature factors for 
the hydrogen atoms which were placed at chemically acceptable positions. The hydrogen 
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atoms were allowed to ride on their parent atoms. After eight cycles of refinement the 
residual converged to 0.0446. The details of crystal data and refinement are given in Tables 1. 
Tables 2 give the list of bond lengths and bond angles respectively which are in good 
agreement with the standard values. Table 3 gives atomic coordinates and equivalent thermal 
parameters of the non-hydrogen atoms and Table 4 gives hydrogen-bonding geometry. The 
ORTEP of the molecule with thermal ellipsoids drawn at 50% probability is shown in Fig. 2 
and Fig. 3 shows packing of the molecules down along b-axis. 
 
The title compound shows planar conformation. The dihedral angle between the least squares 
planes O1-C2-C3-C4-C5-C10 and C5-C6-C7-C8-C9-C10 is 1.13(1)º. Total puckering 
amplitude Q for ten membered ring O1-C2-C3-C4-C5-C6-C7-C8-C9-C10 is 0.045(2)Å. The 
torsion angles about C3-C2-S11-C12 and C2-C3-C4-O16 being 168(2)º and 179.3(2)º show 
anti-periplanar  and anti-periplanar conformations. The molecule exhibits inter-molecular 
hydrogen bonds of the type C-H...O. The inter-molecular hydrogen bonds C9-H9...O15 and  
C12-H12A...O16, have lengths of 3.341(3)Å and 3.332(3)Å, with angles of 161º and 144º  
respectively, with the symmetry codes x,  y, 1+z  and -x, 1-y, -z. 
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Figure 2: ORTEP of the molecule with thermal ellipsoids drawn at 50% probability. 
 
 
 
 
 
Figure 3: Packing of the molecules when viewed down the b-axis. The dashed lines 
represent the hydrogen bonds. 
 
 
Studies on Bioactive Heterocycles  211 
 
Chapter 6  Single Crystal X-Ray Diffraction Study 
  
Table 1: Experimental details and other measurement data  
 
Empirical formula C10H7NO4S 
Formula weight 237.23 
Temperature 293(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Spacegroup P21/c 
Cell dimensions a = 7.7940(8)Å 
b = 17.3990(16)Å 
c = 8.1600(7)Å 
β = 117.998(6)° 
 
Volume 977.05(16)Å3
Z 4 
Density(calculated) 1.613 Mg/m 3
Absorption coefficient 0.328 mm -1
F000 488 
Crystal size 0.3 x 0.25 x 0.25 mm 
θ range for data collection 2.34° to 25° 
Index ranges -9 ≤ h ≤ 9 
-20 ≤  k ≤ 20 
-9 ≤  l ≤ 8 
 
Reflections collected 2713 
Independent reflections 1530 [R int = 0.0239] 
Refinement method Full-matrix least-squares on F 2
Data / restraints / parameters 1530 / 0 / 147  
Goodness-of-fit on F2 1.23 
Final R indices [I>2σ(I)] R1 = 0.0446, wR2 = 0.1162 
R indices (all data)  R1 = 0.0528, wR2 = 0.1312 
Extinction coefficient 0.43(4) 
Largest diff. peak and hole 0.412 and -0.376  e.Å -3
CCDC Deposition 760004 
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Table 2: Various Bond lengths (Å) and Bond angles (˚) 
 
Atoms Length (Å) Atoms Length (Å) 
O1-C2  1.338(2) C5-C6 1.404(3) 
 O1-C10 1.387(2)  C6-C7 1.371(3) 
C2-C3 1.375(3) C7-C8 1.392(4) 
C2-S11 1.734(2)  C8-C9  1.380(3) 
 C3-N13 1.441(3) C9-C10 1.381(3) 
C3-C4 1.467(3) S11-C12 1.797(3) 
C4-O16  1.218(2)  N13-O15 1.220(2) 
C4-C5 1.473(3) N13-O14 1.233(2) 
C5-C10 1.381(3)   
Atoms Angle(˚) Atoms Angle(˚) 
C2-O1-C10  120.83(2) C6-C5-C4  121.08(2)  
O1-C2-C3 121.13(2) C7-C6-C5 120.3(2) 
O1-C2-S11  112.59(1) C6-C7-C8 120.4(2) 
C3-C2-S11 126.27(2) C9-C8-C7 120.6(2) 
C2-C3-N13 118.22(2) C8-C9-C10 117.9(2) 
C2-C3-C4 122.83(2) C5-C10-C9  123.15(2) 
N13-C3-C4 118.95(2) C5-C10-O1 121.17(2) 
O16-C4-C3 125.45(2) C9-C10-O1 115.67(2) 
 O16-C4-C5 121.89(2) C2-S11-C12  101.66(1)  
C3-C4-C5 112.66(2)  O15-N13-O14  123.00(2) 
C10-C5-C6 117.63(2) O15-N13-C3 119.17(2) 
C10-C5-C4 121.29(2) O14-N13-C3 117.83(2) 
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Table 3: Atomic coordinates and equivalent thermal parameters of the non-hydrogen 
atoms. 
 
Atom x y z Ueq
O1 0.2126(2) 0.5367(7) 0.3081(2) 0.0404(4) 
C2 0.1982(3) 0.5767(1) 0.1622(3) 0.0357(5) 
C3 0.2395(3) 0.5435(1) 0.0319(3) 0.0370(5) 
C4  0.3097(3)  0.4642(1) 0.0473(3) 0.0368(5) 
C5 0.3291(3) 0.4251(1)  0.2152(3) 0.0370(5) 
C6 0.3984(3) 0.3494(1) 0.2565(3) 0.0465(5) 
C7 0.4119(3) 0.3134(1) 0.4116(4) 0.0522(6) 
C8 0.3586(3)  0.3517(1) 0.5304(3) 0.0499(6) 
C9 0.2923(3)  0.4265(1) 0.4947(3) 0.0436(5) 
C10 0.2789(3) 0.4614(1) 0.3371(3)   0.0365(5) 
S11 0.1206(8) 0.6704(3) 0.1594(8) 0.0443(3) 
C12 0.0475(4) 0.6672(1)  0.3379(4) 0.0501(6) 
N13 0.2147(3)  0.5892(1) -0.1251(3) 0.0444(5) 
O14  0.2283(3) 0.6596(9) -0.1058(3)  0.0668(6) 
O15 0.1811(3)  0.5571(1) -0.2701(2) 0.0649(6) 
O16 0.3500(2) 0.4323(8) -0.0631(2)  0.0467(4)  
 
 
 
 
 
 
Table 4: Geometry of intermolecular hydrogen interactions 
 
Atoms D-H H-A Length (Å) Angle(˚) Symmetry codes 
 C9-H9...O15 0.93 2.45 3.341(3) 161 x, y, 1+z 
C12-H12A...O16 0.96 2.51 3.332(3) 144 -x,1-y,-z 
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6.7 CONCLUSION 
 
We have demonstrated the crystal and molecular structure of newly synthesized compounds 
3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one and 2-(methylthio)-
3-nitro-4Hchromen-4-one by the singly crystal x-ray diffraction technique. In compound 3,4-
dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one, the pyrimidine ring 
adopts a flattened boat conformation and the phenyl ring 1 (C7-C8-C9-C10-C11-C12) and 
phenyl ring 2 (C18-C19-C20-C21-C22-C23) adopts an axial and equatorial conformations 
with the pyrimidine ring, respectively. The nitro group is almost coplanar with the pyrimidine 
ring. The structure exhibits intermolecular hydrogen bonds of the type N-H…O and O-H…O, 
which bind the molecules into one-dimensional polymeric chains. The compound 2-
(methylthio)-3-nitro-4Hchromen-4-one shows planar conformation and molecule exhibits 
inter-molecular hydrogen bonds of the type C-H...O.  
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Summary 
 
 
The work presented in the Thesis entitled “Studies on Bioactive Heterocycles” can be 
summarized as below. 
 
Chapter 1, we have demonstrated the utility of ω-nitro acetophenone for the synthesis of 
pyrimidine heterocycle via cyclocondensation using bisphosphonic acid (EDA) as a catalyst. 
We have examined the catalytic utility of various bisphosphonic acids and found the 
etidronic acid was efficient for the synthesis of nitro bearing pyrimidines. The use of 
etidronic acid was well tolerated with a range of aldehydes. This protocol is general and 
provides dihydropyrimidines in good to excellent yields depending on the reactivity of 
arylaldehydes. Thus, the present synthesis of pyrimidines will serve as an exclusive method 
of preparative importance for this class of compounds. However, the newly synthesized 
compounds were inactive against HIV-1 IIIB and ROD strains. 
 
Chapter 2 and 3, we have exhibited a solution-phase library of pyrazoles/isoxazoles 
functionalized with methyl, sulfone and carboxamide groups in two steps with excellent 
yield and chemical purity for biological interest. Water was emerged as an efficient and 
green solvent in the condensation reaction of various ketene dithioacetals with binucleophile 
such as; hydrazine hydrate and hydroxyl amine. Further, the oxidation of sulfide was 
achieved by sodium perborate to synthesized sulfone group containing pyrazoles/isoxazoles. 
Sodium perborate is more efficient and effective for oxidation of sulfide to sulfone in 
aqueous medium. This procedure offers a good scope for the synthesis of a wide variety of 
pyrazoles containing caboxamide and sulfone in two steps with excellent yield, purity and 
simple isolation of products. The biological screening of the synthesized compounds is under 
process.  
 
Chapter 4, we have demonstrated a novel synthetic strategy for the synthesis of substituted 
3-nitro-4H-chromen-4-ones through [5+1] heteroannulation of readily accessible 2-hydroxy-
ω-nitro acetophenone with carbon disulfide and followed by straightforward nucleophilic 
addition through elimination of methylthio with various amines. The direct C-N bond 
formation reaction at C2 was achieved by the presence of nitro functionality at C3 position 
of chromenone. The newly developed methodology allows direct access to 2-substituted-3-
nitro chromenone in excellent yield and high chemical purity. The presence of nitro 
functionality further makes them useful substrates for various transformations for biological 
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interest. Thus, the ω-nitro acetophenone has been useful for the synthesis of nitro group 
containing chromenones. The biological screening of the synthesized compounds is under 
process.  
 
Chapter 5, we have described the synthesis substituted pyrazolopyridone derivatives in 
excellent yields. The reaction of various ketene dithioacetals with cyanoacetamide was 
afforded the pyridone derivatives in the presence of base with good yields. Sodium 
isopropoxide was found as an efficient base for the synthesis of pyridones. The pyridones 
were further reacted with hydrazine hydrate to furnished pyrazolopyridones in excellent 
yields with short reaction time. The synthesized compounds were found inactive against 
HIV-1 IIIB and ROD strains. 
 
Chapter 6, We have demonstrated the crystal and molecular structure of newly synthesized 
compounds 3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one and 2-
(methylthio)-3-nitro-4H-chromen-4-one by the singly crystal x-ray diffraction technique. In 
compound 3,4-dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one, the 
pyrimidine ring adopts a flattened boat conformation and the phenyl ring 1 (C7-C8-C9-C10-
C11-C12) and phenyl ring 2 (C18-C19-C20-C21-C22-C23) adopts an axial and equatorial 
conformations with the pyrimidine ring, respectively. The nitro group is almost coplanar 
with the pyrimidine ring. The structure exhibits intermolecular hydrogen bonds of the type 
N-H…O and O-H…O, which bind the molecules into one-dimensional polymeric chains. 
The compound 2-(methylthio)-3-nitro-4H-chromen-4-one shows planar conformation and 
molecule exhibits inter-molecular hydrogen bonds of the type C-H...O.  
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Water Mediated Construction of Trisubstituted Pyrazoles/Isoxazoles
Library Using Ketene Dithioacetals
Mahesh M. Savant, Akshay M. Pansuriya, Chirag V. Bhuva, Naval Kapuriya,
Anil S. Patel, Vipul B. Audichya, Piyush V. Pipaliya, and Yogesh T. Naliapara*
Department of Chemistry, Chemical Research Laboratory, Saurashtra UniVersity, Rajkot 360005, India
ReceiVed September 24, 2009
A small molecule library of alkyl, sulfone, and carboxamide functionalized pyrazoles and isoxazoles has
been developed via a rapid sequential condensation of various R-acylketene dithioacetals (1a-o) with
hydrazine hydrate or hydroxylamine hydrochloride, followed by oxidation of sulfide to sulfone using water
as the reaction medium. An efficient and safe oxidation of sulfides (4/5a-o) to the corresponding sulfones
(6/7a-o) using sodium per borate system in aqueous medium is reported. The concise and two step synthesis
of trisubstituted pyrazoles and isoxazoles was investigated under variety of reaction condition. The newly
developed methodology has the advantage of excellent yield and chemical purity with short reaction time
using water as a solvent.
Introduction
In recent decades, combinatorial chemistry tools have
enabled the rapid synthesis of a large number of heterocyclic
small molecule libraries and it is recognized now as a key
element of early drug discovery.1 The main advantage of
the combinatorial technique is the speed at which diverse
types of organic compounds can be synthesized, formulated,
and tested for a particular application. Moreover, in com-
binatorial study the quantity of required material is less in
comparison to conventional methods, which makes it more
suitable when the materials are expensive.2
The development of new methods for the synthesis of five
member heterocyclic compound libraries, both in solution
and in solid phase, is an ever-expanding area in combinatorial
chemistry. Specifically, those containing the pyrazole and
isoxazole nucleus have been widely used as key building
blocks for pharmaceutical agents. Its derivatives are endowed
with high pharmacological properties, for example, hypogly-
cemic, analgesic, anti-inflammatory, antibacterial, anti-HIV,
and anticancer activity,3 as well as useful activities in
conditions like schizophrenia, hypertension, and Alzheimer’s
disease.4 In addition, they also have agrochemical properties
including herbicidal and soil fungicidal activity; thus, they
have been used as pesticides and insecticides.5 Recently,
pyrazoles containing aryl substituted emerged as p38 Kinase
inhibitors, antiparasitic activities.6
Among these, pyrazoles and isoxazoles bearing sulfone
and carboxamide moieties demonstrated to have significant
pharmacological applications. For examples, cyclooxyge-
nase-2 (COX-2) selective inhibitors, celecoxib (1),7 rofecoxib
(2),8 and valdecoxib (3)9 are currently prescribed for the
treatment of arthritis and inflammatory diseases (Figure 1,
1-3). These COX-2 inhibitors exhibited anti-inflammatory
activity with reduced gastrointestinal side effects. Oxacillin
and its derivatives are useful compounds because of their
narrow spectrum anti biotic properties10 (Figure 1, 4).
Recently, pyrrolyl aryl sulfones have been reported by
Silvestri et al.11 and Artico et al.12 as a new class of human
immunodeficiency virus type 1 (HIV-1) RT inhibitors acting
at the non-nucleoside binding site of this enzyme. Haruna
et al.,13 have synthesized the propargylic sulfones with
various planar molecules and evaluated their DNA binding
properties and DNA cleavage activity. Moreover, the 1-(4-
methylsulfonyl)benzene and 4-(4-methylsulfonyl)benzene
substituted pyrazole compounds containing a nitric oxide
donating group at the 3-position of the pyrazole ring,
respectively, have been synthesized and evaluated for their
ability to inhibit COX isoenzymes in human whole blood.14
Pyrazoles containing a sulfone group at N position have been
exhibited promising antimicrobial activity.15 Furthermore,
amide groups linked with isoxazole derivatives are found to
* To whom correspondence should be addressed. E-mail: naliaparachem@
yahoo.co.in. Phone: +91 9428036310. Fax: +91 281 2576802.
Figure 1. Biologically active pyrazoles and isoxazoles containing
alkyl, sulfone, and carboxamide groups (1-5).
J. Comb. Chem. 2010, 12, 176–180176
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have combined R2-adrenoceptor antagonistic and serotonine
reuptake inhibiting activities.16 The isoxazoles containing aryl
and carboxamide (Figure 1, 5) were also shown to have
potent in vivo antithrombotic efficacy.17
As described above, the tremendous biological potential
of the sulfone group and carboxamide group bearing pyrazole
and isoxazole scaffolds have attracted many chemists to
synthesize this class of molecules. The classical methods to
synthesized pyrazoles and isoxazoles involves the condensa-
tion of a 1,3-dicarbonyl compound or its synthetic equivalent
with hydrazine in appropriate organic solvent.18 On the other
hand, functionalized ketene dithioacetals are versatile inter-
mediates in organic synthesis for the construction of sub-
stituted heterocycles such as pyrazoles and isoxazole. The
nucleophilic displacement of one of the alkylthio groups from
ketene dithioacetals either in an organic solvents or using
microwave irradiation which followed by cyclization to
afforded the heterocycles.19 The sulfone group containing
synthesis of pyrazoles and isoxazoles library from 2-sulfo-
nylacetonitriles using solid-phase strategy is reported. How-
ever, it required a long reaction time, 40 h, and a lengthy
workup process.20 Thus, the practical synthesis of structurally
diverse isoxazole/pyrazole based small molecules is of great
significance.
Nowadays, a great deal of effort has been focused on the
field of green chemistry in adopting methods and processes.
As a part of this “green” concept, toxic and/or flammable
organic solvents are replaced by alternative non-toxic and
nonflammable media. In this context, many efforts have been
made to use aqueous media. Among alternative green
solvents, water has been the solvent of choice for a variety
of transformations.21 Given the importance of sulfone and
carboxamide group containing pyrazoles and isoxazoles, we
set out to prepare a small molecule library of 3-methyl-5-
(methylsulfonyl)-N-aryl-1H-pyrazole/isoxazole-4-carboxam-
ide derivatives using ketene dithioacetals in aqueous medium
(Figure 1, 6/7a-o).
Herein, we wish to report a novel synthesis of alkyl,
methylsulfonyl, and carboxamide functionalized pyrazole or
isoxazole heterocyles via condensation of R-acylketene
dithioacetals (R-AKDTAs) with hydrazine hydrate or hy-
droxyl amine hydrochloride and followed by oxidation of
sulfide to sulfone using sodium per borate (SPB) in aqueous
medium. To our knowledge, this is the first attempt to
construct 3-methyl-5-(methylsulfonyl)-N-aryl-1H-pyrazole/
isoxazole-4-carboxamide in solution phase.19a,22
Results and Discussions
A series of various R-AKDTAs 1a-o was prepared by
some modification in reported procedure.23 Initially, con-
densation of R-AKDTA 1a with hydrazine hydrate 2 took
place smoothly in isopropyl alcohol reflux to afford the
3-methyl-5-(methylsulfonyl)-N-phenyl-1H-pyrazole-4-car-
boxamide 4a in good yield (Scheme 1; Entry 1, Table 1).
The condensation of 1a with 2 to generate pyrazole 4a was
investigated using a variety of solvents, as a part of the “green
chemistry” concept and to optimize the yield, and the results
are summarized in Table 1.
The condensation reaction was clean in water, and the
yield of desired product was higher (Entry 7, Table 1). On
the other hand, the reaction was relatively fast when iPrOH
was used as a solvent with 12% lower yield (Entry 1, Table
1). The yield of desired product was reasonable when MeOH,
EtOH, and dioxane were used as a solvent (Entry 2,3,6, Table
1). The other solvents, tetrahydrofuran (THF) and acetoni-
trile, gave lower yield with higher reaction time (Entry 4,5,
Table 1). Thus, it is clear from the aforementioned experi-
ments that the best yield of pyrazoles 4a could be obtained
by employing water as a solvent without using any phase
transfer catalyst.
To test the generality of the condensation and to realize
the synthesis of a small combinatorial library of substituted
pyrazoles and isoxazoles, 15 R-AKDTAs 1a-o were reacted
with hydrazine hydrate 2 or hydroxyl amine hydrochloride
3 and potassium hydroxide to furnish pyrazoles 4a-o and
isoxazoles 5a-o in excellent yield using water as a solvent
(Scheme 1, Table 2). The synthesized compounds were
characterized by spectral data. The 1H NMR spectra of
compound 4c displayed characteristic singlet for methyl,
mehtylthio, and methoxy hydrogen, respectively, at δ 2.54,
2.64, and 3.92. The two singlets appeared for pyrazole NH
at δ 10.12 and amide hydrogen at δ 9.62 which revealed
the formation of pyrazole ring. However, in 1H NMR of
isoxazole 5b a characteristic singlet for amide proton
appeared at δ 9.19 and hydrogen of methylthio group
displayed a singlet at δ 2.63.
Because of the remarkable utility of sulfone group in
pharmaceuticals and to develop a library of pyrazole and
isoxazole functionalized with alkyl, carboxamide, and sul-
fone, we next planned to oxidize the sulfides to sulfones.
Although sulfides can be easily oxidized by a wide variety
of oxidizing reagents, unfortunately some of these reagents
are not satisfactory for the oxidation of sulfide to sulfone
because of low yields of products, toxicity, and expensive
reagents or catalysts.24 The reaction condition for oxidation
of sulfide to sulfone was optimized with a variety of
oxidizing agent in various solvent (Table 3, Scheme 2).
Scheme 1. Synthesis of Trisubstituted Pyrazoles and
Isoxazoles in Aqueous Medium
Table 1. Synthesis of 3-Methyl-5-(methylthio)-N-phenyl-1H-
pyrazole-4-carboxamide 4a Using Variety of Solvents
entrya solvents time, h yieldb %
1 iPrOH 2.8 85
2 MeOH 4.0 81
3 EtOH 3.5 83
4 THF 4.5 79
5 CH3CN 4.0 75
6 dioxane 3.5 80
7 water 3.0 97
a All solution-phase reactions were conducted at reflux temperature of
the solvent used. b Isolated yield after purification.
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The results gathered in Table 3 indicate that when
dichloromethane was used as a solvent the yield of sulfone
was higher with m-chloroperbenzoic acid (mCPBA) as
compared to sodium per carbonate (SPC) and SPB, but it
required high reaction time (Entry 1,4,7, Table 3). The yields
of desired products were very poor when acetone was used
as solvent, and the products were isolated using column
chromatography (Entry 2,5,8, Table 3). The best results were
obtained when water was used as solvent with the SPB, and
the sulfide underwent oxidation to the corresponding sulfone
in 45 min with excellent yield (Entry 6, Table 3). However,
an excess amount of SPC did not improve yield. When the
amount of SPB was reduced, the yield of desired product
was lower. The above results indicate, the cheap, environ-
mentally friendly and effective oxidizing agent in water was
SPB and gave quantitatively yield of product without use of
any activator. With this oxidizing system, all the synthesized
compounds 4/5a-o were oxidized to generate sulfone
containing pyrazoles and isoxazole based small molecule
library using solution phase synthesis, and the results are
gathered in Table 4. The chemical purity of all newly
synthesized compounds was examined using UPLC at 254
nm. Among all the final compounds, compounds 6k and 7l
shown less than 95% chemical purity and other showed more
than 95% chemical purity (Figure 2). The 1H NMR spectrum
of pyrazole 6j displayed two characteristic singlets for the
methyl and mehtylthio proton, respectively, at δ 2.53 and
3.64. However, two singlets appeared for pyrazole NH at δ
12.97 and amide hydrogen at δ 9.61. Compound 7a displayed
a characteristic singlet for amide proton at δ 9.88 and two
singlets for methyl and mehtylthio hydrogen, respectively,
at δ 2.69 and 3.33. The overall study indicates that this is
the simple and facile methodology to introduce sulfone and
caboxamide group to pyrazole and isoxazole scaffold in
excellent yield and chemical purity.
Conclusion
In summary, we have synthesized a solution-phase library
of pyrazoles and isoxazoles functionalized with methyl,
Table 2. 3-Methyl, 5-Methylthio, 4-Carboxamide Substituted
Pyrazoles and Isoxazoles
entry R time, h yielda % mp, °C
4a Ph 3.0 97 120-122
4b 4-CH3Ph 3.5 95 125-127
4c 4-CH3OPh 3.0 96 118-120
4d 4-FPh 2.8 94 132-134
4e 2-CH3OPh 2.9 92 126-128
4f 2-CH3 3.2 93 122-124
4g 4-ClPh 3.8 94 128-130
4h 4-EtPh 3.5 95 130-132
4i 4-NO2Ph 2.5 91 135-137
4j 3-Cl,4-FPh 3.2 90 128-130
4k 5-Cl,2-CH3OPh 3.0 93 136-138
4l 2,5-diClPh 3.4 89 126-128
4m 2,5-diCH3Ph 3.2 91 122-124
4n 4-Cl,2-CH3Ph 2.9 94 121-123
4o 3,4-diFPh 3.2 93 130-132
5a Ph 2.5 94 135-137
5b 4-CH3Ph 2.8 92 141-142
5c 4-CH3OPh 3.0 92 128-130
5d 4-FPh 3.2 90 142-144
5e 2-CH3OPh 2.6 88 136-138
5f 2-CH3 3.0 87 133-135
5g 4-ClPh 2.9 89 145-147
5h 4-EtPh 3.3 90 147-148
5i 4-NO2Ph 2.5 87 149-151
5j 3-Cl,4-FPh 3.4 88 134-136
5k 5-Cl,2-CH3OPh 3.6 90 151-153
5l 2,5-diClPh 2.8 89 142-144
5m 2,5-diCH3Ph 2.9 98 136-138
5n 4-Cl,2-CH3Ph 3.0 87 137-139
5o 3,4-diFPh 3.2 91 146-148
a Isolated yield after purification.
Table 3. Optimization of the Reaction Condition for Oxidation
of 4a and 5a to Its Sulfone
entrya oxidantb solvent yieldc % 6a: 7a time, min
1 mCPBA CH2Cl2 74:76 125
2 mCPBA acetone 56:60 95
3 mCPBA water 65:64 75
4 SPB CH2Cl2 79:82 110
5 SPB acetone 62:64 95
6 SPB water 91:94 60
7 SPC CH2Cl2 59:60 120
8 SPC acetone 52:55 90
9 SPC water 75:77 60
a All solution phase reactions were heated at reflux temperature of the
solvent used. b Oxidant: mCPBA-2 equiv, SPB-3 equiv, and SPC-3
equiv. c Isolated yields after purification.
Scheme 2. Water Mediated Synthesis of Pyrazoles and
Isoxazoles Containing Methyl, Sulfone, and Carboxamide
Groups
Table 4. 3-Methyl, 5-Sulfone, 4-Carboxamide Functionalized
Library of Pyrazoles and Isoxazoles
entry R time, min yielda % mp, °C
6a Ph 60 91 168-170
6b 4-CH3Ph 45 92 172-174
6c 4-CH3OPh 55 89 166-168
6d 4-FPh 50 88 175-177
6e 2-CH3OPh 60 90 170-172
6f 2-CH3 50 94 165-167
6g 4-ClPh 55 89 173-175
6h 4-EtPh 65 92 177-179
6i 4-NO2Ph 55 92 181-183
6j 3-Cl,4-FPh 50 91 176-178
6k 5-Cl,2-CH3OPh 50 93 186-188
6l 2,5-diClPh 65 88 176-178
6m 2,5-diCH3Ph 60 87 170-172
6n 4-Cl,2-CH3Ph 55 89 171-173
6o 3,4-diFPh 50 85 181-183
7a Ph 60 94 186-188
7b 4-CH3Ph 50 95 192-194
7c 4-CH3OPh 60 93 188-190
7d 4-FPh 55 91 191-193
7e 2-CH3OPh 65 94 184-186
7f 2-CH3 55 96 179-181
7g 4-ClPh 60 92 185-187
7h 4-EtPh 65 95 192-194
7i 4-NO2Ph 60 93 196-198
7j 3-Cl,4-FPh 55 92 188-190
7k 5-Cl,2-CH3OPh 55 91 195-197
7l 2,5-diClPh 60 90 188-190
7m 2,5-diCH3Ph 55 91 181-183
7n 4-Cl,2-CH3Ph 50 88 187-189
7o 3,4-diFPh 65 89 189-191
a Isolated yield after purification.
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sulfone and carboxamide moieties in two steps with excellent
yield and chemical purity for medicinally interesting mol-
ecules. Water emerged as an efficient and green solvent in
the condensation reaction of various ketene dithioacetals with
hydrazine hydrate or hydroxyl amine hydrochloride. Further,
the facile synthesis of sulfone containing pyrazoles and
isoxazoles was achieved via oxidation of sulfide to sulfone.
A comparative study of various oxidants has been performed,
and revealed that SPB is more efficient and effective for
oxidation of sulfide to sulfone in aqueous medium. This
procedure offers a good scope for the synthesis a wide variety
of pyrazoles and isoxazoles containing caboxamide and
sulfone in two steps. The present procedure is significant
over the existing methods to develop this class of molecules
with excellent yield, purity, and simple isolation of products.
Currently, we are engaged to make further diversification
of pyrazoles and isoxazoles at the C-3 position.
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Abstract A simple, convenient and efficient one-pot
cyclocondensation reaction of 1-(2-hydroxyphenyl)-2-
nitroethanone, arylaldehydes and urea using etidronic acid
to furnish nitro dihydropyrimidine derivatives is described.
A new and efficient protocol is developed as a homogenous
catalyst for the synthesis of dihydropyrimidines using
substituted x-nitro acetophenone. Various bisphosphonic
acids were examined to synthesized pyrimidines via mul-
ticomponent cyclocondensation reaction. This methodol-
ogy has the advantage of excellent yields with short
reaction time.
Keywords Etidronic acid  Homogenous catalyst 
Cyclocondensation  Nitro-dihydropyrimidine 
Multicomponent
1 Introduction
The Biginelli reaction [1], one of the most useful multi-
component reactions, offers an efficient way to access
multifunctionalized 3,4-dihydropyrimidin-2-(1H)-ones (DH
PMs) and related heterocyclic compounds [2]. However, in
biginelli reaction 1,3 diketone is used as a synthone. The
ability of nitro group to enhance biological and therapeutic
activities of certain organic compounds has led to wide-
spread interest in the selective introduction of nitro groups
into organic compounds [3] especially those heterocyclic
molecules which possess potential biological activities. For
example, DHPMs are important heterocycles in both natural
and synthetic compounds, which exhibit various pharma-
cological properties such as calcium channel blockers,
antihypertensive agents, antitumor, anti-inflammatory and
neuropeptide antagonists [3, 4]. Dihydropyridines and
dihydropyrimidinones contain an ester group in the position
5 of the heterocycle [2, 5]. However, Substitution of NO2 for
COOAlk in the dihydropyridines alters their biological
action. Reports reveal that nitro group functionalized dihy-
dropyrimidines which might have potential biological
activities were less studied [6].
A major drawback to Biginelli’s original reaction was
poor to moderate yields [7]. Recently, many improved
procedures have been reported using InBr3 [8], InCl3 [9],
LiClO4 [10], FeCl36H2O or NiCl26H2O [11], p-TsOH
[12], LaCl37H2O [13], IR radiation [14], Bi(OTf)3 [15],
La(OTf)3 [16], BF3 OEt2 [17], ionic liquids (BMIm PF6
and BMIm BF4) [18], TEBA [19], natural HEU type zeolite
[20], I2 [21], N-bromosuccinimide (NBS) [22], polyani-
line–bismoclite complex [23] and other Lewis acids [24]
heteropoly acid [25], sulfated zirconia [26], Sr(NO3)2 [27],
and covalently anchored sulfonic acid onto silica [28], PPE
[29], Phosphoric acid [30]. However, some of the newer
reported methods also suffer from drawbacks such as
unsatisfactory yields, cumbersome product isolation pro-
cedures, and environmental pollution. Moreover, the main
disadvantage of almost all existing methods is that the
catalysts are destroyed in the workup procedure and cannot
be recovered or reused. Therefore, still there is need for
versatile, simple, and environmentally friendly processes
whereby DHPMs may be formed under milder and prac-
tical conditions.
In continuation of our work on the development of
useful synthetic methodologies by employing solid acid
catalysts [31], we observed that bisphosphonic acid is an
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efficient catalyst for the synthesis of pyrimidines via bigi-
nelli condensation. To explore further, the utility of this
catalyst in multicomponent cyclocondensation, herein we
report some new nitro group containing dihydropyrimidine
derivatives from substituted x-nitro acetophenone instead
of 1,3 diketone with excellent yield under various reaction
conditions.
2 Experimental Section
2.1 Materials
Chemicals were supplied by E. Merck (Germany) and S. D.
Fine Chemicals (India) and used without purification. The
solvents were analytical grade. THF was distilled over
sodium/benzophenone prior to use. Analytical thin layer
chromatography (TLC) was performed on Silica Gel 60
F254 precoated plates. Silica gel (Loba, 100–200 mesh,
60 A˚) for column chromatography was used as received.
2.2 Instrumentation
1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were
recorded in DMSO, and TMS was used as an internal ref-
erence on a Bruker AVANCE II spectrometer. Mass spectra
were determined using direct inlet probe on a GCMS-
QP2010 mass spectrometer. IR spectra were recorded on
KBr discs, using FTIR-8400 spectrophotometer. The syn-
theses were carried out in a Questron Technologies Corpo-
ration QPro-M microwave synthesizer. Melting points were
measured in open capillaries and are uncorrected.
2.3 General Procedure for the Synthesis of Nitro
dihydropyrimidines 4a–n
To a mixture of various aromatic aldehydes (10 mmol, 2a–n)
and urea (10 mmol, 0.60 g) in dry THF (5 mL) was added
etidronic acid (0.1 mmol, 0.2 g) and stirred it for 5 min at r.t.
to this add 1-(2-hydroxyphenyl)-2-nitroethanone (10 mmol,
0.18 g) and subjected to microwave irradiation at 360 W for
appropriate time (Table 3). The reaction being monitored by
TLC. After completion of the reaction, the reaction mixture
was concentrated under reduced pressure. The separated
solid was washed with water and followed by methanol,
filtered, dried and crystallized from glacial acetic acid to
furnish analytically pure products. The water layer is evap-
orated to recycle the catalyst.
2.3.1 Spectral Data for Selected Compounds
2.3.1.1 3,4-Dihydro-6-(2-hydroxyphenyl)-5-nitro-4-phenyl-
pyrimidin-2(1H)-one (4a) Lemon yellow solid; mp
241–243 C; IR (KBr): 3,624 (–OH), 3,076 (–NH), 1,674
(C=O) cm-1; 1H NMR: d 5.74 (d, 1H, J = 3.16 Hz), 6.90–
7.59 (m, 9H, Ar–H), 7.68 (s, 1H, NH), 8.97 (s, 1H, NH), 9.64
(s, 1H, OH); 13C NMR: 55.30, 114.54, 116.08, 119.31, 120.38,
126.99, 128.73, 131.61, 142.12, 146.22, 151.53, 166.05; MS
m/z: 311(M?); Anal. calcd. for C16H13N3O4: C, 61.73; H,
4.21; N, 13.50%. Found: C, 61.58; H, 4.08; N, 13.33%.
2.3.1.2 3,4-Dihydro-6-(2-hydroxyphenyl)-4-(3-chlorophe-
nyl)-5-nitropyrimidin-2(1H)-one (4b) Yellow solid; mp
255–257 C; IR (KBr): 3,556 (–OH), 3,290(–NH), 1,672
(C=O) cm-1; 1H NMR: d 5.71 (d, 1H, J = 3.52 Hz), 6.91–
7.93 (m, 8H, Ar–H), 7.94 (s, 1H, NH), 9.17 (s, 1H, NH),
9.78 (s, 1H, OH); 13C NMR: 54.40, 115.52, 117.18, 120.25,
122.31, 127.63, 129.63, 134.63, 145.22, 148.34, 153.53,
163.12; MS m/z: 345(M?); Anal. calcd. for C16H12ClN3O4:
C, 55.58; H, 3.50; N, 12.15. Found: C, 55.42; H, 3.38; N,
12.03%.
2.3.1.3 3,4-Dihydro-6-(2-hydroxyphenyl)-4-(4-methoxyph-
enyl)-5-nitropyrimidin-2(1H)-one (4c) Pale yello solid;
mp 246–248 C; IR (KBr): 3,649 (–OH), 3,292 (–NH),
1,678 (C=O) cm-1; 1H NMR: d 3.79 (s, 1H, OCH3), 5.65
(d, 1H, J = 3.36 Hz), 6.86–7.49 (m, 8H, Ar–H), 7.95
(s, 1H, NH), 9.42 (s, 1H, NH), 9.71 (s, 1H, OH); 13C NMR:
54.65, 55.28, 113.91, 115.97, 119.24, 128.22, 128.61,
131.22, 134.45, 135.44, 136.30, 151.52, 159.28, 172.96,
181.34; MS m/z: 341(M?); Anal. calcd. for C17H15N3O5:
C, 59.83; H, 4.43; N, 12.31%. Found: C, 59.66; H, 4.32; N,
12.18%.
2.3.1.4 3,4-Dihydro-6-(2-hydroxyphenyl)-4-(4-nitrophenyl)-
5-nitropyrimidin-2(1H)-one (4h) Lemon yellow solid;
mp 268–270 C; IR (KBr): 3,487 (–OH), 3,304 (–NH),
1688 (C=O) cm-1; 1H NMR: d 5.82 (d, 1H, J = 3.64 Hz),
6.92–7.84 (m, 6H, Ar–H), 8.14 (s, 1H, NH), 8.20-8.22
(q, 2H, Ar–H), 9.31(s, 1H, NH), 9.76 (s, 1H, OH); MS m/z:
356 (M?); Anal. calcd. for C16H12N4O6: C, 53.94; H, 3.39;
N, 15.73%. Found: C, 53.75; H, 3.24; N, 15.26%.
3 Results and Discussions
Etidronic acid [(1-hydroxyethylidene) bisphosphonic acid]
is one of the bisphosphonic acid derivative and also known
P
O
OH
P
O
OHHO
HO
OHR
Fig. 1 Bisphophonic acid
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as bisphosphonate having molecular formula C2H8O7P2.
The two PO3 (phosphonate) groups covalently linked to
carbon atom (Fig. 1).
It differs from Polyphosphate ester and polyphosphoric
acid. Various bisphosphonic acids are known [32, 33].
Etidronic acid is mild enough as compare to another strong
acid such as polyphosphoric acid etc. moreover, the cata-
lyst did not affect acid sensitive aldehydes.
Indeed, condensation of the 1-(2-hydroxyphenyl)-
2-nitroethanone 1 with benzaldehyde 2a and urea 3 took
place smoothly in the presence of EDA in THF resulted in
the formation of dihydropyrimidine 4a in 89% yield (entry 1,
Table 1). We found that the final product obtained was
dihydro biginelli product 4a (Scheme 1). The condensation
of 1 with 2a and 3 to generate 4a was investigated under a
variety of conditions (Table 1), as a test case, to optimize the
yield, and the results are gathered in Table 1. The conden-
sation took place even with a catalytic amount of EDA (10%,
entry 3). Though the condensation reaction with a catalytic
amount of EDA was cleaned, it took a longer time (6 h). On
the other hand, the reaction was relatively fast (4 h) when
one equiv. of EDA was employed (entry 1). However, the
reaction carried out under microwave irradiation gave
excellent yields (entry 4, 2). The yield of desired product 4a
was moderate when methanol and ethanol was used as sol-
vent (entry 5–8) and in this case product 4a was separated by
column chromatography over silica gel using hexane/EtOAc
(7:3) as an eluent.
With the optimized conditions in hand, the reactions of 1
with benzaldehyde 2a and urea 3 with various bisphos-
phonic acids were examined to explore the utility of these
catalysts in multicomponent cyclocondensation reaction
under microwave irradiation in THF. We found that bis-
phosphonic acid linked with alkyl amines (Table 2, entry
2–4) or with heterocyclic moieties (Table 2, entry 5–8)
showed very poor catalytic activity compared to EDA
(Table 2, entry 1). This can be explained by the fact that
electron donating moieties attached with bisphosphonic
acid at C2 position may decreases the reactivity of these
catalysts leading to moderate or poor yields of 4a. Thus, it
is clear from the aforementioned experiments that the best
yield of compound 4a could be obtained by employing
catalytic amount of etidronic acid in THF under microwave
irradiation.
When the reaction of the 1-(2-hydroxyphenyl)-2-nitro-
ethanone 1 with various arylaldehydes 2a and urea 3 was
conducted it was observed that the electron deficiency and
nature of the substituents on the aromatic ring aldehydes
effect the conversion rate; aromatic aldehydes having
electron-withdrawing groups on the aromatic ring (Table 3,
Table 1 Optimization of the reaction conditions for the synthesis of
4a
Entry Catalyst
(equiv.)
Solvent Yield
(%)
Time
1 EDA (1.0) THFa 89c 4.0 h
2 EDA (1.0) THFb 95d 3.5 min
3 EDA (0.1) THFa 86c 6.0 h
4 EDA (0.1) THFb d
5 EDA (0.1) MeOHa 73e 11.5 h
6 EDA (0.1)) MeOHb 82e 6.5 min
7 EDA (0.1) EtOHa 78e 9.0 h
8 EDA (0.1) EtOHb 86e 5.5 min
a All solution-phase reactions were conducted at reflux temperature
of the solvent used All solution-phase reactions were conducted at
reflux temperature of the solvent used
b The reaction was conducted under microwave irradiation (360 W)
c After 4–6 h reflux
d Isolated yield after purification
e After column chromatography
NO2
O H O
R1
H2N O
NH2
+
THF
Etidronic Acid N
H
NH
O
4a-n
1
2a-n
3
mw
R1
OH
O2N
HO
Scheme 1 Etidronic acid
catalyzed one-pot synthesis
of nitro functionalized
dihydropyrimidines under
microwave irradiation
Table 2 Synthesis of nitro dihydropyrimidines 4a using various cat-
alyst and THF under microwave irradiation
Entry R Catalyst (equiv.) Yield
(%)
Time
(min)
2 –CH2NH2 Pamidronic acid (0.1) 65 9.5
3 –CH2NH2 Pamidronic acid (1.0) 68 8.0
4 –(CH2)2NH2 Alendronic acid (0.1) 66 8.0
5 –(CH2)2NH2 Alendronic acid (1.0) 67 9.5
6 -3-Pyridyl Risedronic acid (0.1) 55 11.0
7 -3-Pyridyl Risedronic acid (1.0) 59 9.5
8 -1-Imidazolyl Zoledronic acid (0.1) 45 11.5
9 -1-Imidazolyl Zoledronic acid (1.0) 51 11.0
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93 3.0 min
1 –H Etidronic acid (0.1) 93 3.0
entries 6, 8, 9) reacted faster than electron-donating groups
(Table 3, entries 2, 11, 12). The synthesized compounds
were characterized by spectroscopy analysis. In mass
spectrum of 4a molecular ion peak appears at 311 m/z
which reveal the formation of dihydropyrimidine. The 1H
NMR spectrum of 4a displayed one characteristic doublet
for the methane proton at 5.74 d ppm and one –OH proton
at 9.64 d ppm. The overall study indicates the catalyst is
efficient to synthesize nitro dihydropyrimidines.
4 Conclusions
In summary, we have demonstrated a simple route for the
synthesis of nitro group containg dihydropyrimidines via
cyclocondensation reactions using etidronic acid as an
efficient homogeneous catalyst. The use of etidronic acid
was well tolerated with a range of aldehydes. This protocol
is general and provides dihydropyrimidines in good to
excellent yields depending on the reactivity of arylalde-
hydes. Thus, the present synthesis of pyrimidines will serve
as an exclusive method of preparative importance for this
class of compounds. We are currently engaged in the
application of this catalyst for the electrophilic substitution.
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Abstract 
The three component reaction between 4-hydroxycoumarin, malononitrile and carbonyl 
compounds in ethanol in the presence of morpholine as a catalyst was studied. Only cyclic 
aliphatic ketones afford spiro 2-amino-3-cyanopyrano[3,2-c]chromene derivatives. 
 
Keywords: 4-Hydroxycoumarin, malononitrile, cyclic aliphatic ketone, spiro, pyrano[3,2-
c]chromene  
 
 
 
Introduction 
 
A key intermediate in the synthesis of warfarin (rodenticide, a blood anticoagulant) is 2-amino-3-
cyano-5-oxo-4-phenyl-4,5-dihydropyrano[3,2-c]chromene 3 prepared by heating  4-
hydroxycoumarin 1 with benzylidenemalononitrile 2 in pyridine1 or water.2 Acid hydrolysis of 
the pyrano[3,2-c]chromene 3 affords compound 4, which is subsequently transformed into 
warfarin 5.1-5 
O
OH
O
Ph CN
CN O
O
O
NH2
CN
Ph
O
PhOH
OCOOHO
PhOH
O
O
1 2 3
45
+
H+
 
Figure 1 
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 2-Amino-4-aryl-3-(thiocarbamoyl, alkoxycarbonyl, or cyano)-5-oxo-4,5-dihydropyrano[3,2-
c]chromenes were also obtained3,6 by morpholine catalyzed reaction between 4-
hydroxycoumarin with arylidenecyanothioacetamide, alkyl arylidenecyanoacetates, or 
arylidenemalononitrile in hot benzene or ethanol. Despite modest achievements in recent years 
for the synthesis of compounds of  type 3 having substituents in position 4, the preparation and 
isolation of unsaturated nitriles 2, which are analogs of toxic agents (2-
chlorobenzylidene)malononitrile (CS),7-23 may substantially complicate the aforementioned 
synthesis (Figure1). In some cases, the condensation does not yield the target unsaturated nitrile 
at all. For instance reaction between pyridine-4-carbaldehyde and malononitrile yields 1-amino-
2,4,4,6,6-pentacyano-3,5-di(4-pyridyl)cyclohex-1-ene.24 This precludes the synthesis of 
pyrano[3,2-c]chromenes containing the 4-pyridyl substituent in position 4. 
 N-Substituted piperidine-4-one derivatives were failed to afford spiro[piperidine-4,4´-
pyrano[3,2-c]chromenes],25 while proficient to afford spiro[piperidine-4,4´-pyrano[3,2-
c]quinoline]26 derivatives by one-pot multicomponent reaction of 4-hydroxyquinolone, 
cyanoacetic acid derivatives and substituted piperidine-4-one derivatives. However, isatin 
derivatives are proficient as cyclic ketone to afford spiro[2–amino–5–oxo–4,5–
dihydropyrano[3,2–c]chromenes]25 by cross coupling reaction of 4-hydroxycoumarin, 
cyanoacetic acid derivatives and isatin derivatives. 
 In further investigations of cross coupling between cyanoacetic acid derivatives and 
carbonyl compounds with the aim of developing one step syntheses of functionalized 
heterocycles, we studied three component system reactions of 4-hydroxycoumarin, 
malononitrile, and carbonyl compounds (cyclic and non-cyclic aliphatic ketones). 
 
 
Results and Discussion 
 
Brief heating of 4-hydroxycoumarin 1(a,b) with cyclic aliphatic ketones (cyclopentanone, 
cyclohexanone, and cycloheptanone) 6(a-c) and malononitrile 7 in boiling ethanol in the 
presence of morpholine as a catalyst gave 2-amino-3-cyanopyrano[3,2-c]chromene derivatives 
8(a-f) in high yields (65–85%). The observed high regioselectivity is most probably associated 
with the reaction sequence outlined in scheme 1. Initial Knoevenagel  reaction between cyclic 
ketones 6 and malononitrile 7 produces the unsaturated nitrile 9, which, undergoes a Michael 
reaction with the base derived coumarin anion 10. The resulting Michael adduct 11 then 
undergoes intramolecular cyclization producing the annelated iminopyran 12. Subsequent 
tautomeric [1,3]sigmatropic shift gives compound 8 (Scheme 1). 
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Scheme 1. Mechanistic pathway towards 8(a-f). 
 
 Under these conditions, the reaction proceeds sufficiently rapidly and smoothly to afford the 
target chromenes 8(a-f) in high yields without Michael adducts 11 being  detected. However, the 
proposed mechanism is supported to some degree by isolation of analogous Michael adducts in 
the previously studied reaction of 4-hydroxycoumarin with arylidenecyanoacetamides.3 
 On the other hand the three component reaction system of 4-hydroxycoumarin 1a, 
malononitrile 7 and substituted acetophenones 13(a-c) as the carbonyl compound under 
analogous conditions failed to produce any chromenes 15(a-c). It was found that the 
acetophenones 13(a-c) did react with malononitrile 7 to give unsaturated nitriles 14(a-c) but 
these did not undergo Michael reaction with the coumarin anion. The plausible reason for the 
formation of spiro molecules with cyclic ketones is, in cyclic ketone the electrons are not 
localized in C−C bond but are actually spread out over the whole system, moreover the C in 
cyclic saturated ketones has sp3 hybridization. While in aromatic ketones C in benzene ring has 
sp2 hybridization due to this effect it may be cannot take part in cyclization. 
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Scheme 2. Synthetic approach towards spiropyrano[3,2-c]chromene using acetophenones as 
carbonyl compounds. 
 
 The pyranochromenes 8(a-f) obtained are air stable and colorless solid powders, which are 
well soluble in acetone, DMF and DMSO. The structures of these compounds were confirmed by 
IR, Mass spectrometry, 1H NMR, 13C NMR spectroscopy and elemental analysis. The IR spectra 
of pyranochromene 8(a-f) exhibit characteristic absorption bands of the amino, nitrile, and 
methylene fragments: ν (NH2) 3300-3500 cm-1, ν (CN) 2200-2350 cm-1, and ν (CH2) 2800-2900 
cm-1. The IR spectra of pyranochromenes show a particular absorption band of the lactone group 
at 1680-1720 cm-1. All the mass spectra show a molecular ion peak in agreement with the 
molecular weight of the respective compound. The 1H NMR spectra show signals for the proton 
of amino group and methylene group at 5.6 to 5.8 δ ppm and 1.5 to 2.8 δ ppm, respectively. The 
signals for the benzenoid protons of coumarin are observed at in the interval 7.3 to 7.8 δ ppm. 
The 13C NMR spectral data for compound 8a are consistent with the assigned structure. 
 
 
Conclusions 
 
In the three component system between 4-hydroxycoumarin, malonitrile and ketones for the 
formation of spiro 2-amino-3-cyanopyrano[3,2-c]chromene derivatives the ketones have to be 
cyclic in nature. 
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Experimental Section  
 
General. Melting points were determined on an electro thermal apparatus using open capillaries 
and are uncorrected. Thin-layer chromatography was performed on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck).  Visualization was made with UV light (254 and 365nm) or with 
iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer using DRS (diffusion 
reflectant spectroscopy) probe. 1H NMR spectra were recorded on a Bruker AVANCE II (400 
MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as 
an internal standard. Mass spectra were determined using a direct inlet probe on a GCMS-QP 
2010 mass spectrometer (Shimadzu).  All reagents were purchased from Fluka, Sigma Aldrich, 
Merck and Rankem and used without further purification. 
 
Preparation of spiro pyrano[3,2-c]chromene derivatives: General procedure 
A stirred mixture of 4-hydroxycoumarin 1(a,b) (10 mmol), carbonyl compound 6(a-c) 
(cyclopentanone, cyclohexanone, and cycloheptanone) (10 mmol), malononitrile 7 (10 mmol), 
and morpholine (0.5 mmol) in anhydrous EtOH (50 mL) was heated under reflux for  20 min and 
allowed to crystallize at 4 °C for 12 h. The precipitate that formed was filtered off, washed with 
ethanol and hexane, and recrystallized from 1,4-dioxane to give compounds 8(a-f) as  white 
powders. 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cyclopentane) (8a). White solid; mp 
230-232°C; Yield – 83%. IR (KBr): 3450, 2928, 2904, 2865, 2845, 2360, 1724, 1602, 1558, 
1313 cm-1. 1H NMR: δ = 7.82 (d, 1H, Ar), 7.60–7.55 (m, 1H, Ar), 7.34–7.30 (m, 2H, Ar), 5.78 
(s, 2H, NH2), 2.39–2.33 (m, 2H, CH2), 2.06–1.90 (m, 4H, CH2), 1.89–1.64 (m, 2H, CH2). 13C 
NMR: δ = 159.7, 154.6, 152.4, 152.2, 132.3, 124.3, 122.3, 119.2, 116.5, 113.0, 109.3, 70.9, 43.1, 
41.0, 27.6. Mass: m/z = 295 [M++1], 294 [M+]. Anal. Calcd for C17H14N2O3: C, 69.38; H, 4.79; 
N, 9.52. Found: C, 69.19; H, 4.51; N, 9.43. 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cyclohexane) (8b). White solid; mp 
230-232 °C; Yield – 78 %. IR (KBr): 3595, 2928, 2368, 1718, 1678, 1649, 1539, 1321, 1084 cm-
1. 1H NMR: δ = 7.78 (m, 1H, Ar), 7.60–7.54 (m, 1H, Ar), 7.29–7.28 (m, 2H, Ar), 5.78 (s, 2H, 
NH2), 2.41–2.35 (m, 4H, CH2), 2.12–2.01 (m, 4H, CH2), 1.89–1.61 (m, 2H, CH2). Mass: m/z = 
308 [M+]. Anal. Calcd for C18H16N2O3: C, 70.12; H, 5.23; N, 9.09. Found: C, 70.06; H, 4.56; N, 
8.82. 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cycloheptane) (8c). White solid; mp 
225-226 °C; Yield – 66 %. IR (KBr): 3458, 2930, 2868, 2344, 1720, 1649, 1545, 1080 cm-1. 1H 
NMR: δ = 7.78 (m, 1H, Ar), 7.68–7.63 (m, 1H, Ar), 7.36–7.29 (m, 2H, Ar), 5.79 (s, 2H, NH2), 
2.41–1.69 (m, 12H, CH2). Mass: m/z = 322 [M+]. Anal. Calcd for C19H18N2O3: C, 70.79; H, 5.63; 
N, 8.69. Found: C, 70.23; H, 5.34; N, 8.51. 
 
Spiro(2–amino–3–cyano–9–methyl pyrano[3,2–c]chromene–4,1’–cyclopentane (8d). White 
solid; mp 228-230 °C; Yield–85 %. IR (KBr): 3464, 2983, 2928, 2856, 2846, 2364, 1690, 1645, 
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1554, 1371, 1317, 1024 cm-1. 1H NMR: δ = 7.83–7.65 (m, 1H, Ar), 7.34–7.21 (m, 2H, Ar), 5.77 
(s, 2H, NH2), 2.37–2.33 (m, 4H, CH2), 2.31 (s, 3H, CH3), 2.12–1.88 (m, 4H, CH2). Mass: m/z = 
308 [M+]. Anal. Calcd for C18H16N2O3: C, 70.12; H, 5.23; N, 9.09. Found: C, 69.94; H, 5.08; N, 
8.98. 
Spiro(2–amino–3–cyano–9–methyl pyrano[3,2–c]chromene–4,1’–cyclohexane) (8e). White 
solid; mp 231-232 °C; Yield–72 %. IR (KBr): 3502, 2960, 2956, 2845, 2304, 1678, 1649, 1545, 
1368, 1321, 1045 cm-1. 1H NMR: δ =  7.68–7.54 (m, 1H, Ar), 7.41–7.28 (m, 2H, Ar), 5.78 (s, 
2H, NH2), 2.40–2.31 (m, 4H, CH2), 2.31 (s, 3H, CH3), 2.12–1.75 (m, 6H, CH2). Mass: m/z = 322 
[M+]. Anal. Calcd for C19H18N2O3: C, 70.79; H, 5.63; N, 8.69. Found: C, 70.55; H, 5.48; N, 8.51. 
Spiro(2–amino–3–cyano–9–methyl pyrano[3,2–c]chromene–4,1’–cycloheptane) (8f). White 
solid; mp 220-222 °C; Yield–70 %. IR (KBr): 3478, 2928, 2910, 2300, 1692, 1664, 1539, 1380, 
1308, 1023 cm-1. 1H NMR: δ = 7.65–7.52 (m, 1H, Ar), 7.40–7.29 (m, 2H, Ar), 5.78 (s, 2H, NH2), 
2.32 (s, 3H, CH3), 2.34–1.60 (m, 12H, CH2). Mass: m/z = 336 [M+]. Anal. Calcd for C20H20N2O3: 
C, 71.41; H, 5.99; N, 8.33. Found: C, 71.30; H, 5.76; N, 8.24. 
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